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Thesis Abstract 
Regulated protein degradation in eukaryotes is performed predominantly by the 
ubiquitin-proteasome pathway. Prior to their degradation by the 26S proteasome, protein 
substrates become covalently modified with ubiquitin chains. Such ubiquitination enables 
the 19S regulatory particle of the proteasome to recognize the doomed protein substrate. 
My thesis research focuses on defining how the 19S regulatory particle of the proteasome 
recognizes ubiquitinated substrates. When I began my thesis research, S5a/Rpn10 was the 
only known proteasomal ubiquitin receptor; yet, it is not essential for degradation of 
ubiquitinated substrates by the proteasome. My thesis research helped establish 
Adrm1/ARM1/Rpn13 as the missing proteasomal ubiquitin receptor. I used NMR 
spectroscopy to provide mechanistic insights into how human Rpn13 binds ubiquitinated 
substrates. I adapted a protocol developed by the late Cecile Pickart to fine tune 
polyubiquitin synthesis for use in NMR structural studies. By using this approach, I 
selectively labeled individual subunits within polyubiquitin to determine Rpn13’s 
selective binding to the proximal subunit of K48-linked diubiquitin (diUb). These results, 
along with additional results from my lab and our collaborators’ labs, are described in 
Chapters 2 and 3.  
 I continued to explore Rpn13’s role as a ubiquitin receptor by testing whether it is 
able to work in cooperation with S5a/Rpn10. Along with other members of my lab, we 
solved the structure the S5a/K48-linked diUb complex by utilizing the method I 
optimized for synthesizing selectively labeled polyubiquitin. I then helped expand this 
work to reveal that Rpn13 and S5a are able to bind a common ubiquitin chain and thereby 
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work cooperatively to capture ubiquitinated substrates. These results are described in 
Chapter 4. 
In Chapter 5, I describe a novel interaction of Rpn13’s Pru domain to a ubiquitin 
processing enzyme, namely E2 ubiquitin conjugating enzyme Cdc34. NMR experiments 
reveal that an Rpn13 surface that neighbors its ubiquitin-binding loops binds to Cdc34’s 
unique C-terminal tail and that this interaction does not restrict Rpn13 binding to 
ubiquitin. Immunoprecipitation experiments performed on HeLa cells with endogenous 
protein levels demonstrate Rpn13 and Cdc34 to be in complex in the cellular 
environment. The Rpn13:Cdc34 interaction suggests that Rpn13 may play a role in SCF-
mediated ubiquitination.  
Proteasome dysfunction is implicated in many diseases, such as cancer, cystic 
fibrosis, heart disease, and neurodegenerative diseases and the ubiquitin-proteasome 
pathway has therefore become a major pharmaceutical target. My thesis research in 
trying to understand how the proteasome recognizes ubiquitinated substrates provides 
structural and mechanistic information that could be used to help develop new drugs and 
possible treatments for these diseases.   
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1.1 Synopsis 
Post-translational modification by ubiquitin (ubiquitination, ubiquitylation, 
ubiquitinylation) is used as a robust signaling mechanism in a variety of processes that 
are essential for cell homeostasis. Its signaling specificity is conferred by the inherent 
dynamics of ubiquitin, the multivalency of ubiquitin chains, and its subcellular context, 
often defined by ubiquitin receptors and the substrate. Greater than 150 ubiquitin 
receptors have been found and their ubiquitin-binding domains (UBDs) are structurally 
diverse and include alpha-helical motifs, zinc fingers (ZnF), pleckstrin-homology (PH) 
domains, ubiquitin conjugating (Ubc)-related structures and src homology 3 (SH3) 
domains. New UBD structural motifs continue to be identified. In this manuscript, we 
highlight several ubiquitin receptors from the multiple UBD folds with a focus on the 
structural characteristics of their interaction with ubiquitin.  
 
1.2 Introduction: ubiquitin and protein ubiquitination 
 The 76-amino acid protein ubiquitin is attached covalently to other proteins to in 
turn, modify or expand their cellular activities. The most common sites of ubiquitin 
attachment are Lys epsilon-amino groups and the substrate’s amino terminus, as reviewed 
in (1). In rare cases, ubiquitin can also be attached to Ser hydroxyl and Cys thiol groups 
(2, 3). Ubiquitination is tightly regulated and generally requires a 3-step catalytic cycle 
that includes E1 activating, E2 conjugating, and E3 ligating enzymes (Figure 1.1A). The 
human genome has been demonstrated to encode two E1 (Uba1 and Uba6), ~40 E2, and 
greater than 600 E3 enzymes, as reviewed in (4). E1 enzymes activate ubiquitin with a 
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two-step ATP-dependent reaction to form an E1-thiolester~ubiquitin intermediate (5), 
from which ubiquitin is transferred to an E2 catalytic Cys by a thioester transfer reaction, 
as reviewed in (6, 7). The transfer of activated ubiquitin to a substrate generally requires 
an E3 ligase. Depending on the E2-E3 pair, ubiquitin is either transferred to the target 
substrate directly from the E2 or after passage to an E3 catalytic Cys. The former 
mechanism is performed by RING (Really Interesting New Gene) domain E3s, which are 
the most populated class of E3. These act as scaffolds by orienting E2s for ubiquitin 
transfer to a substrate, as reviewed in (4). HECT (Homologous to E6AP C-Terminus) 
domain E3s, by contrast, form a thioester bond with ubiquitin en route to its substrate 
transfer, as reviewed in (8). Recently, the mechanistic distinction between RING and 
HECT E3s has become blurred as two E3s that belong to the RING-in-between-RING 
(RBR) family were proposed to act as RING/HECT hybrids by forming a 
thiolester~ubiquitin intermediate via a conserved RING domain cysteine prior to 
ubiquitin transfer to substrate (9). 
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Figure 1.1 Ubiquitination (A) E1-E2-E3 enzymatic cascade leading to substrate 
ubiquitination, (B) Diversity of ubiquitin modification. 
 
A single passage through an E1-E2-E3 enzymatic cascade results in a 
monoubiquitinated substrate. Additional passages yield multiubiquitinated substrates, 
with ubiquitin moieties at multiple sites, and/or polyubiquitinated substrates, with 
additional ubiquitins ligated to previously attached ones (Figure 1.1B). Ubiquitin 
moieties are linked by an isopeptide bond between a Gly76 carboxyl group and either a 
Lys sidechain primary amino group (Lys6, Lys11, Lys27, Lys29, Lys33, Lys48, or 
Lys63) or the ubiquitin amino terminus (Met1) (10-12). Quantitative mass spectrometry 
(MS) experiments in Saccharomyces cerevisiae (13) and mammalian cells (HEK293) 
(14) revealed differences in polyubiquitin linkage abundance. Although Lys48 and Lys63 
  5 
linked chains are abundant in both cell types, their population is greater in HEK293 cells, 
as S. cerevisiae contained more Lys6 and Lys11 linkages (Table 1.1). It is possible that 
these differences are of physiological origin, but they may also be due to the use of 
different experimental procedures. The S. cerevisiae study captured His-tagged ubiquitin 
conjugates for MS analyses, whereas isotope enriched media was used to grow the 
HEK293 cells with total cell lysate used for subsequent MS experiments (13, 14).  
Table 1.1. Ubiquitin linkage abundance determined by quantitative mass spectrometry  
 
HEK293 Mammalian Cells (14) 
Lys6 ≤ 0.5% 
Lys11 2% 
Lys27 ≤ 0.5% 
Lys29 8% 
Lys33 ≤ 0.5% 
Lys48 52% 
Lys63 38% 
Saccharomyces cerevisiae (13) 
Lys6 10.9% ± 1.9% 
Lys11 28.0% ± 1.4% 
Lys27 9.0% ± 0.1% 
Lys29 3.2% ± 0.1% 
Lys33 3.5% ± 0.1% 
Lys48 29.1% ± 1.9% 
Lys63 16.3% ± 0.2% 
 
Ubiquitin’s seven lysines can be used to synthesize homotypic chains of one 
linkage type or heterotypic chains with multiple linkage types, as reviewed in (15). 
Certain E2-E3 enzyme pairs have been shown in vitro to synthesize exclusively 
homotypic chains, as in the case of UbcH5-Nedd4, or heterotypic chains, as in the case of 
UbcH5-Mdm2 (16). UbcH5-Mdm2 has an added capacity of forming branched 
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heterotypic chains (Figure 1.1B) in vitro. The physiological role and abundance of 
branched heterotypic chains is speculative, but they have been proposed to act as 
dominant negative inhibitors of the proteasome (16). Distinct functional roles have been 
associated with certain ubiquitin chain linkage types. Lys48-linked chains target their 
substrates for degradation by the 26S proteasome, as reviewed in (17), or lysosome, as 
reviewed in (18). Lys63 linked chains function in NF-kappaB signaling, DNA repair, and 
receptor endocytosis, as reviewed in (19, 20). Linear ubiquitin chains have also been 
implicated in the regulation of NF-kappaB activity, as reviewed in (21). Function specific 
to the other linkages has not yet been assigned, although some associations exist. Lys29-
linked chains can target proteins for degradation by lysosome and are synthesized in vitro 
by the E3’s AIP4 (atrophin-1-interacting protein 4) and UBE3C/KIAA10, although both 
of these enzymes also synthesize Lys48-linked chains (22, 23). Heterotypic 
Lys29/Lys33-linked chains are found on ARK5/NUAK1 (AMPK Related Kinase 5) and 
MARK4 (Microtubule-Affinity-Regulating Kinase 4). These two substrates belong to the 
AMPK-related kinase family, which is involved in cell polarity and proliferation and 
blocking kinase activation by interfering with phosphorylation sites (24). Homotypic 
Lys11-linked chains are associated with many cellular processes, including ERAD 
(Endoplasmic Reticulum Associated Degradation), endocytosis, TNF (Tumor Necrosis 
Factor) signaling, WNT signaling, and cell cycle control, as reviewed in (25). Lys6- and 
Lys27-linkages are the least well characterized; however, Lys6 may regulate DNA repair 
(26) and Lys27 may function in stress response pathways (27).  
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1.3 Ubiquitin: a protein modifier 
1.3.1. Monoubiquitin: placidity for multifaceted recognition 
Ubiquitin adopts a compact globular fold that is formed by a 5-stranded beta-
sheet, a short 310 helix, and a 3.5-turn alpha-helix (Figure 1.2A). This fold is also the 
foundation of a larger family of ubiquitin-like (UBL) domains, which will not be 
discussed in this manuscript, but are reviewed in (28, 29). The majority of UBDs interact 
with a hydrophobic patch formed on the surface of ubiquitin’s beta-sheet by Leu8, Ile44 
and Val70 (Figure 1.2A). The amino acids surrounding this hydrophobic triad are 
disparate in terms of charge and size enabling diverse UBD binding modes to this 
common surface (Figure 1.2B) (30). For example, TSG101’s UEV (Ubiquitin-
conjugating enzyme E2 Variant) domain directly contacts ubiquitin’s Gln62 (31), 
whereas this amino acid is not contacted by the Hrs DUIM (Double-sided Ubiquitin-
Interacting Motif) (32). Comparison of multiple UBD:ubiquitin complexed structures 
demonstrates differences in ubiquitin with its various binding partners. This variability is 
not generated by UBD binding, but rather present in free ubiquitin due to its intrinsic 
motions, according to NMR experiments (33). UBDs thus appear to select for their 
optimal conformer from ubiquitin molecules that have variable amino acid sidechain 
exposure for the canonical UBD recognition surface, including Leu8 and the beta1-beta2 
loop (Figure 1.1A) (33). Despite its conformational placidity, ubiquitin is a very stable 
protein that retains its fold at pH 4 up to ~75°C (34); for comparison, ubiquitin-like 
protein SUMO (Small Ubiquitin-like MOdifier) of similar fold and size denatures at 
~52°C (pH 5.6) (35). Ubiquitin’s placidity, coupled with its multifaceted recognition 
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surface, enables a broad spectrum of structural folds to be used as UBDs, 24 of which are 
listed in Table 1.2.  
 
Figure 1.2. Features of monoubiquitin (A) Ribbon diagram of monoubiquitin (PDB 
1D3Z) highlighting its seven lysines (blue), hydrophobic triad (Leu8, orange; Ile44, 
yellow; Val70, pink), and termini (Met1 and Gly76, beige). Secondary structural 
elements are labeled. (B) Electrostatic surface diagram of monoubiquitin rendered over 
its ribbon diagram with positive and negative charges displayed on the surface in blue 
and red, respectively, and hydrophobic regions in white. Heavy atoms of several charged 
amino acids, as well as those mentioned in the text are rendered as sticks and labeled. 
 
1.3.2 Polyubiquitin: diversity in chains 
Ubiquitin chains contribute an additional layer of diversity to the ubiquitin 
modifier, as these vary in both length and linkage type, as discussed in Section 1.2. They 
also expand the placidity present in monoubiquitin, as the linker region connecting 
ubiquitin moieties is flexible and allows diverse configurations for UBD-bound 
complexes (Figure 1.3).  For example, Lys63-linked diubiquitin adopts a more compact 
conformation when bound to a Lys63-linkage specific antibody (36) than when bound to 
AMSH (Associated Molecule with the Src Homology 3 domain of signal-transducing 
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adapter molecule), an endosome-associated ubiquitin isopeptidase (37). When not bound 
to a UBD, Lys48-linked tetraubiquitin exchanges (38) between a compact configuration 
with its ubiquitin moieties packed tightly against each other (39) and a more extended 
one (40) . The canonical UBD-binding surface is not accessible in the compact form of 
Lys48-linked diubiquitin (41) (Figure 1.3B) or tetraubiquitin (39) and UBDs are therefore 
expected to bind moieties in the extended form. For example, hHR23a’s C-terminal UBA 
(UBiquitin-Associated) domain interacts with the hydrophobic patches of both ubiquitin 
moieties from Lys48-linked diubiquitin (Figure 1.4C), which are inaccessible in its 
compact form (42). 
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Figure 1.3. Diversity of ubiquitin polymers. Ribbon representation of diubiquitin with 
the ubiquitin moieties linked via Gly76 and (A) Lys11 (PDB 2XEW), (B) Lys48 (PDB 
1AAR), (C) Lys63 (PDB 2JF5), and (D) Met1, so-called linear (PDB 2W9N). In all 
cases, the ubiquitin moiety with its Gly76 available for conjugation to a substrate is 
displayed in light blue whereas the more distal moiety is dark blue. The hydrophobic 
triad is colored as in Figure 1.2A and the lysine ligated to Gly76 is displayed in green for 
Lys11, Lys48, and Lys63 linkages or beige for Met1. 
 
Steric clashes prevent the ubiquitin moieties of Lys63-linked and linear 
polyubiquitin from packing against each other (43) (Figure 1.3C and D), whereas this 
configuration is possible for Lys11-linked chains as demonstrated by X-ray 
crystallography (44, 45) (Figure 1.2A) and predicted by molecular modeling (46). Lys6 
and Lys27 linkages are predicted to enable a compact conformation, whereas Lys29 and 
Lys33 linkages are not (46). It is possible that the isolation of ubiquitin hydrophobic 
patches that occurs in compactly configured ubiquitin chains prevents them from 
engaging in non-specific interactions. 
 
1.4 Ubiquitin-binding domains (UBDs) 
1.4.1 Structural diversity of UBDs 
 No general ubiquitin binding consensus element has been identified, requiring all 
UBDs to be discovered experimentally. As a group, UBDs use all structural elements to 
bind ubiquitin, and new UBDs continue to be identified. UBDs can be alpha-helical, ZnF, 
PH, Ubc-related, SH3, or WD40 beta-propellers. The following sections describe binding 
modes and functions of various UBD structural folds (summarized in Table 1.2). 
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Table 1.2. UBD structures 
Structural 
Fold 
Subclass Example 
Proteins 
Ubiquitin 
Signaling Role 
Referen
ces 
A
lp
ha
-h
el
ic
al
 
 
 
UIM 
Rap80 DNA repair (47,	  48) 
Vps27 Endocytosis (49) 
S5a/Rpn10 Proteasomal 
degradation 
(50-­‐52) 
STAM Endocytosis (53) 
Epsins (54) 
Ataxin 3 Deubiquitination (55) 
IUIM/MI
U 
Rabex-5 Endocytosis (56-­‐58) 
RNF168 DNA repair (59) 
DUIM Hrs Endocytosis (32) 
 
UBM 
Polymerase 
iota 
DNA repair (60,	  61) 
Reversionles
s 1 
(60) 
 
UBAN 
NEMO NF-kappaB 
signalling 
(62,	  63) 
ABIN1/2/3 (64) 
 
 
UBA 
hPLIC/Dsk2 Proteasomal 
degradation 
(65,	  66) 
hHR23/Rad2
3 
(66-­‐68) 
NBR1 Autophagy (69) 
p62 (70) 
CUE Vps9  
 
Endocytosis 
 
 
(71) 
 
GAT 
TOM1 (72,	  73) 
GGA3 (74,	  75) 
 
VHS 
STAM (76,	  77) 
GGA3 (78) 
UMI RNF168  
DNA repair 
(79) 
Zi
nc
-f
in
ge
r (
Zn
F)
 
 
UBZ 
Polymerase 
eta 
(80) 
Polymerase 
iota 
(81) 
TAX1BP1 NF-kappaB 
signaling 
(82) 
 
NZF 
TAB2/3 (83-­‐85) 
Vps36 Endocytosis (86) 
Npl4 ERAD (87) 
 
ZnF A20 
Rabex-5 Endocytosis (56-­‐58) 
A20 NF-kappaB 
signalling 
(88) 
 
ZnF UBP 
IsoT/USP5 Deubiquitination (89) 
HDAC6 Autophagy (90,	  91) 
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Pl
ec
ks
tri
n-
ho
m
ol
og
y 
(P
H
)  
PRU 
 
Rpn13 
Proteasomal 
degradation 
(92,	  93) 
 
GLUE 
 
Eap45 
Endocytosis (94-­‐96) 
U
bi
qu
iti
n 
co
nj
ug
at
in
g 
(U
B
C
)-
re
la
te
d  
UEV 
TSG101 Viral budding and 
VPS 
(31,	  97) 
Mms2 DNA repair (98) 
 
UBC 
 
UbcH5c 
Ubiquitin 
conjugation/chain 
assembly 
(99) 
Sr
c 
ho
m
ol
og
y 
(S
H
)  
 
SH3 
 
Sla1 
 
 
Endocytosis 
(100,	  
101) 
 
CIN85 
(102) 
W
D
40
  
WD40 
beta-
propeller 
PLAA/Doa1 ERAD  (103) Cdc4 Ubiquitin chain 
assembly 
A
dd
iti
on
al
 U
B
D
s 
PFU PLAA/Doa1 ERAD (104,	  
105) 
JAB1/MP
N 
Prp8 Pre-mRNA 
processing 
(106) 
DC-
UbP_N 
DC-UbP Ubiquitinated 
substrate delivery 
(104) 
MDA-9/ 
syntenin 
UBD 
 
MDA-
9/syntenin 
 
Endocytosis 
(107) 
Abbreviations: UIM (Ubiquitin-Interacting Motif), IUIM/MIU (Inverted UIM/Motif 
Interacting with Ubiquitin), DUIM (Double-sided UIM), UBM (Ubiquitin Binding 
Motif), UBAN (Ubiquitin Binding in ABIN and NEMO), UBA (UBiquitin Associated), 
GAT (GGA And TOM), CUE (Coupling of Ubiquitin conjugation to Endoplasmic 
reticulum degradation), VHS (Vps27/Hrs/STAM), ubiquitin-like binding domain of 
Ufd2, UMI (UIM- and MIU-related), UBZ (Ubiquitin-Binding ZnF), NZF (Npl4 
(Nuclear protein localization 4) Zinc Finger), ZnF A20 (Zinc Finger A20), ZnF 
UBP/PAZ (Zinc Finger UBiquitin-specific Protease/Polyubiquitin Associated Zinc 
finger), PRU (Pleckstrin-like Receptor for Ubiquitin), GLUE (Gram-Like Ubiquitin-
binding in Eap45), UEV (Ubiquitin-conjugating enzyme E2 Variant), UBC (UBiquitin-
Conjugating), SH3 (Src Homology 3), PFU (PLAA Family Ubiquitin binding), 
Jab1/MPN (Jun Activation-domain Binding protein 1/Mpr-Pad1-N-terminal), DC-UbP_N 
(Dendritic Cell-derived UBiquitin-like Protein N-terminal domain), WD40 beta-
propellers (WD40 beta-Prps), MDA-9/syntenin (Melanoma Differentiation Associated 
gene 9), ERAD (Endoplasmic Reticulum Associated Degradation), VPS (Vacuolar 
Protein Sorting) 
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1.4.1.1 Alpha-helical motifs 
Ubiquitin binding surfaces are most commonly formed by alpha-helices (Table 
1.2). A single alpha helix can define a UBD, as in the case of the UIM (Ubiquitin 
Interacting Motif), IUIM/MIU (Inverted UIM/Motif Interacting with Ubiquitin), UMI 
(UIM- and MIU-related) and DUIM (Double-sided UIM) domains. Ubiquitin binding is 
localized to a single surface of UIMs, MIUs, and the UMI. Experimentally derived 
structures of UIMs and an MIU have been solved complexed with ubiquitin; however, no 
experimental structure is available for the UMI, which is expected to be alpha-helical 
based on its sequence composition and so-named because of its sequence similarity to 
UIMs and MIUs (79). UIMs use a conserved LeuXXAlaLeu motif to bind the 
hydrophobic patch of ubiquitin, reviewed in (108, 109), whereas MIUs bind in an 
opposite orientation (LeuAlaXXLeu). The RING-finger ubiquitin ligase RNF168 
contains two MIUs and a UMI (59, 79), which uses a dileucine motif and not the 
conserved Ala residue of UIMs and MIUs to interact with ubiquitin (79). DUIMs harbor 
two ubiquitin-binding surfaces at opposite sides of a helix, as displayed in the X-ray 
crystallographic structure of Hrs (Hepatocyte growth factor-Regulated tyrosine kinase 
Substrate) complexed with two monoubiquitin molecules (32); Hrs functions in protein 
sorting during endocytosis, as reviewed in (110, 111).  
Alpha-helical ubiquitin-binding elements are invariably just one functional 
module within a multi-domain ubiquitin receptor, which can have multiple UBDs that are 
used together in novel ways to increase affinity for ubiquitin chains and in some cases, to 
define ubiquitin chain linkage specificity. Proteasome component S5a (51, 52), 
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endosomal sorting protein Vps27 (49), deubiquitinating enzyme Ataxin-3 (55), and DNA 
repair protein Rap80 (47, 48) are examples of ubiquitin receptors with multiple UIMs. In 
all cases, the UIMs are separated by flexible linker regions that are exploited to fit the 
signaling needs of the ubiquitin receptor. S5a’s two UIMs are poorly defined relative to 
each other when unbound or complexed with monoubiquitin (51). In binding to Lys48-
linked diubiquitin, however, S5a’s flexible linker region adapts to enable each UIM to 
contact a ubiquitin moiety simultaneously and thereby confer a significant increase in 
affinity compared to that for monoubiquitin (8.9 microM versus 350 microM to UIM1 
and 73 microM to UIM2) (52) (Figure 1.4A). The pliability of the region linking S5a’s 
UIMs likely contributes to its ability to also bind Lys63-linked chains with similar 
binding affinity (51, 112) and Lys29-, Lys6-, and Lys11-linked chains, albeit with lower 
affinity (112-114).  The adaptability of S5a’s UIM region may contribute to the 
proteasome’s capacity to degrade substrates of all ubiquitin chain linkages, an ability 
indicated by mass spectrometry-based experiments in S. cerevisiae (13). By contrast, the 
region linking Rap80’s UIMs undergoes a conformational switch to generate a 
continuous helix that spans its two UIMs and orients them optimally to bind Lys63-
linked chains (47, 48). The resulting specificity for Lys63-linked chains is consistent with 
Rap80’s role in DNA damage response (DDR) pathways, as reviewed in (115). 
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Figure 1.4. Alpha-helical ubiquitin-binding motifs. Ribbon representation of (A) S5a’s 
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UIM region (purple and pink) bound to Lys48-linked diubiquitin (PDB 2KDE), (B) 
NEMO’s UBAN domains (pink and magenta) bound to two linear diubiquitins (PDB 
2ZVO), and (C) hHR23a’s UBA domain (gold) sandwiched between the two ubiquitin 
moieties of Lys48-linked diubiquitin (PDB 1ZO6). The coloring scheme for diubiquitin 
follows that of Figure 1.3. 
 
UBDs can also gain ubiquitin linkage specificity by oligomerization. The UBAN 
(Ubiquitin Binding in ABIN and NEMO) domain of NEMO (NF-kappaB Essential 
MOdifier) (62, 63, 116) forms a coiled-coil homodimer that binds preferentially to 
Lys63-linked (63, 116-118) and linear ubiquitin chains (43, 62, 116). Its affinity for 
linear ubiquitin chains however is 100-fold higher than Lys63-linked chains (116), as the 
UBAN monomers bind in a bipartite manner to neighboring ubiquitin moieties of linear 
chains. Hydrophobic amino acids of one monomer interact with the Leu8-Ile44-Val70 
triad of the distal ubiquitin while polar amino acids of the other monomer interact with a 
surface adjacent to the proximal ubiquitin’s hydrophobic patch (62) (Figure 1.4B). When 
binding to Lys63-linked chains, NEMO recapitulates the interactions of the hydrophobic 
residues only, resulting in a single site-binding mode (63). The bipartite binding mode of 
UBAN to linear ubiquitin chains appears to be important for NEMO’s function as an NF-
kappaB activator, as mutation of either ubiquitin-binding site leads to the loss of 
IkappaBalpha degradation following TNF-alpha induction (62). 
Multiple alpha-helices can also define a UBD, as in the case of the UBM 
(Ubiquitin Binding Motif), CUE (Coupling of Ubiquitin conjugation to Endoplasmic 
reticulum), GAT (GGA and TOM), UBA (UBiquitin Associated), and VHS 
(Vps27/Hrs/STAM) domains. The UBM domains of the Upsilon DNA polymerase iota 
(Pol iota) and Reversionless 1 (Rev1) are the smallest multiple helical UBDs with two 
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amphipathic helices that bind a ubiquitin surface centered on Leu8 (119, 120). CUE, 
GAT, and UBA domains make up the bulk of the multiple alpha-helical domains and are 
comprised of a three-helix bundle. CUE and UBA domains are structurally similar, 
despite low sequence identity (17% between Vps9p CUE and Rad23 internal UBA 
(UBA1)) (71). Both use their alpha1 and alpha3 helices to bind ubiquitin’s hydrophobic 
patch, but UBA domains use a conserved Met/Leu-Gly-Phe/Tyr motif (121), whereas 
CUE domains use a Met-Phe-Pro motif (71). UBA domains are diverse in their 
preferences for ubiquitin chains of certain length and linkage type (112). Whereas the 
UBA from hPLIC1 (ubiquilin1) shows little preference between Lys29-, Lys48-, and 
Lys63-linked polyubiquitin (112, 122), hHR23a’s C-terminal UBA domain (UBA2) 
prefers Lys48 linkages over Lys63 linkages, as it sandwiches between neighboring 
ubiquitin moieties of Lys48-linked chains (Figure 1.4C) (42, 112, 123).  Full length 
hHR23a has two UBA domains that can bind concomitantly to ubiquitin (124), and its 
UBA1 also exhibits stronger affinity for Lys48-linked chains (67). Whereas dimeric UBA 
domains become monomeric to bind ubiquitin (125), CUE domains can bind to 
monoubiquitin as homodimers, as in the case of the Vps21p GTPase exchange factor 
Vps9p (71). CUE domains are published to prefer monoubiquitin, based on S. cerevisiae 
two-hybrid screens with ubiquitin mutants that lack primary sites for ubiquitin chain 
formation (126). They have however been found to bind to Lys48-linked chains in vitro 
(127). In contrast to CUE and UBA domains, GAT domains have been reported to bind 
two ubiquitin molecules through two distinct binding sites, or one ubiquitin molecule and 
an additional binding partner, as in the case of ESCRT (Endosomal Sorting Complex 
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Required for Transport) pathway proteins Tom1 (Target of Myb1) and GGA3 (Golgi-
localized, Gamma-ear-containing, ARF-binding protein 3) (72, 74).  
 VHS domains contain the most alpha helices of a UBD known to date with eight 
alpha-helices, and this UBD has recently been found to have Lys63-linkage specificity 
(53, 77). A surface that is primarily composed of amino acids from alpha2 and alpha4 is 
used by the VHS domains of ESCRT proteins Stam1 (76, 128) and Stam2 (77) to bind 
ubiquitin.  
   
1.4.1.2 Zinc finger (ZnF) 
 The second most abundant UBD structural fold is the ZnF domain, which is 
relatively small and stabilized by its coordination of one or more Zn ions. These have 
been shown to bind to three different regions of ubiquitin. Some bind to the Leu8-Ile44-
Val70 hydrophobic patch, such as UBZ (Ubiquitin-Binding ZnF) and NZF (Npl4 
(Nuclear protein localization 4) Zinc Finger) domains. NF-kappa B activator proteins 
TAB2 (TAK1-Binding protein 2) and TAB3 (TAK1-Binding protein 3) contain NZF 
domains that contact the Ile44-centered surface of neighboring ubiquitin moieties of 
Lys63-linked chains simultaneously (83, 85) (Figure 1.5) to preferentially bind this chain 
type (21, 83-86). The distal ubiquitin moiety binds a Thr-Phe dipeptide motif that is 
highly conserved among NZF domains and also used by Npl4’s NZF domain to bind 
monoubiquitin (83, 85-87). Direct contact to the Lys63 isopeptide linkage is not made by 
these NZF domains; however, the placement of the ubiquitin’s other lysines and Met1 
demonstrates that concurrent contact to the two distinct binding surfaces is likely to be 
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prohibited for chains formed by linkages other than Lys63 (Figure 1.5).  
 
Figure 1.5. Zinc-finger domain of TAB2. Ribbon diagram of TAB2’s NZF domain 
(green) complexed with K63-linked diubiquitin (PDB 3A9J). TAB2’s single zinc ion is 
rendered as a gold sphere and the coloring for diubiquitin follows that of Figure 1.3. 
 
The ZnF UBD of the E3 ligase Rabex-5 (Rab5 guanine Exchange factor) binds to 
a ubiquitin surface centered on Asp58 (Figure 1.2B) to which its Ser36 forms two 
hydrogen bonds (56, 57). Key contacts are also formed by two aromatic amino acids 
(Tyr25 and Tyr26) of Rabex-5 to ubiquitin’s Arg54, Thr55, Ser57, Asp58, Tyr59 and 
Asn60 (56, 57). This dityrosine motif plays an integral role in Rabex-5’s ability to bind to 
a ubiquitin-loaded E2 (UbcH5c), as binding is lost by its mutation to Ala (56). 
Deubiquitinating enzymes disassemble ubiquitin chains by catalyzing the 
hydrolysis of the isopeptide bonds that link the individual moieties together. These 
linkage sites use ubiquitin’s C-terminal Gly76, which was demonstrated to be required 
for interaction between ubiquitin and the ZnF UBP/PAZ of deubiquitinating enzyme 
isopeptidase T (IsoT/USP5) (89). This UBD has a deep pocket into which Gly75 and 
Gly76 insert and IsoT amino acids that interact with these glycines are required for its 
catalytic activation (89). A newly deposited crystal structure of HDAC6’s UBP/PAZ 
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domain bound to ubiquitin (PDB 3PHD) demonstrates ubiquitin’s C-terminal amino acids 
to be similarly sequestered into a deep pocket. IsoT/USP5 and HDAC6 use analogous 
contacts to ubiquitin’s C-terminal tail, as all but two of the seven interacting amino acids 
are conserved or functionally equivalent (89). 
 
1.4.1.3 Pleckstrin-homology (PH) 
Pleckstrin-homology (PH) domains are comprised of a 7-stranded beta-sheet with 
a C-terminal alpha-helix and many bind phosphoinositides (PIs) within membranes to 
function in intracellular signaling. Two PH domains have been reported to bind to 
ubiquitin, including that within ESCRT-II Eap45, termed GLUE (Gram-Like Ubiquitin-
binding in Eap45) (96), and the proteasome component Rpn13, termed PRU (Pleckstrin-
like Receptor for Ubiquitin) (92, 93). A region of Eap45’s GLUE domain that contains 
the C-terminal end of its alpha-helix, beta5, beta6, and the beta6-beta7 loop binds to the 
Ile44 centered surface of ubiquitin, as demonstrated by X-ray crystallography (94, 95) 
(Figure 1.6A). This ubiquitin-binding surface is at an opposite location relative to the 
proposed site that binds PIs, thereby suggesting that these two surfaces are used together 
to bring ubiquitinated cargo to the endosomal membrane (94, 95, 129, 130).  
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Figure 1.6. Pleckstrin-homology domains. Ribbon representation of (A) Eap45’s GLUE 
domain (red) bound to monoubiquitin (PDB 2DX5) and (B) Rpn13’s PRU domain (grey 
with ubiquitin-binding loops in red) bound to Lys48-linked diubiquitin (generated from 
PDB 2Z59 and 1D3Z). The ubiquitin coloring is as described in Figure 1.3, but with 
His68 included in beige. 
 
Rpn13’s PRU domain by contrast does not appear to bind to PIs, but rather uses a 
surface opposite to its ubiquitin-binding one to dock into the proteasome (93) (Figure 
1.6B). It uses three loops to contact ubiquitin (Figure 1.6B), including its beta4-beta5 
loop, which contains two Asp’s (Asp78 and Asp79) that form hydrogen bonds with 
ubiquitin’s His68. Phe76 from this loop interacts with ubiquitin’s Ile44, Gln49, and 
Val70 and its mutation to Arg abrogates Rpn13’s ability to bind to ubiquitin (93). 
Rpn13’s PRU has a high affinity for ubiquitin (300 nanoM for monoubiquitin, 90 nanoM 
for Lys48-linked diubiquitin) (92) compared to S5a (52), the proteasome’s other ubiquitin 
receptor. This affinity however is reduced in the full length protein due to interactions 
between its PRU domain and its C-terminal Uch37-binding domain (131), as discussed 
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further in Section 1.4.2. When binding to a Lys48-linked chain, Rpn13 prefers the 
proximal subunit (Figure 1.6B), most likely due to the loss of charge on its Lys48 (93). 
The use of loops to bind ubiquitin highlights the difficulty in predicting UBDs based on 
sequence information alone and the discovery that Rpn13 is a ubiquitin receptor in the 
proteasome (92) was 14 years after S5a was reported to be one (132).  
 
1.4.1.4 Ubiquitin-conjugating (Ubc)-related 
Ubc (UBiquitin-Conjugating) domains are found in E2 enzymes and are 
comprised of ~150 amino acids that fold into four standard helices and a 4-stranded 
antiparallel beta-sheet, as reviewed in (133). Generally, Ubc domains contain a conserved 
catalytic cysteine that forms a thiolester bond with ubiquitin, as discussed in Section 1.2. 
All E2’s interact with ubiquitin covalently, but noncovalent interaction surfaces have also 
been identified, as in UbcH5c (99). UbcH5c’s non-covalent ubiquitin-binding surface is 
opposite to the E2 catalytic Cys (Figure 1.7A) and is essential for the processive nature of 
BRCA1 (BReast CAncer type 1)-mediated polyubiquitination, allowing multiple 
ubiquitination cycles to a bound substrate (99). UbcH5a and UbcH5b also use this non-
covalent ubiquitin-binding surface (134), and UbcH5a has an additional ubiquitin-binding 
surface that is proposed to govern Lys11-linked chain formation, as a surface adjacent to 
its catalytic Cys interacts with a ubiquitin surface that flanks its Lys11 (135). 
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Figure 1.7. Ubc-like domains complexed with ubiquitin. Ribbon representation of (A) 
UbcH5c (cyan, PDB 2FUH) and (B) TSG101 UEV (green, PDB 1S1Q) bound to 
monoubiquitin colored as in Figure 1.3. UbcH5c’s catalytic cysteine (Cys85) is displayed 
in red. 
 
The UEV (Ubiquitin-conjugating enzyme E2 Variant) domain has an alpha/beta 
fold similar to Ubc domains, but has an additional N-terminal helix, an extended beta-
hairpin linking beta1 and beta2 and lacks Ubc’s two C-terminal helices (31). UEV 
domains are not E2’s as they lack the catalytic Cys residue, but they can bind ubiquitin 
non-covalently, as in the case of TSG101, which functions in Human Immunodeficiency 
Virus-1 (HIV-1) budding and MVB (MultiVesicular Body) sorting (31). TSG101’s UEV 
domain and UbcH5c bind ubiquitin differently (Figure 1.7), as the extended beta-hairpin 
is used by this UEV as well as the loop that follows beta4 (Figure 1.7B) (31, 99).  
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1.4.1.5 Src homology 3 (SH3) 
Approximately 300 SH3 domains are encoded in the human genome (136). They 
are formed by ~60 amino acids, which assume a beta-barrel fold and tend to promote 
protein-protein interactions, most often by binding to proline-rich regions (ProXXPro) 
(137). SH3 domains of S. cerevisiae Sla1 (101), its mammalian orthologue CIN85 (102), 
and amphiphysin (100) are reported to bind to ubiquitin. Sla1’s third SH3 (SH3-3) 
domain uses complementary hydrophobic residues from a shallow groove present in all 
SH3 domains to bind the hydrophobic patch of monoubiquitin, as revealed by solution 
NMR (101) (Figure 1.8). This shallow groove is typically used to bind ProXXPro or 
ProXXProArg motifs (100-102), suggesting a competition between ubiquitin and 
ProXXPro/Arg binding partners. Like its yeast orthologue, CIN85 contains three SH3 
domains, but in contrast to Sla1, all three bind ubiquitin (100, 102).  
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Figure 1.8. SH3 domain of Sla1. Ribbon representation of the SH3 domain of Sla1 
(yellow) bound to monoubiquitin colored as in Figure 1.3 (PDB 2JT4). 
 
1.4.1.6 Additional UBDs 
 Many other structural folds have evolved ubiquitin-binding surfaces. In the past 
year, novel UBD structural folds have been described in the N-terminal domain of DC-
UbP (104), WD40 beta-propellers (103), and MDA-9/syntenin (107). DC-UbP’s N-
terminal ubiquitin-binding domain forms an alpha-alpha-alpha-beta-beta pattern with a 
short C-terminal alpha-helix (104). It binds to ubiquitin’s hydrophobic patch and C-
terminal residues (Leu71, Arg72, and Leu72) by using amino acids from the alpha1-
alpha2 loop, alpha2, alpha3, and the beta1-beta2 loop (104). The C-terminal region of 
DC-UbP contains a UBL domain (138), thereby linking it to the UBL-UBA family of 
proteins, which include hHR23 and hPLIC, discussed in Section 1.4.1.1.  
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WD40 beta-propellers from functionally diverse proteins bind to ubiquitin’s 
hydrophobic patch through a conserved surface made up of loops; these include 
components of SCF ubiquitin E3 ligases and AAA ATPase Cdc48/p97 adaptor 
Doa1/Ufd3 (103). Doa1/Ufd3 also contains a PFU domain (PLAA family Ub-binding 
domain), which binds to ubiquitin (105). It is not yet known whether Doa1’s UBDs are 
used synergistically to confer specificity for ubiquitin chain linkage type, however it 
appears to bind preferentially to longer ubiquitin chains (139).  
  
1.4.2 UBD Regulation 
There are many mechanisms to keep UBDs in check, which have perhaps arisen 
due to their widespread use and abundance. UBD regulation can occur through 
intramolecular activities involving the ubiquitin receptor or alternatively, by modification 
of the substrate. Intramolecular interactions between UBDs and other domains within a 
ubiquitin receptor or that involve a ubiquitin conjugated to the receptor itself can reduce a 
receptor’s affinity for ubiquitinated substrates. Ubiquitin receptors Rpn13 and hHR23a, 
which function in proteasome-mediated protein degradation, have additional domains that 
interact with their UBDs. Rpn13’s PRU binds its C-terminal Uch37-binding domain, 
which reduces the exposure of its ubiquitin binding surface and in turn, its affinity for 
ubiquitin (131). Rpn13 docking into the proteasome appears to abrogate this 
intramolecular interaction, thereby functionally coupling its activity as a ubiquitin 
receptor to its localization to proteasome (131). hHR23a’s UBA and UBL domains 
similarly interact to reduce ubiquitin accessibility (140). Moreover, monoubiquitination 
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of UBD-containing proteins causes the UBD to interact with its own conjugated ubiquitin 
rather than a substrate-attached one. This process, termed coupled monoubiquitination 
(141, 142), regulates Eps15 (UIM), Sts1 (UBA), Sts2 (UBA), Hrs (DUIM) and the MDA-
9/syntenin UBD (141, 143, 144). Intermolecular interactions involving UBDs can also 
regulate ubiquitin receptor binding to ubiquitinated substrates, as in the case of p47, 
which is unable to bind monoubiquitin via its UBA domain unless it is complexed with 
p97 (145, 146). Post-translational modifications of substrates can also regulate UBD 
activity, including selective methylation of Lys residues, phosphorylation (as reviewed in 
(147)), and conjugation with ubiquitin-like proteins (such as SUMO, as reviewed in (29, 
148)).  Methylation of Lys side-chains prevents ubiquitination, causing loss of UBD 
interaction and prolonged protein half-life (149). A recent MS study done on the S. 
cerevisiae 26S proteasome suggests that 43% of Lys methylation sites in over 40 proteins 
are also sites for ubiquitination (150).  
 
1.5 Perspective: summary and future 
Ubiquitin’s signaling prowess was first discovered for its ability to target 
substrates for degradation by proteasome (151, 152), but has now expanded to encompass 
a myriad of processes including regulatory roles in DNA repair, transcription, pre-mRNA 
splicing, endocytosis and autophagy, as reviewed in (18). Its function as a signaling 
molecule in such a broad spectrum of activities is tightly coupled to its multilingualism 
for a plethora of diverse receptors, which is contributed by monoubiquitin’s dynamic 
sampling of slightly different confomers, the diversity of the region connecting moieties 
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within a ubiquitin chain, and the variations available in ubiquitin chain length and 
linkage. Structures of UBDs complexed with ubiquitin polymers have provided valuable 
insights into how ubiquitin signals for such a large repertoire of events with specificity. 
Some questions remain however. With the notable exception of ZnF domains, which can 
bind to three different ubiquitin surfaces, the vast majority of UBDs seek a common 
surface on ubiquitin, thus suggesting a packing problem as ubiquitin is shuttled from one 
receptor to another, or as multiple receptors are present and available for binding. It is 
tantalizing to speculate that these potential hurdles have been evolutionarily exploited, 
such as by preventing two receptors from distinct pathways from battling over where to 
shuttle their commonly bound substrate. New UBDs and mechanisms for their regulation 
continue to be discovered and it is interesting that so many structural domains can form 
surfaces that bind ubiquitin. Yet, it is not always clear how one domain type assumed 
ubiquitin-binding capacity for some of its members. Finally, it is often challenging to 
extrapolate the intricacies of a ubiquitin signaling cascade from the snapshots provided 
by UBD:ubiquitin complexes. It is hopeful that the future will offer atomic resolution 
images of ubiquitinated substrates complexed with their ubiquitin receptors as they are 
shuttled through a ubiquitin signaling pathway. Such information would provide a greater 
appreciation of how individual UBDs are integrated into the ubiquitin signaling highway. 
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2.1 Synopsis 
Proteasomal receptors that recognize ubiquitin chains attached to substrates are 
key mediators of selective protein degradation in eukaryotes. In this chapter we report the 
identification of a new ubiquitin receptor, Rpn13/ARM1, a known component of the 
proteasome. Rpn13 binds ubiquitin through a conserved amino-terminal region termed 
the pleckstrin-like receptor for ubiquitin (Pru) domain, which binds K48-linked 
diubiquitin with an affinity of approximately 90  nM. Like proteasomal ubiquitin receptor 
Rpn10/S5a, Rpn13 also binds ubiquitin-like (UBL) domains of UBL-ubiquitin-associated 
(UBA) proteins. In yeast, a synthetic phenotype results when specific mutations of the 
ubiquitin binding sites of Rpn10 and Rpn13 are combined, indicating functional linkage 
between these ubiquitin receptors. Because Rpn13 is also the proteasomal receptor for 
Uch37, a deubiquitinating enzyme, our findings suggest a coupling of chain recognition 
and disassembly at the proteasome. 
 
2.2 Introduction 
In eukaryotes, selective protein degradation is performed primarily by the 
ubiquitin–proteasome pathway. The 26S proteasome is a huge macromolecular machine 
that contains a proteolytically active 20S core particle capped at one or both ends by a 
19S regulatory particle (153). The regulatory particle recognizes ubiquitinated substrates, 
deconjugates ubiquitin chains and unfolds substrates before their translocation into the 
core particle. Proteasome subunit Rpn10/S5a was shown to bind ubiquitin chains through 
ubiquitin-interacting motifs (UIMs) (132). Receptors were subsequently identified that 
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are not integral proteasome subunits, but deliver ubiquitinated targets to the proteasome 
(for reviews, see refs (154) and (155)). Canonical members of this UBL/UBA family of 
receptors are Rad23 (hHR23a/b in humans), Dsk2 (hPLIC-1/2 in humans) and Ddi1 (refs 
(156-160)). UBA domains of this protein family bind ubiquitin(124, 161, 162), whereas 
(163) their UBL domains interact reversibly with the proteasome, principally through 
Rpn1, but potentially also through Rpn10 (refs (164-166)). 
Another interesting component of the proteasome is Rpn13/ADRM1/ARM1 (refs 
(163, 167-171)), which docks at the regulatory particle through an N-terminal region that 
binds Rpn2 (refs (169), (163, 172, 173)). Its carboxy-terminal region binds 
deubiquitinating enzyme Uch37/UCHL5 and enhances its isopeptidase activity(169, 171). 
Uch37 may function as an editing isopeptidase that rescues poorly ubiquitinated 
substrates from being degraded (174). 
 
2.3 Results 
2.3.1 A ubiquitin-interactor screen identifies Rpn13 
Using a yeast two-hybrid screen, with a bait of ubiquitin lacking the last two 
glycines to prevent its conjugation (119), we identified the N-terminal segment of human 
Rpn13 (hRpn13) as a ubiquitin-binding partner. The interaction was confirmed using 
murine Rpn13 (mRpn13) as bait against monoubiquitin and Rpn2 as prey (Figure 2.1A). 
Rpn13 from Saccharomyces cerevisiae (scRpn13) aligns with the ubiquitin-binding N-
terminal region of hRpn13 (Figure 2.1B). Comprehensive sequence analysis using 
profiles and hidden Markov models failed to reveal similarity to known ubiquitin- or 
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proteasome-binding motifs (Figure 2.1C and data not shown). Deletion mutants 
encompassing residues 1–150 were tested for tetraubiquitin binding, thus mapping the 
minimal binding domain to residues 1–130 (Figure 2.1D). Although smaller fragments of 
mRpn13 also showed detectable binding to ubiquitin, they were unstable and expressed 
poorly as glutathione S-transferase (GST) fusions. 
 
Figure 2.1. Murine Rpn13 binds ubiquitin chains. (A) mRpn13 cDNA fragments were 
cloned into pYTH9 vector in frame with the Gal4 DNA-binding domain. The resulting 
bait vectors were transformed into yeast strain Y190 with prey pACT2 vectors containing 
wild-type ubiquitin, I44A ubiquitin or hRpn2 (positive binding control) cDNA in frame 
with Gal4 DNA-activating domain. (B) Architecture of Rpn13 from various species. The 
N-terminal domain is generally conserved (black box) whereas the C-terminal region 
(grey box) is absent in S. cerevisiae and has diverged beyond recognition in one of the 
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two Saccharomyces pombe proteins (S. pombe (1)). S. pombe (1) = SPCC16A11.16; S. 
pombe (2) = SPBC342.04. The percentage identity to the conserved hRpn13 Pru domain 
is provided at right. (C) Alignment of Rpn13 N-terminal sequences. Residues that are 
invariant or conserved in at least 50% of sequences are shaded in black or grey, 
respectively. (D) To identify the minimal region required for ubiquitin binding, mRpn13 
deletion mutants were expressed as GST-fused proteins, purified and tested for their 
binding to linear tetraubiquitin by immunoblotting with anti-ubiquitin antibodies. 
Tetraubiquitin was obtained by thrombin cleavage of GST-fused tetraubiquitin (GST 
4×Ub) and equivalent amounts of GST-fused deletion mutants were used in GST pull-
down assay. 
The significance of the ubiquitin–Rpn13 interaction would be supported if it were 
conserved from yeast to mammals, particularly as budding yeast Rpn13 is truncated and 
the conserved N-terminal region (Figure 2.1C) is only 25% identical to mammalian forms 
(Figure 2.1B). The existence of an unidentified ubiquitin receptor in yeast had been 
evident to us from the viability of an rpn10-uim rad23Δ dsk2Δ ddi1Δ mutant (data not 
shown). rpn13Δ mutants, which are viable but show defects in protein degradation (167, 
175), were used to test whether Rpn13 binds ubiquitin chains in the context of intact, 
purified proteasomes. 
 
2.3.2 Rpn13 docks ubiquitin conjugates at the proteasome 
Ubiquitin chain binding by purified proteasomes can be assayed by native gel 
electrophoresis(156, 165). Proteasomes are visualized in this system by an activity stain, 
using a fluorogenic peptide substrate. For wild type, the predominant proteasome species 
contains one regulatory particle on either end of the core particle cylinder (RP2CP). 
Ubiquitin chains, produced by the E2 enzyme Cdc34, bind to the proteasomes and confer 
reduced mobility (Figure 2.2A). This shift is not dependent on UBL/UBA proteins, 
because the proteasomes were prepared from rad23Δ dsk2Δ ddi1Δ mutants. A block 
  35 
substitution within the UIM in Rpn10 results in attenuation of the shift, reflecting 
Rpn10’s known ubiquitin receptor function (Figure 2.2A; refs (156) and (157)). 
However, the existence of marked residual electrophoretic retardation by added chains 
(lane 4) indicates the presence of at least one additional ubiquitin receptor in purified 
proteasomes. 
 
Figure 2.2. Rpn13 contributes to recognition of ubiquitin conjugates by the proteasome. 
(A) rpn13Δ proteasomes show defects in ubiquitin conjugate binding. Proteasomes were 
purified from strains (SY733, SY729, SY725 and SY722) bearing the indicated 
mutations. Proteasomes (4  pmol) were mixed with autoubiquitinated Cdc34 (16  pmol), 
resolved by native PAGE, and visualized using N-succinyl-Leu-Leu-Val-Tyr-(7-amino-4-
methylcoumarin) (LLVY–AMC). Note that UBL/UBA proteins cannot contribute to 
ubiquitin chain binding in these experiments, because all proteasomes used in this figure 
are from a rad23Δ dsk2Δ ddi1Δ genetic background. ubp6Δ is also in the genetic 
background, to prevent chain disassembly during the assay. (B) Proteasome composition 
is maintained in the absence of Rpn13. Proteasomes from (A) (25  µg) were resolved by 
SDS–PAGE and stained with Coomassie blue. An asterisk marks contaminating protein. 
(C) Reconstitution of ubiquitin conjugate binding. A subset of proteasomes from (A) 
(4  pmol each) was incubated with scRpn13 (20  pmol) cleaved from the GST moiety (+ 
lanes) or GST alone (remaining lanes) to allow reassembly, then mixed with 
autoubiquitinated Cdc34 (16  pmol). Complexes were resolved by native PAGE and 
visualized as in (A). 
 
Addition of conjugates to proteasomes lacking Rpn13 resulted in an 
electrophoretic shift comparable to that of rpn10-uim samples (Figure 2.2A). Thus the 
yeast orthologue of mRpn13 is active in ubiquitin chain binding and can bind ubiquitin in 
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the context of intact proteasomes. Indeed, its capacity for chain binding in this assay 
compares well with that of Rpn10. Remarkably, we observed an ostensibly complete 
abrogation of chain-dependent electrophoretic retardation when rpn10-uim rpn13Δ 
proteasomes were used (Figure 2.2A), suggesting that Rpn10 and Rpn13 are the two 
major ubiquitin receptors in the yeast proteasome. However, by varying the conditions of 
this assay, we could, as shown below, detect residual ubiquitin chain binding with rpn10-
uim rpn13Δ proteasomes, consistent with the existence of a still-unidentified proteasomal 
ubiquitin receptor. The greater abundance of the RP1CP and core particle bands in 
rpn13Δ samples suggests that Rpn13 contributes to the stability of the regulatory 
particle–core particle interaction in vitro (175). 
To determine whether rpn13Δ proteasomes were properly assembled, they were 
analyzed by SDS–polyacrylamide gel electrophoresis (SDS–PAGE) (Figure 2.2B). Apart 
from the absence of Rpn13 itself, the mutant proteasomes appeared to be wild type in 
composition. When recombinant Rpn13 was reconstituted onto mutant proteasomes after 
purification, their chain-binding defect was corrected (Figure 2.2C). Thus, the chain-
binding assay appears to report on a specific Rpn13–ubiquitin chain interaction, and not a 
gross structural defect of rpn13Δ proteasomes. GST pull-down assays also indicated 
direct interaction of scRpn13 with ubiquitin (data not shown). In summary, these data 
indicate that Rpn13 is a novel proteasomal ubiquitin receptor. 
 
2.3.3 Loops of yeast Rpn13 bind ubiquitin 
To create mutants of scRpn13 deficient in ubiquitin binding and to study the 
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functional significance of the interaction in vivo subsequently, we initially used NMR to 
solve the structure of full-length scRpn13. These studies revealed that Thr6–Leu101 
forms two contiguous, antiparallel β-sheets with a configuration similar to the pleckstrin-
homology structural domain (Figure 2.3A). In particular, a β-sheet comprising four 
antiparallel β-strands formed by I8–R11, E32–P37, W46–W50, and I64–L66 packs 
against a three-stranded sheet formed by M74–V76, I86–V90, and R96–W100. 
Juxtaposed to the three-stranded sheet are two β-strands formed by C15–N18 and L23–
P26. The configuration of the β-strands centers around interactions between conserved 
aromatics within the protein core, including F10, F48, W50, W75, F87, F91, F98, F99 
and W100. These findings are consistent with the crystal structure, described in Chapter 
3, of mRpn13. We thus named this domain pleckstrin-like receptor for ubiquitin (Pru). In 
a canonical pleckstrin-homology domain, K117–N130 of scRpn13 would be α-helical, 
consistent with secondary structure predictions for K119–G127. Residues S106–G127 are 
absent, however, from all acquired spectra, suggesting that this region undergoes 
conformational exchange and does not form a rigid helix. In contrast, the cognate 
residues in mRpn13 and hRpn13 do form helices (93). K117–N130 of scRpn13 shares 
35.7% sequence identity with mRpn13, but the presence of a glycine at position 127 
likely destabilizes the helix, as might substitution of the sequence QDE at the beginning 
of the helix with the more basic sequence KDK in scRpn13. Also, a salt bridge, described 
in Chapter 3, between E119 and R122 of mammalian Rpn13 is lost, as R122 is 
substituted with N123 in scRpn13. 
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Figure 2.3. Rpn13 uses loops to bind ubiquitin. (A) Stereo view of scRpn13, spanning 
residues T6–L101, in which β-strands are indicated in blue and hydrophobic side chains 
in yellow. (B) NMR titration experiments reveal scRpn13 residues that contact ubiquitin. 
The data were prepared as described in Methods and plotted. (C) ScRpn13 residues that 
bind ubiquitin are within the S2–S3, S4–S5 and S6–S7 loops. Residues significantly 
affected by ubiquitin addition are displayed and labeled in red with their secondary 
structures in blue. (D) scRpn13-KKD affinity for monoubiquitin is significantly reduced 
compared with wild type. Normalized chemical-shift perturbation values are plotted 
against molar ratios of monoubiquitin to wild-type scRpn13 (WT, red, green) or 
monoubiquitin to scRpn13-KKD (KKD, blue, purple). Each data line represents a 
specific amino acid, namely F45 (red and blue) and E72 (green and purple). Using 
Matlab version 7.2, the data were fitted to determine a binding constant of 65  µM for 
wild-type scRpn13 and an eightfold reduction in the affinity of scRpn13-KKD for 
monoubiquitin. 
 
To determine how scRpn13 binds ubiquitin, we performed an NMR titration 
series (Figure 2.S1), which implicated E41, E42, G44, F45, L66, E72, F91, S93 and R96 
as being at the ubiquitin contact surface (Figure 2.3B). Interestingly, these residues are in 
the S2–S3, S4–S5 and S6–S7 loops (Figure 2.3C). The S4–S5 loop is strongly conserved 
in higher eukaryotes, as is F91, which is in the S6–S7 loop (Figures 2.1C and 2.3A). 
scRpn13 binding to monoubiquitin is in ‘fast exchange’ by NMR, which is ideal for 
determining binding affinity by this method, and the affinity of scRpn13 for 
monoubiquitin was determined to be 65  µM (Figure 2.3D). 
 
2.3.4 Rpn13 binds K48-linked diubiquitin with high affinity 
 We used NMR titration experiments to determine the stoichiometry of hRpn13 for 
monoubiquitin, K48-linked diubiquitin and tetraubiquitin (see Section 2.7.1). 
Monoubiquitin and diubiquitin bound to Rpn13 with 1:1 stoichiometry, whereas two 
Rpn13 molecules bound one tetraubiquitin (Figure 2.4A,B). Therefore, although three 
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potential diubiquitin elements exist within tetraubiquitin, no more than two Rpn13 
molecules can be accommodated simultaneously. The exclusion of a third Rpn13 
molecule is consistent with model structures of Rpn13–tetraubiquitin, in which steric 
clashes arise when three hRpn13 molecules bind neighboring K48-linked ubiquitin 
subunits (Figure 2.S2). That Rpn13 binds diubiquitin elements of K48-linked chains is 
further validated in Chapter 3. 
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Figure 2.4. Rpn13 binds to ubiquitin and UBLs of proteasomal receptors. (A),(B) 
hRpn13 Pru binds K48-linked diubiquitin and monoubiquitin with 1:1 stoichiometry, 
whereas two hRpn13 Pru molecules bind one K48-linked tetraubiquitin. Normalized 
chemical shift perturbation values are plotted against varying molar ratios of Rpn13 to 
tetraubiquitin ((A), shades of blue), diubiquitin ((B), shades of red), or monoubiquitin 
((A), shades of green) to reveal respective Rpn13–ubiquitin binding stoichiometries of 
2:1, 1:1 or 1:1. Each data line represents a specific amino acid as indicated in the figure, 
with values determined as described in Section 2.6.1 (C) Binding curves for hRpn13 Pru 
binding to monoubiquitin or K48-linked diubiquitin as determined by intrinsic tryptophan 
fluorescence. Normalized fluorescence intensity values are plotted for two data sets 
against varying concentrations of monoubiquitin (red and orange) or diubiquitin (blue 
and light blue). The data were fitted by assuming 1:1 binding for hRpn13 Pru and 
monoubiquitin (orange) or diubiquitin (light blue). (D) Table of hRpn13 Pru binding 
affinities for K48-linked diubiquitin, monoubiquitin and the UBL domain of hHR23a. 
Values for ubiquitin binding were determined by using the fluorescence data of (C). 
NMR titration curves were used to determine the value for the UBL domain of hHR23a. 
(E) mRpn13 Pru binds to the hydrophobic patch of ubiquitin containing I44. mRpn13 Pru 
domain was used in GST pull-down assays to assess binding to GST-tagged 
monoubiquitin and its mutant derivatives (I44A and triple mutant (3M*) L8–I44–V70). f, 
mRpn13 Pru domain was used in GST pull-down assays (as in (E)) to assess its binding 
to GST-fused ubiquitin-like protein modifiers. (G) Rpn13 binds to the hPLIC2 and 
hHR23A UBL domains. 1H, 15N heteronuclear single-quantum coherence spectra of 15N-
labelled hRpn13 Pru alone (black) and with twofold molar excess hPLIC2 (red) or 
hHR23A (blue) UBL domain indicates their direct interaction. Although the effect is 
greater for hPLIC2, these two UBL domains affect common residues in hRpn13 Pru, 
suggesting that they bind the same surface. 
 
In contrast to scRpn13, resonances broaden and shift as hRpn13 Pru binds 
monoubiquitin (Figure 2.S3). This behavior is associated with stronger Kd values, but 
prohibits their accurate calculation by the method used to determine the scRpn13–
ubiquitin affinity. Fluorescence spectrophotometry was therefore used to determine 
hRpn13’s affinity for monoubiquitin and diubiquitin, as hRpn13 (residues 1–150) 
contains two tryptophan residues and ubiquitin none. hRpn13 showed a surprisingly high 
affinity, with a Kd value for monoubiquitin of about 300  nM (Figure 2.4C,D) and for 
diubiquitin of about 90  nM (Figure 2.4C,D). The value for diubiquitin binding is about 
15-fold lower than that of hHR23a for tetraubiquitin (67). The higher affinity of hRpn13 
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for ubiquitin, compared with scRpn13, reflects amino-acid substitutions at the contact 
surface. For example, residues F76 and D78 of hRpn13 were implicated in hRpn13 
binding to monoubiquitin, as discussed in Chapter 3. In scRpn13, however, these residues 
are substituted with isoleucine and glycine, respectively. 
 
2.3.5 Rpn13 recognizes a subset of ubiquitin-like proteins 
 We next analyzed whether Rpn13 exhibits specificity for ubiquitin or broadly 
recognizes ubiquitin family members. Using GST pull-down assays, we confirmed that 
ubiquitin binds to full-length mRpn13 and that this interaction requires ubiquitin’s 
hydrophobic patch, consisting of L8, I44 and V70 (Figure 2.4E). mRpn13 bound more 
potently to linear tetraubiquitin expressed as a GST fusion (GST 4×Ub) or to purified 
K48-linked chains than to monoubiquitin (Figure 2.4E and data not shown). Under the 
same experimental conditions, no binding was observed between the mRpn13 Pru 
domain and SUMO, Nedd8, ISG15 or FAT10 (Figure 2.4F). By contrast, mRpn13 
appeared to bind to the UBL domains of multiple UBL/UBA proteins (Figures 2.S4 and 
2.S5). We verified that hRpn13 Pru binds directly to the hHR23a and hPLIC2 UBL 
domains by NMR (Figure 2.4G), and determined a Kd value of 36  µM for the hRpn13 
Pru–hHR23a UBL domain complex (Figures 2.4G and 2.S5). Overlapping residues in 
hRpn13 were affected by the addition of these UBL domains (Figure 2.4G) or ubiquitin 
(93), suggesting that these interactions may be mutually exclusive. 
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2.3.6 Rpn13 mutant defective in ubiquitin recognition 
Experiments described above implicated residues in Rpn13’s S2–S3, S4–S5 and 
S6–S7 loops in binding ubiquitin (Figure 2.3). After introducing non-conservative 
substitutions for these residues individually or in combination, the resulting proteins were 
expressed in Escherichia coli, purified and characterized. We sought mutants that were 
defective in ubiquitin chain binding while being properly folded and proficient in 
proteasome binding. Separation of these functions is critical, as exemplified by previous 
studies of proteasomal ubiquitin receptor Rpn10. The rpn10Δ phenotype does not 
accurately reflect its function in ubiquitin recognition, because Rpn10 plays additional 
roles in the proteasome (157, 176). The proteasome is destabilized in the absence of 
Rpn10 (ref. (176)), as is also observed in rpn13Δ mutants, at least under certain in vitro 
conditions (Figure 2.2; ref. (175)). For Rpn13, unlike Rpn10, proteasome and ubiquitin 
binding are conferred by the same structural domain, and thus can be effectively 
separated only by precisely targeted mutations. Moreover, ubiquitin contact residues in 
Rpn13 are distributed over three distinct loops, and thus differ from those of Rpn10 by 
being non-contiguous and so not subject to simple block mutagenesis. 
We assayed Rpn13–proteasome binding by adding GST–Rpn13 to purified 
proteasomes. Because of the GST moiety, the fusion protein results in strong 
electrophoretic retardation in native gels; this effect is seen with rpn13Δ but not wild-
type proteasomes (Figure 2.5A). Thus Rpn13 assembled into the proteasome was not 
exchangeable with added GST–Rpn13, indicating that scRpn13 is a true proteasome 
subunit. Two putative ubiquitin contact-site mutants of Rpn13 were shown to be 
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proficient in proteasome assembly (Figure 2.5B). Several other mutants failed to pass this 
and other preliminary assays, typically because of global folding defects (data not 
shown). E41 and E42 are in the S2–S3 loop, and S93 in the S6–S7 loop (Figure 2.5C). 
These sites, though greater than 22  Å apart, are both situated proximally to bound 
ubiquitin in a model based on the mRpn13–monoubiquitin structure described in Chapter 
3 (Figure 2.5C). 
  46 
 
Figure 2.5. An Rpn13 mutant specifically defective in ubiquitin chain binding. (A) 
Reconstitution of proteasomes with recombinant GST–Rpn13. Proteasomes were purified 
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from strains containing or lacking Rpn13 (SY775 and SY723). GST–Rpn13 (40 pmol) or 
buffer was mixed with proteasomes (5 pmol), which were resolved on native PAGE and 
visualized using suc–LLVY–AMC. The mobility shift caused by GST–Rpn13 is an 
indicator of its assembly into proteasomes. The presence of GST on Rpn13 is required to 
cause a mobility shift. All proteasomes used in this figure are from an rpn10-uim ubp6  
genetic background. (B) Mutations in Rpn13 do not attenuate assembly of Rpn13 into the 
proteasome. Reconstitution assays were performed as in (A), but using a fourfold molar 
excess of GST–Rpn13. (C) Structural model with mutations. Mutated residues (see (D)-
(F)) were mapped onto a model structure of scRpn13 (dark grey) complexed with 
monoubiquitin (light grey). E41, E42 and S93 are displayed in red, ubiquitin-binding 
loops in blue. These residues map to the S2–S3 (E41K, E42K) and S6–S7 (S93D) loops. 
(D) Mutations in single loops of Rpn13 attenuate its proteasomal ubiquitin receptor 
function. Rpn13 variants (12 pmol) cleaved from GST were incubated with proteasomes 
(3 pmol) to allow reassembly. Autoubiquitinated Cdc34 (18 pmol) was then added. After 
15 min at 30 °C, complexes were resolved by native PAGE and visualized using suc–
LLVY–AMC. (E) Rpn13 mutant E41K, E42K, S93D (Rpn13-KKD) abrogates the 
ubiquitin receptor activity of Rpn13. Experiment performed as in (D). (F) Superposition 
of 1H, 15N heteronuclear single-quantum coherence spectra of wild-type Rpn13 (black) 
and Rpn13-KKD (red). Shifted resonances are labeled in grey, and those corresponding 
to E41, E42 and S93 in black. Chemical shift assignments are only available for the wild-
type protein. 
 
To assay mutational effects on ubiquitin chain binding, we used the native gel-
based assay introduced in Figure 2.2A. Note that the mobility shift resulting from 
addition of GST–Rpn13 to the proteasome (Figure 2.5A,B) is irrelevant to the chain-
binding assay, because Rpn13 itself does not affect proteasome migration in gels. Only 
the larger GST-tagged form of Rpn13 can do so, and, in the ubiquitin chain-binding 
assay, untagged Rpn13 was used. Neither the S93D mutant nor the E41K, E42K mutant 
conferred a strong defect in the proteasome–ubiquitin interaction, although both 
conferred reduced mobility shifts compared with wild-type Rpn13 (Figure 2.5D). To 
impair ubiquitin binding further, we combined the S2–S3 and S6–S7 mutations. The 
resulting protein, a E41K, E42K, S93D triple mutant, referred to as scRpn13-KKD, was 
comparable to a buffer control in its influence on the proteasome’s electrophoretic 
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mobility in the presence of ubiquitin conjugates (Figure 2.5E). NMR titrations revealed 
that scRpn13-KKD binds monoubiquitin approximately eightfold more weakly than wild 
type (Figure 2.3D; see also Section 2.7). To ensure that these mutations did not affect 
Rpn13 structural integrity, we compared a 1H, 15N heteronuclear single-quantum 
coherence spectrum recorded on 15N-labelled scRpn13-KKD with that of wild type 
(Figure 2.5F). Only resonances corresponding to the mutated residues or their immediate 
neighbors were shifted, indicating that these surface mutations did not affect Rpn13’s 
structure. In addition, we identified the hRpn13 surface that binds Rpn2, which is remote 
from the substituted residues (93). The corresponding surface in scRpn13 is preserved in 
Rpn13-KKD as none of the residues within it were affected. Thus, Rpn13-KKD appeared 
to be suitable for in vivo analysis of the physiological function of ubiquitin recognition by 
Rpn13. 
 
2.3.7 Phenotype of the Rpn13-ubiquitin binding-site mutant 
To test the biological significance of the Rpn13–ubiquitin interaction, we 
integrated the triple mutant allele into yeast in place of the wild-type chromosomal 
sequence. Functional defects in proteasomes can be revealed by plate assays such as 
sensitivity to the arginine analogue canavanine, whose incorporation into proteins causes 
misfolding and accelerated degradation. The enhanced substrate load is lethal to mutants 
lacking proper proteasome function (see, for example, ref. (156)). rpn13-KKD mutants 
proved sensitive to 8  µg  ml-1 of canavanine when in the genetic background of an rpn10-
uim mutation (Figure 2.6A). Thus, the rpn13-KKD mutation leads to a defect in 
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proteasome function, and interacts synthetically with another specifically targeted 
proteasomal ubiquitin receptor mutation. Because Rpn13 can bind UBL/UBA proteins 
(Figure 2.4G), we also investigated its genetic relationship with Dsk2 and Rad23. rpn13-
KKD also showed a strong synthetic interaction with a null allele of proteasomal 
ubiquitin receptor Dsk2 (Figure 2.6A). In the case of Rad23, the genetic interaction was 
comparatively modest. These data support the view that the docking of ubiquitin 
conjugates at the proteasome by UBL/UBA proteins is not mediated obligatorily by 
Rpn13. In addition, binding assays performed with purified proteasomes and the UBL 
domains of Rad23 and Dsk2 indicate that Rpn13 is not the sole receptor for UBL/UBA 
proteins on the proteasome (Figure 2.S7). The results of the binding assays are consistent 
with our previous report that proteasome subunit Rpn1 binds UBL/UBA proteins (165). 
Further work is required to define more precisely the extent to which Rpn13-dependent 
docking of ubiquitin conjugates at the proteasome is mediated or regulated by UBL/UBA 
proteins. 
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Figure 2.6. Phenotypic effects of the loss of ubiquitin receptor function by Rpn13. (A) 
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Canavanine sensitivity of single and double mutants in ubiquitin receptor genes. Cells in 
late log phase (top: SY998b, SY980f, SY1004c and SY920b; middle: SY1076, SY1073a, 
SY1012a and SY1080a; bottom: SY1076, SY1074a, SY1012a and SY1082a) were 
serially diluted and stamped on plates using a pin array. Plates were incubated at 30 °C 
for either 2 (left) or 3 (right) days. (B) Endogenous ubiquitin conjugate levels in 
proteasomal ubiquitin receptor mutants. Cells (SY998a, SY980a, SY1004a and SY920a) 
were grown to log phase, and whole-cell extracts prepared. Proteins were resolved by 4–
12% gradient SDS–PAGE, transferred to polyvinylidene fluoride, and probed with 
antibody against ubiquitin. The membrane was stripped and probed with antibody against 
eIF5a. (C) Substrate stabilization in rpn13-KKD mutants. Cells (SY992b, SY1004b) 
expressing UbV76–Val-e K– -gal from a GAL promoter were grown to mid-log phase 
under inducing conditions. Protein synthesis was quenched at time zero by adding 
cycloheximide. Aliquots were withdrawn at the time points indicated, and lysates 
prepared. Proteins were visualized by SDS–PAGE/immunoblot analysis, using an 
antibody to -galactosidase, and quantified with imaging software (KodakEDAS 290). 
The rate of degradation of UbV76–Val-e K– -gal was reduced approximately twofold in 
the rpn13-KKD mutant compared with wild type. Asterisks indicate distinct -
galactosidase-derived partial breakdown products, whose relative intensities differ 
between wild type and mutant. (D) rpn13-KKD mutants are not deficient in proteasome 
levels. Cells (SY992a, SY1004a) were grown and lysed as in e. Extract (150 g) was 
resolved by native PAGE, and proteasome complexes visualized using suc–LLVY–AMC 
(top) and Coomassie blue as a loading control (middle). The asterisk indicates the 
expected position of the proteasome core particle, which is not visualized owing to low 
levels. Extracts were also subject to a quantitative proteasome assay, using suc–LLVY–
AMC (bottom). (E) Proteasomes from rpn13-KKD mutants are loaded with Rpn13-KKD 
protein. Cells (SY933, SY936, SY950 and SY952) were grown to late log phase at 30 °C 
in yeast extract (10 g l-1), peptone (20 g l-1) and dextrose (20 g l-1) (YPD), harvested and 
lysed as described (see Section 2.6.1). Extract (100 g) was incubated with 1 g of either 
GST–Rpn13 (+ lanes) or GST only (samples where GST–Rpn13 is absent) on ice. 
Proteasome complexes were resolved by native PAGE and visualized by suc–LLVY–
AMC overlay assay. 
 
To test whether amino-acid substitutions in the ubiquitin-binding loops of Rpn13 
can lead to global defects in ubiquitin metabolism, whole-cell extracts from our mutants 
were examined by immunoblotting. High molecular mass ubiquitin conjugates, which are 
enriched in proteasome substrates, accumulated in the rpn13-KKD rpn10-uim double 
mutant (Figure 2.6B). The defect is synthetic, as with the canavanine sensitivity of the 
double mutant (Figure 2.6A). We also observed an in vivo proteolytic defect in the rpn13-
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KKD mutant (Figure 2.6C), using the model proteasome substrate UbV76–Val-eΔK–β-gal 
(ref. (177)), which was previously found to be stabilized in an rpn13Δ mutant (167). 
Defects in proteasome assembly have been observed in rpn13Δ proteasomes 
(Figure 2.2; ref. (175)), and could potentially account for the phenotypes observed in 
Figure 2.6A–C. We therefore analyzed the assembly state of rpn13-KKD proteasomes by 
running native gels on freshly prepared, unfractionated cell extracts (178). We observed 
no significant change in level, assembly or peptidase activity in rpn13-KKD proteasomes 
(Figure 2.6D). Surprisingly, no assembly defect was observed for rpn13Δ proteasomes 
(Figure 2.6E). Thus, assembly defects previously observed for rpn13Δ proteasomes are 
apparently a result of in vitro handling. 
Although the recombinant Rpn13-KKD protein is properly folded and assembled 
onto purified proteasomes in vitro, it remained possible that the mutant protein would be 
absent from proteasomes in vivo as a result of its being rapidly degraded. To assess the 
extent of Rpn13-KKD loading of endogenous proteasomes, we used the GST–Rpn13 
add-back assay of Figure 2.5a, where purified proteasomes were used. In unfractionated 
cell extracts, GST–Rpn13 similarly shifted rpn13Δ proteasomes (Figure 2.6E). rpn13-
KKD proteasomes behaved as wild type in this assay, indicating that they were fully 
loaded with Rpn13-KKD. We conclude that the phenotypes of the rpn13-KKD mutant do 
not reflect deficient proteasome assembly or deficient loading of Rpn13 onto 
proteasomes, but are specifically related to its impaired ubiquitin-binding site. 
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2.4 Discussion 
We report here the identification of a new ubiquitin receptor for the proteasome, 
Rpn13, which is unrelated to Rpn10 and the three UBL/UBA proteins. Moreover, Rpn13 
defines a new class of ubiquitin recognition surfaces, differing dramatically from other 
proteasomal ubiquitin receptors. First, whereas the UBL/UBA proteins (and perhaps 
Rpn10) have distinct ubiquitin- and proteasome-binding domains that are separated by 
flexible linkers, Rpn13 is docked into the proteasome through a surface that is in close 
spatial proximity to its ubiquitin-binding region. Thus Rpn13 may provide for a ubiquitin 
chain with precise positioning and polarity. Second, the UBL/UBA proteins, having a 
large population free of the proteasome and often multiple ubiquitin-binding domains, are 
better equipped than Rpn13 to capture ubiquitinated substrates and then deliver them to 
the proteasome. Third, UBL/UBA proteins are also capable of protecting the chain during 
transit to the proteasome, as they inhibit deubiquitination (157, 179, 180). In striking 
contrast, Rpn13 promotes chain deubiquitination (163, 169, 171). Binding to Rpn13 both 
facilitates the deubiquitinating activity of Uch37 (refs (171) and (163)) and links Uch37 
to the proteasome, suggesting that Rpn13 plays a major role in ubiquitin chain 
disassembly at the proteasome. Third, Rpn13 is exceptionally proficient at binding 
monoubiquitin and diubiquitin compared with other ubiquitin receptors associated with 
proteasome-mediated degradation. Although it is widely supposed that extended ubiquitin 
chains are required for degradation, contrary observations have been reported, in which 
monoubiquitin targets proteins to the proteasome (174, 181, 182). Such substrates, 
although possibly rare, may be more strongly dependent on Rpn13 than those marked by 
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chains. 
Rpn13 resembles Rpn10 in its ability to bind ubiquitin-like domains of the 
UBL/UBA ubiquitin receptors (Figure 2.4D,G and Figures 2.S4 and 2.S5), implying that 
Rpn13 may recruit substrates to the proteasome directly or indirectly through UBL/UBA 
proteins. These observations support a hypothetical model whereby conjugates bind 
UBL/UBA family members, which dock them to the proteasome and pass them to the 
intrinsic receptors Rpn10 and Rpn13. In addition, compound complexes may be formed, 
in which a single conjugate is simultaneously bound by an intrinsic ubiquitin receptor and 
a UBL/UBA protein. Compound complexes may be favored when longer chains are 
delivered, leading to more stable chain–proteasome interactions, and thus more rapid 
substrate degradation. 
Ubiquitin and the proteasome are both essential, but remarkably the inactivation 
of all five known proteasomal ubiquitin receptors in the same yeast strain does not appear 
to be lethal (data not shown). In our assays, the residual chain-binding capacity of rpn10-
uim rpn13-KKD rad23Δ dsk2Δ ddi1Δ proteasomes is modest (Figure 2.5E), suggesting 
that the highest-affinity intrinsic receptors are now known. The unidentified receptor may 
be of lower affinity but comparable functionality, or it may be a receptor of typical 
affinity that is not intrinsic to the proteasome, such as Rad23/hHR23. 
The phenotypic properties of multiply receptor-deficient strains suggest functional 
redundancy (Figure 2.6; refs (156) and (179)). This may reflect robustness in their 
principal function of delivering substrate to the proteasome. Given the number of known 
receptors, it is likely that docking of the chain at any of multiple locations in the 
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proteasome will support breakdown of the target protein. However, there is apparently a 
deeper and more interesting functional relationship among ubiquitin receptors as well, in 
which they play distinct roles. For example, they have various phenotypes in isolation, 
albeit not lethal ones. Furthermore, proteasome function appears substantially 
compromised in multiple receptor-deficient strains (refs (156) and (179), and S.E. and 
D.F., unpublished observations). When different receptor mutants are compared, the 
relative strengths of the degradation defects vary from substrate to substrate (157). Thus, 
the receptors show in vivo specificity, although it remains unclear how specific they are 
and what the mechanistic basis of this specificity is. Finally, functionally redundant 
behavior as inferred from mutant phenotypes may not reflect the functioning of the wild-
type system in a straightforward manner, because compensation can mask differentiated 
activities. With more detailed characterization, the individuality of proteasomal ubiquitin 
receptors and its mechanistic basis should become clearer. 
 
2.5 Methods summary 
2.5.1 Yeast genetics and two-hybrid screen 
Standard methods were used for yeast genetics, growth assays and protein 
turnover assays (see Section 2.7.1). A complete list of yeast strains is given in Section 
2.7.1.12 (Table 2.1). Sequences corresponding to mouse ubiquitin lacking two terminal 
glycines (UbΔGG) were subcloned into pYTH9 vector (183), creating fusion proteins 
with the Gal4 DNA-binding domain (bait). Yeast strain Y190 was transformed with bait 
vector, and human fetal brain complementary DNA (cDNA) library (Clontech) was 
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screened as previously described (183). 
 
2.5.2 Antibodies and plasmids 
Antibodies used were: anti-myc (9E10) and anti-Ub (P4D1) from Santa Cruz 
Biotechnology; anti-ADRM1 (anti-Rpn13) from Biomol; and anti-β-galactosidase 
(Promega). All constructs used in this study are described in Section 2.7.1. 
 
2.5.3 Protein purification and biochemical assays 
Recombinant proteins were expressed in and purified from Rosetta cells 
(Novagen). Proteasome was affinity-purified essentially as described (184). 
Immunoprecipitation, immunoblotting and GST pull-down assays were performed as 
previously described (119). Native gel analysis was performed as in ref. (156). More 
detailed descriptions are available in Section 2.7.1. 
 
2.5.4 NMR spectroscopy 
We determined the structure of full-length scRpn13 as described in Section 2.7.1, 
with the data summarized in Table 2.S1. The resulting structures are available through 
Protein Data Bank accession number 2Z4D. Binding surfaces and affinities were 
determined as described in Section 2.7.1. 
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2.6 Supplementary information 
2.6.1 Material and methods 
2.6.1.1 Plasmids for expression of mammalian proteins 
The expression construct encoding full-length wild-type mRpn13 was kindly 
provided by Dr. N. Lamerant and described previously(185). Full-length mRpn13 cDNA 
was subcloned into pcDNA3-myc (EcoRI/XhoI) and pGEX-4T1 (BamHI/XhoI, 
Amersham) vectors and used for subsequent subcloning of different deletion mutants. 
UBL domains of hHR23A, hHR23B, hPLIC2 and Ddi1 were subcloned into pGEX-4T1 
(BamHI, Amersham). Fat10-pGEX-4T3 was a generous gift of M. Groettrup. GST-Ub, 
GST-4xUb, GST-SUMO1, GST-SUMO2 and Nedd8-pGEX-2TK were kindly provided 
by Drs. L. Hicke, E. Friedberg, J. Palvimo, F. Melchior and K. Tanaka, respectively. 
ISG15 was subcloned into pGEX-4T1. 
 
2.6.1.2 GST pull-down assays 
For assaying binding of ubiquitin to immobilized ligands, GST-fused 
tetraubiquitin was absorbed to resin, then cleaved with thrombin (Novagen) for 4 h at 4°C 
in a cleavage buffer containing 20 mM Tris-HCl (pH 8.4), 150 mM NaCl, 2.5 mM CaCl2 
and 1 mM DTT. Thrombin was inactivated with addition of PMSF, and GST bound to 
resin was removed by centrifugation. Supernatant was incubated with immobilized GST-
fusion proteins in incubation buffer (cleavage buffer with 10% glycerol and 1% Triton X-
100). After 5 hours of incubation at 4°C, beads were washed three times with incubation 
buffer. Bound proteins were boiled for 5 minutes in SDS sample buffer and analyzed by 
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SDS-PAGE and immunoblotting. The same approach was used for assaying binding of 
GST-fused mRpn13 cleaved with thrombin to different ubiquitin mutants and UBLs, 
which were expressed as GST-fused proteins. 
 
2.6.1.3 Plasmids for expression of yeast proteins 
An expression construct for GST-scRpn13 was generated by cloning the scRpn13 
ORF into a derivative of pGEX-6P1 (GE Healthcare), which includes an HMK site 
(TRRASV). The PreScission protease site (LEVLFQGP) in this variant is followed by 
LTRRASVGS, where GS coincides with an in-frame BamHI site used for cloning. The 
scRPN13 ORF follows the GS directly. Mutations giving rise to scRPN13 variants were 
made by using a matched pair of oligos and amplifying with iProof (BioRad). They were 
verified by sequencing. RPN13 integrating constructs were prepared by assembling a 
series of modules: the RPN13 ORF, the 3' UTR from CYC1, the natMX cassette (186) 
and the RPN13 3'UTR. For the rpn13- E41K, E42K, S93D mutation, a diagnostic 
restriction site was engineered upstream of the mutations. Further details are available 
upon request. 
 
2.6.1.4 Strain construction 
Disruptions of RAD23, DSK2, DDI1, and UBP6 are precise ORF replacements 
using the markers indicated. (For marker descriptions, see (186-188)) The Protein A 
sequence fused to RPN11 has been described previously (184). The reporter construct 
Pcup-Ub-K-TRP1::hphMX is as described previously (189), except that the original 
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natMX marker has been replaced by hphMX through recombination via the regions of 
homology within the MX cassettes. Modifications in the RPN10 gene are as described 
previously (156), except that the kanMX cassette was used in place of the previously 
reported natMX cassette. Modifications at the RPN13 locus were made using the 
integrative constructs described above. 
 
2.6.1.5 Proteasome purification 
Proteasomes were purified essentially as described (156). Cells were grown to late 
log phase (OD600 of roughly 6.0) and harvested by centrifugation. Cells were resuspended 
in lysis buffer (50 mM Tris-HCl [pH 8.0], 1 mM EDTA, 5 mM MgCl2, and 1 mM ATP), 
and lysed by French press. Extract was cleared by centrifugation at 20,000 g and 4°C for 
30 minutes, then filtered through coarse filter paper (porosity excluding 25 μm particles 
[VWR]). Cleared extract was incubated with IgG Sepharose (MP Biomedicals) for 90 
min at 4°C with tumbling. Resin was washed with 25 bed volumes of column buffer (50 
mM Tris-HCl [pH 7.4], 1 mM EDTA, 5 mM MgCl2, 1 mM ATP, and 100 mM NaCl), 
then with 10 bed volumes of elution buffer (50 mM Tris-HCl [pH 7.4], 1 mM EDTA, 5 
mM MgCl2, 1 mM ATP). Protein was released from the column by incubation with TEV 
protease (Invitrogen), which acts on the cleavage site between Protein A and Rpn11. For 
visualization of proteasome in extract, extract was prepared as described above through 
the filtration step, and in the presence of protease inhibitors (250 ug/ml AEBSF, 160 
ug/ml benzamidine, and 1 ug/ml leupeptin [Sigma]). Core particle was purified 
conventionally (190). 
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2.6.1.6 Recombinant Rpn13 
GST-Rpn13 and mutant variants were expressed in pGEX-based vectors. Cells 
were grown at 24°C to an OD600 of roughly 0.8, and expression was induced by the 
addition of IPTG to 250 μM. Induction was allowed to continue overnight. Cells were 
harvested by centrifugation, then resuspended and lysed in lysis buffer (50 mM Tris-HCl 
[pH 7.4], 100 mM NaCl, 1 mM DTT, 1 mM ATP, 1 mM EDTA, 1 mM EGTA, 125 μg/ml AEBSF, 160 μg/ml benzamidine, 2.5 μg/ml leupeptin), then cleared by 
centrifugation at 20,000 g and 4°C for 30 minutes. Fusion proteins were adsorbed to 
Glutathione Sepharose (GE Healthcare) for 90 min, and unbound material was removed 
by a series of batch washes with wash buffer (50 mM Tris- HCl [pH 7.4], 100 mM NaCl, 
1 mM DTT). Resin was equilibrated in elution buffer (50 mM Tris-HCl [pH 7.4], 100 
mM NaCl, 1 mM DTT, 10% glycerol), and bound protein was eluted with 20 mM 
glutathione in elution buffer. When required, GST was cleaved from the fusion proteins 
by incubating with PreScission protease (GE Healthcare) overnight at 4°C. 
 
2.6.1.7 Preparation of ubiquitin conjugates 
HIS-Cdc34 and HIS-Uba1 were purified as previously described (165). Ubiquitin, 
purified from bovine red blood cells, was purchased from Sigma. Conjugates were 
prepared by incubating 1.5 μM HIS-Uba1, 2 μM HIS-Cdc34, and 50 μM ubiquitin in 
buffer (20 mM Tris-HCl [pH 7.5], 10 mM MgCl2, 0.1 mM DTT, and 2 mM ATP) for 15 
to 20 hours at 30°C. 
 
  61 
2.6.1.8 Native gel assays 
Native gels were prepared, run, and developed essentially as previously described 
(191). Briefly, native PAGE gels containing 3.6% acrylamide 
(acrylamide:bisacrylamide::40:1) were prepared and run in buffer containing 90 mM Tris 
base, 90 mM boric acid, 6 mM MgCl2, 0.5 mM EDTA, 1 mM ATP. Gels were run at 
4°C, 100 V, and for 2.5 to 3.5 hours. Bands containing catalytically active proteasomes 
were identified by incubating with 100 μM suc- LLVY-AMC in 50 mM Tris-HCl (pH 
7.4), 6 mM MgCl2, and 1 mM ATP for 15 minutes at 30°C. Cleavage products were 
visualized by UV-induced fluorescence. For suc-LLVY-AMC hydrolysis in extract, 20 μl 
(600 μg of extract) was mixed with 80 μl of assay buffer, incubated at 30°C for 10 
minutes, quenched with 1% SDS, and conversion measured with fluorimetry, using an 
excitation and emission wavelengths of 365 nm and 440 nm, respectively. 
 Protein complexes were formed by mixing components in the amounts indicated 
(see Figure Legends) and incubated under various conditions. For experiments involving 
ubiquitin conjugates, proteins were incubated for 20 min at 30°C (Figures 2.2A, 2.2C, 
2.5D, and 2.5E). For experiments with GST-Rpn13, incubations were carried out for 10 
min at 30°C when using purified proteasomes (Figures 2.5A,B), and for 10 min at 4°C 
when using extract (Figure 2.6C). 
 
2.6.1.9 Plating assays 
Strains were inoculated from YPD plates into synthetic medium (2% dextrose, 
0.67% yeast nitrogen base without amino acids, 50 mg/L adenine hemisulfate, 500 mg/L 
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uridine, 200 mg/L phenylalanine, 200 mg/L isoleucine, 300 mg/L valine, 40 mg/L 
tyrosine, 600 mg/L proline, 100 ml/L glycine, 300 mg/L alanine, 300 mg/L serine, 200 
mg/L threonine, 400 mg/L glutamate, 200 mg/L aspartate, 800 mg/L glutamine, 200 
mg/L asparagine, 150 mg/L histidine, 450 mg/L lysine, 150 mg/L methionine, 400 mg/L 
leucine and 400 mg/L tryptophan), grown overnight in a roller drum at 30°C to an OD of 
roughly 4. Cells were diluted to an OD600 of 0.1, and three-fold serial dilutions were 
prepared in microtiter plates using the same synthetic medium. Cells were plated using a 
pin array onto solid synthetic medium with and without 8 μg/ml canavanine. 
 
2.6.1.10 Protein turnover 
Strains were transformed with a plasmid expressing pGAL-UbV76-Val-eΔK-ßgal 
and selected for uracil prototrophy in synthetic plates (2% dextrose, 0.67% yeast nitrogen 
base without amino acids, 20 mg/L arginine, 30 mg/L histidine, 60 mg/L isoleucine, 30 
mg/L leucine, 40 mg/L lysine, 20 mg/L methionine, 60 mg/L phenylalanine, 50 mg/L 
threonine, 40 mg/L tryptophan, and 10 mg/L adenine). Transformants were inoculated 
into synthetic medium while continuing to maintain the selection for uracil prototrophy 
(2% dextrose, 0.67% yeast nitrogen base without amino acids, 0.5% casamino acids, 40 
mg/L tryptophan and 10 mg/L adenine), grown to saturation, then subcultured twice in 
medium inducing the expression of UbV76-Val-eΔK-ßgal (2% raffinose, 2% galactose, 
0.67% yeast nitrogen base without amino acids, 0.5% casamino acids, 40 mg/tryptophan, 
and 10 mg/L adenine). Cells were harvested at an OD600 of roughly 3.0, and resuspended 
at a density of 50 OD600 per ml. Maintaining cells at 30°C using a dry bath, protein 
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synthesis was inhibited by the addition of cycloheximide from a fresh stock of 10 mg/ml 
to a final concentration of 100 μg/ml. 50 μl samples were withdrawn at various time 
points, mixed with an equal volume of ice cold quench mix (300 mM NaCl, 100 mM 
NaF, 2 mM NaN3, 20 mM EDTA), and placed in an ice bath. After the time course, cells 
were harvested in a microcentrifuge for 10 seconds, resuspended in 75 μl lysis solution 
(50 mM NaOH, 2% SDS, 5% β-mercaptoethanol, 10% glycerol, and phenol red 
[sufficient to yield a colored but transparent solution]), and lysed by heating to 98°C for 5 
minutes. pH was titrated to neutrality using 2.5 μl of 1N HCl. Titration was followed by 
the phenol red indicator, which shifts from magenta to red-orange when the pH drops 
below 8.0. Cell debris was removed by spinning in a microfuge for 5 minutes and at 
maximum speed. 12 μl of the supernatant was resolved by SDS-PAGE. 
 
2.6.1.11 Immunoblot analysis of endogenous ubiquitin conjugates 
Cells were grown overnight in YPD at 30ºC, diluted five-fold in YPD, and grown 
to an OD600 of roughly 0.9. Cells were processed as for the protein turnover experiment, 
except that 40 mM 2-deoxyglusocose was used in the quench mix, and cells were not 
concentrated prior to sampling. 
 
 
2.6.1.12 Yeast strains  
All strains were prepared in the SUB62 background (lys2-801 leu2-3, 2-112 ura3-
52 his3- Δ200 trp1-1 (192)) 
 
Table 2.1. Yeast strains produced in study 
Strain	   Genotype	   Figure	  
SY722	   MATa rpn11-TEV-ProA::HIS ubp6::HIS rad23::hphMX 
dsk2::KlTRP1 ddi1::kanMX rpn13::CaURA3MX rpn10- 
2.2	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uim::natMX	  
SY725	   MATarpn11-TEV-ProA::HIS  ubp6::HIS  rad23:: hphMX 
dsk2::KlTRP1  ddi1::kanMX  rpn13::CaURA3MX 
2.2	  
SY729	   MATa  rpn11-TEV-ProA::HIS  ubp6::HIS  rad23::hphMX 
dsk2::KlTRP1  ddi1::kanMX  rpn10-uim::natMX	   2.2	  
SY733	   MATarpn11-TEV-ProA::HIS  ubp6::HIS  rad23::hphMX 
dsk2::KlTRP1  ddi1::kanMX	   2.2	  
SY775	   MATa  rpn11-TEV-ProA::HIS  ubp6::HIS RPN13(wt)::natMX  
rpn10-uim::kanMX	   2.5	  
SY723	   MATarpn11-TEV-ProA::HIS  ubp6::HIS 
rpn13::CaURA3MX  rpn10-uim::natMX	   2.5	  
SY998 b	   MATa  RPN13(WT)::natMX  RPN10(WT)::kanMX	   2.6A, 
top	  
SY980 f	   MATa  RPN13(WT)::natMX rpn10-uim::kanMX	   2.6A, 
top	  
SY1004 c	   MATa  rpn13(41K-42K-93D)::natMX RPN10(WT)::kanMX	   2.6A, 
top	  
SY920 b	   MATa  rpn13(41K-42K-93D)::natMX rpn10-uim::kanMX	   2.6A, 
top	  
SY1076	   MATa  RPN13(WT)::natMX	   2.6A, 
middle 
and 
bottom	  
SY1012 a	   MATa  rpn13(41K-42K-93D)::natMX	   2.6A, 
middle 
and 
bottom	  
SY1073 a	   MATa  RPN13(WT)::NAT  rad23::kanMX	   2.6A, 
middle	  
SY1080 a	   MATa  rpn13(41K-42K-93D)::natMX  rad23::kanMX	   2.6A, 
middle	  
SY1074 a	   MATa  RPN13(WT)::natMX  dsk2::TRP	   2.6A, 
bottom	  
SY1082 a	   MATa  rpn13(41K-42K-93D)::natMX  dsk2::TRP	   2.6A, 
bottom	  
SY998 a	   MATa  RPN13(WT)::natMX  RPN10(WT)::kanMX	   2.6B	  
SY980 a	   MATa  RPN13(WT)::natMX  rpn10-uim::kanMX	   2.6B	  
SY1004 a	   MATa  rpn13(41K-42K-93D)::natMX  RPN10(WT)::kanMX	   2.6B	  
SY920 a	   MATa  rpn13(41K-42K-93D)::natMX  rpn10-uim::kanMX	   2.6B	  
SY992 b	   MATaRPN10(wt)::kanMX	   2.6C	  
SY1004 b	   MATarpn13(41K-42K-93D)::natMX  RPN10(wt)::kanMX	   2.6C	  
SY933	   MATaPcup-Ub-K-TRP1::hphMX 
rpn13-E41K/E42K/S93D::natMX  rpn10-uim::kanMX	   2.6D	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SY936	   MATa  Pcup-Ub-K-TRP1::hphMX  rpn13- 
E41K/E42K/S93D::natMX	   2.6D	  
SY950	   MATa  Pcup-Ub-K-TRP1::hphMX  RPN13(wt)::natMX	   2.6D	  
SY952	   MATa  Pcup-Ub-K-TRP1::hphMX  rpn13(KO)::natMX	   2.6D	  
SY992 a	   MATaRPN10(wt)::kanMX	   2.6E	  
SY1004 a	   MATa  rpn13(41K-42K-93D)::natMX  RPN10(wt)::kanMX	   2.6E	  
 
 
2.6.1.13 Preparation of NMR samples 
scRpn13, mRpn13, and hRpn13 were prepared as described above for scRpn13, 
but in M9 minimal media with 13C, 15N, or 2H incorporated by using 13C labeled glucose, 
15N labeled ammonium chloride or D2O, respectively. hHR23a UBL and hPLIC2 UBL 
were prepared by following the protocols as described in (140, 193).Unlabeled 
monoubiquitin was purchased (Boston Biochem Inc.), and K48-linked diubiquitin and 
tetraubiquitin synthesized by using a previously described method (194). 
 
2.6.1.14 Chemical shift assignments and structure determination 
Chemical shift assignments for scRpn13 were obtained by using modern NMR 
techniques. Briefly, two pairs of triple resonances experiments were acquired, namely 
HNCA/HNCOCA and HNCO/HNCACO, as well as an HNCACB experiment. Each of 
these was acquired on 15N, 13C, and 70% 2H labeled Rpn13 and on Varian 600 or 800 
MHz spectrometers equipped with cryogenically cooled probes. Samples ranged from 0.4 
– 0.7 mM protein concentration and all spectra were acquired in Buffer 1 (20 mM 
NaPO4, 50 mM NaCl, 4 mM DTT at pH 6.5) and at 25°C. All crosspeaks present in the 
1H, 15N HSQC spectrum were assigned. The backbone amide groups of residues T73 – 
I86 and S106 – G127 are absent from all spectra, including the 1H, 15N HSQC spectrum; 
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however, 13C based NOE crosspeaks were available and used to define the structure of 
T73 – P77. Importantly, the secondary structural elements present in the solution 
structure of scRpn13 are supported by chemical shift index values for C’ and Cα	  atoms as 
well as the NOEs present in the 13C dispersed NOESY spectrum. 
 Distance constraints for structure calculations were obtained by using a 3D 15N-
dispersed NOESY spectrum on a 15N, 50% 2H labeled sample (200 ms mixing time) and 
a 13C-dispersed NOESY on a 13C labeled sample dissolved in D2O (80 ms mixing times). 
Each was acquired at 800 MHz and with a cryogenically cooled probe. Backbone φ	  and ϕ	  torsion angle constraints were derived by using the program TALOS (195). Spectra 
were processed by NMRPipe (196) and visualized in XEASY (197). 
 The NOE-derived distance constraints, hydrogen bonds and dihedral angle 
constraints (Table 2.S1) were used in XPLOR version 3.851 to determine the structure of 
scRpn13. Eight structure from 35 starting ones had no NOE or dihedral angle violation 
greater than 0.3 Å or 5°, respectively. 
 
2.6.1.15 NMR titration experiments 
We used chemical shift perturbation analysis to determine protein contact 
surfaces. In all cases 1H, 15N HSQC experiments were recorded on 15N labeled protein 
with increasing molar ratios of unlabeled binding partner. For all but hRpn13 binding to 
hRpn2 (797-953), the binding was in the fast exchange regime, such that affected 
resonances could be readily followed from their free to their bound states as increasing 
amounts of the binding partner was added. The concentration of hRpn13 was kept 
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constant and between 0.20-0.40 mM; the spectra were recorded at 25°C and on either 600 
MHz or 800 MHz NMR spectrometers. Experiments involving scRpn13 were in Buffer 1 
(20 mM NaPO4, 50 mM NaCl, 4 mM DTT at pH 6.5) whereas those involving hRpn13 
were in Buffer 2 (20 mM NaPO4, 30 mM NaCl, 2 mM DTT at pH 6.5). Resulting 
chemical shift perturbation values (Δδavg) for 15N and 1H nuclei were derived from 
Equation 2.1: 
 
 
 
 
 
 
where ΔδN and ΔδH represent the chemical shift perturbation value of the amide nitrogen 
and proton, respectively. 
To determine the binding constants for wild-type scRpn13 binding to 
monoubiquitin, we acquired data at the following molar ratios, 4:1, 2:1, 1:1, 1:2, 1:3, 1:4, 
1:5, 1:6, 1:8. The chemical shift perturbation values for two residues (F45 and E72) were 
normalized and then plotted to obtain a Kd by using Matlab v. 7.2 and the method 
described in (198). Normalized chemical shift perturbation data for scRpn13-KKD 
binding to monoubiquitin was acquired at the following molar ratios, 2:1, 1:1, 1:2, 1:4, 
1:6, 1:8, 1:10, 1:12, 1:15, 1:18. Two residues (F45 and E72) were chosen to determine Kd 
values for scRpn13-KKD binding to monoubiquitin, by using the method described for 
wild-type scRpn13. In this case, saturation was achieved at a molar ratio of 1:15 
scRpn13-KKD:monoubiquitin. The concentration of scRpn13-KKD in these experiments 
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was 0.3 mM, and at the titration points with the higher ubiquitin concentrations, ubiquitin 
aggregation appeared to have compromised the accuracy of our determined Kd value. The 
data could be fit to the standard equation for 1:1 binding only by the exclusion of data 
from the 1:6, 1:8, 1:10, 1:12, 1:15 and 1:18 titration points. 
The Kd value for hHR23a UBL domain binding to hRpn13 Pru was determined by 
acquiring a series of 1H,15N HSQC experiments detecting the amide resonances of 
hHR23a UBL domain at molar ratios 8:1, 4:1, 2:1, 1.5:1, 1:1, 1:1.5, 1:2, 1:3 hHR23a 
UBL:hRpn13. The chemical shift perturbation for three residues (T14, G52, and E68) 
were normalized and then plotted to obtain the Kd value, as described for scRpn13 
binding to monoubiquitin (Figure 2.S3). 
To determine the stoichiometry for hRpn13 Pru binding to mono-, di- and 
tetraubiquitin, we acquired data at varying molar ratios, and plotted the normalized 
chemical shift perturbation values. The plots yielded steep curves and Kd values too small 
to be accurately determined by NMR, which requires high protein concentrations. 
 
2.6.1.16 Affinity measurements by fluorescence spectroscopy 
The Kd values for the hRpn13 Pru binding to mono- or diubiquitin were 
determined by monitoring the change in fluorescence emission spectra of the hRpn13 Pru 
upon their addition at 298K. Intrinsic fluorescence of the two Trp residues in 1 μM 
hRpn13 Pru was measured on a JASCO FP-6200 spectrofluorometer without and with 
increasing molar quantities of ubiquitin or diubiquitin (0.0083 μΜ	  ~ 8 μM), as shown in 
Figure 2.S6. Emission spectra were recorded between 300 and 500 nm, with an excitation 
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wavelength of 280 nm and spectral bandwidths for excitation and emission of 5 nm. The 
change in fluorescence intensity at 348 nm upon addition of monoubiquitin or diubiquitin 
was used to generate the binding curves of Figure 2.4C by using Microsoft Excel and 
curve fitting was achieved with Matlab v. 7.2. 
 
2.6.1.17 Modeling the scRpn13:ubiquitin complex 
Chemical shift perturbation analysis implicated the S2-S3, S4-S5, and S6-S7 
loops within scRpn13 as binding monoubiquitin. In the accompanying manuscript, we 
determined the mRpn13:ubiquitin structure using NOE-derived distance constraints to 
similarly reveal these loops as being at the ubiquitin-contact surface. Therefore, we 
modeled the scRpn13:ubiquitin complex by superimposing the backbone atoms of the 
three ubiquitin binding loops within scRpn13 onto those of mRpn13 in the 
mRpn13:ubiquitin complex structure. 1000 steps of Powell energy minimization 
(SYBYL, Tripos Inc.) were then used to optimize the model structure of 
scRpn13:ubiquitin. 
 
2.6.2 Supplementary table 
 
Table 2.S1. Structural statistics for NMR structure of scRpn13 
NOE distance restraints (total)                                                                                        949 
Inter-residue                                                                                                                    492 
Medium-range (|i-j| ≤ 4)                                                                                                  51 
Long-range (|i-j| > 4)                                                                                                       276 
Hydrogen bonds                                                                                                              56 
Dihedral angle restraints (deg.)                                                                                       79 
φ (C’(i-1) - Ni - Ciα - Ci’)                                                                                                    47 
ψ (Ni - Ciα - Ci’ - N(i+1))                                                                                                    32 
Ramachandran plot 
Most-favorable region (%)                                                                                             66.2 
  70 
Additionally allowed region (%)                                                                                    30.0 
Generously allowed region (%)                                                                                      2.8 
Disallowed region (%)                                                                                                    0.9 
r.m.s.d of backbone atoms from average structure within well defined 
regions (Å) (T6-N38, F45-L68, I86-V90, R96-L101)                                                    0.61 
r.m.s.d of all heavy atoms from average structure within well defined 
regions (Å) (T6-N38, F45-L68, I86-V90, R96-L101)                                                    1.38 
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2.6.3 Supplementary Figures 
 
Figure 2.S1. Superposition of 1H, 15N HSQC spectra of 15N labeled Rpn13 alone (black)  
and with equimolar ubiquitin (red) reveals residues at the ubiquitin contact surface. 
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Figure 2.S2. Example of steric problems in structures generated with three hRp13 Pru 
molecules (red, yellow, or green) bound to neighboring subunits of K48- linked 
tetraubiquitin (grey). In this example, two neighboring Rpn13 Pru molecules interact and  
exhibit steric clashes between N130 and Q51 (displayed  in  cyan) of the structure 
displayed in and K34, G35, T36 and T37 (displayed in black) of the structure displayed 
in red. The interaction of these residues is not supported by additional chemical shift 
perturbations when Rpn13 binds tetraubiquitin versus monoubiquitin. Other 
geometries are also yielded from the calculations, which are performed in XPLOR using 
the intermolecular NOE interactions between hRpn13 Pru and monoubiquitin; however, 
in all cases unsupported interactions and steric clashes occur, either between hRpn13 Pru 
molecules or the ubiquitin subunits. It is worth noting that the steric problems will be 
increased when full length hRpn13 interacts with polyubiquitin in this manner. It is 
formally possible that a structure exists with no steric clashes, which is not found due to 
the computational limitations of having so many atoms in this system; however, the clear 
entropic disadvantages of forming what would be a very restricted configuration most 
likely contribute to the experimental results indicating that this binding arrangement is 
not detectable. 
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Figure 2.S3. Monoubiquitin   binding   to   hRpn13   causes   resonance attenuation as 
well as shifting. Superposition of 1H,15N HSQC spectra of 15N-labeled hRpn13 Pru 
without (black) or with monoubiquitin acquired at molar ratios of 8:1 (green), 4:1 (dark 
blue), 2:1 (yellow), 1:1 (light blue), and 1:2 (red) hRpn13:monoubiquitin. 
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Figure 2.S4. Rpn13 binds UBLs of polyubiquitin receptors. Pru domain of mRpn13 was 
expressed as GST-fused protein, cut with thrombin and used in GST pull-down assays to 
access its binding to UBLs of polyubiquitin receptors hHR23A, hHR23B, and 
hDdi1, which were expressed as GST-fused proteins. 
 
 
 
 
 
GS
T U
b
GS
T
GS
T 4
xU
b
GS
T h
HR
2
B,
UB
L
3
 
GS
T 
3
 
hH
R2
A,
UB
L
n
u
5%
 
i p
t
GS
T h
Dd
i1,
 
UB
L
IB: anti-Rpn13
Ponceau S
25 kDa
37 kDa
50 kDa
  75 
 
Figure 2.S5. hRpn13 Pru binds hHR23a UBL domain. Normalized chemical shift 
perturbation values are plotted against varying molar ratios of hRpn13 Pru to hHR23a 
UBL domain. Each data line represents a specific amino acid as indicated in the figure. 
The data were fit (solid black line) to determine a binding constant of 36µM by using 
Matlab v. 7.2. 
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Figure 2.S6. Fluorescence emission spectra of hRpn13 Pru in the absence and presence 
of different concentrations of monoubiquitin (A) or diubiquitin (B). The hRpn13 Pru 
concentration is kept at 1 µM in 20 mM NaPO4, 30 mM NaCl (pH 6.5) buffer. The 
molar ratio of hRpn13 Pru to ubiquitin (A) or diubiquitin (B) is indicated. 
 
  77 
 
Figure 2.S7. Binding of UBL domains to proteasomes does not require Rpn13. Four 
pmol of proteasomes (see Figure 2.2A, lanes 1 and 5) were incubated with 400 pmol of 
Rad23 and Dsk2 UBL domains fused to GST for 10 minutes at 30°C. Proteasome 
complexes were resolved by native PAGE and visualized by suc-LLVY-AMC overlay 
assay. 
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3.1 Synopsis 
Targeted protein degradation is largely performed by the ubiquitin–proteasome 
pathway, in which substrate proteins are marked by covalently attached ubiquitin chains 
that mediate recognition by the proteasome. It is currently unclear how the proteasome 
recognizes its substrates, as the only established ubiquitin receptor intrinsic to the 
proteasome is Rpn10/S5a (ref. (132)), which is not essential for ubiquitin-mediated 
protein degradation in budding yeast (199). In this chapter we report that Rpn13 (refs 
(163, 167, 169-171)), a component of the nine-subunit proteasome base, functions as a 
ubiquitin receptor (92), complementing its known role in docking de-ubiquitinating 
enzyme Uch37/UCHL5 (refs (163, 169, 171)) to the proteasome. Here we merge 
crystallography and NMR data to describe the ubiquitin-binding mechanism of Rpn13. 
We determine the structure of Rpn13 alone and complexed with ubiquitin. The co-
complex reveals a novel ubiquitin-binding mode in which loops rather than secondary 
structural elements are used to capture ubiquitin. Further support for the role of Rpn13 as 
a proteasomal ubiquitin receptor is demonstrated by its ability to bind ubiquitin and 
proteasome subunit Rpn2/S1 simultaneously. Finally, we provide a model structure of 
Rpn13 complexed to diubiquitin, which provides insights into how Rpn13 as a ubiquitin 
receptor is coupled to substrate deubiquitination by Uch37. 
 
3.2 Results 
The structure of murine Rpn13 (mRpn13) (amino acids 1–150) was determined at 
1.7-Å resolution by X-ray crystallography, and found to contain a pleckstrin-homology 
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domain (PHD) fold (Figure 3.1A, B) (structure determination and refinement statistics 
are provided in Section 3.6). In particular, whereas the first 21 amino- and last 20 
carboxy-terminal amino acids are unstructured, residues 22–130 form a PHD fold. This 
result was surprising, as primary sequence alignment did not identify Rpn13 as being 
homologous to previously characterized proteins. This finding, coupled with its ubiquitin 
receptor properties (92), prompted us to name the N-terminal domain of Rpn13 
pleckstrin-like receptor for ubiquitin (Pru). 
 
Figure 3.1. Crystal structure of mRpn13 Pru reveals typical pleckstrin-homology fold. 
(A) Ribbon representation of Rpn13 pleckstrin-like receptor for ubiquitin (Rpn13 Pru). 
The pleckstrin-homology fold consisting of a seven-stranded -sandwich structure (1–7) 
capped by the C-terminal -helix. (B) Stereo representation of the structural alignment of 
Rpn13 Pru (red) and the PHD (blue) from Pleckstrin (PDB accession code 1PLS). 
 
Though very divergent at their sequence level, all PHDs have a common β-
sandwich fold. The PHD of Rpn13 is composed of a four-stranded twisted antiparallel β-
sheet (β1–4: residues 22–34, 45–52, 56–62, 71–74) that packs almost orthogonally against 
a second triple-stranded β-sheet (β5–7: residues 80–85, 92–98, 103–110) (Figure 5.S1). 
Like other PHDs, Rpn13 Pru forms a hydrophobic core containing conserved 
hydrophobic residues (F26, V47, I49, F59, F82, Y94, L96, F107 and M109), which are 
located within β-sheets. One end of the β-sandwich is capped by a long C-terminal 
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amphipathic α-helix (residues 117–128), which is stabilized by interactions between 
V124 and L128, whereas the other corner of the hydrophobic core is closed by three 
loops formed by residues located between strands S1/S2, S3/S4 and S6/S7 (Figure 3.1A 
and 3.S1). 
Despite much effort, we were unable to crystallize the Rpn13 Pru–ubiquitin 
complex; however, we determined the structure of this complex by molecular docking, 
based on the crystal structure of mRpn13 Pru and intermolecular nuclear Overhauser 
enhancements (NOEs) as well as data from chemical shift perturbation derived by NMR 
titration experiments. The topology of the complexed structure was readily defined by 12 
unambiguous intermolecular NOE interactions between human Rpn13 (hRpn13) Pru and 
ubiquitin (Figure 3.2A). We were able to use the hRpn13:ubiquitin NOEs with the 
mRpn13 crystal structure because all of the amino acids exhibiting intermolecular NOEs 
are strictly conserved between murine and human Rpn13. Importantly, the mRpn13 Pru–
ubiquitin structure reveals a novel ubiquitin-binding mode in which residues of the S2–
S3, S4–S5 and S6–S7 loops capture ubiquitin (Figure 3.2B). At the core of the contact 
surface, hydrogen bonds are formed between side-chain oxygens of D78 and D79 in 
hRpn13, and Nϵ2 and Nδ1 of H68 in ubiquitin, respectively. Moreover, F76 engages in 
hydrophobic interactions with I44, Q49 and V70 of ubiquitin (Figure 3.S2). These 
contacts are enabled by the strictly conserved P77, which causes the S4–S5 loop to turn. 
The intermolecular NOE data for this complex were fully satisfied without Rpn13 Pru or 
ubiquitin structural rearrangements, and the root mean squared deviations between the 
free and complexed state of Rpn13 Pru and ubiquitin were 0.91 and 0.75  Å for backbone 
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atoms, and 1.20 and 1.15  Å for all non-hydrogen atoms, respectively. 
 
Figure 3.2. Structure of Rpn13 Pru-ubiquitin complex defines a novel ubiquitin-binding 
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motif. (A) Representative NOE interactions identified between Rpn13 Pru and ubiquitin. 
Each panel contains a selected region of a 15N-dispersed nuclear Overhauser 
enhancement spectroscopy experiment recorded on 15N-, 13C- and 70% 2H-labelled 
hRpn13 Pru mixed with equimolar quantities of unlabeled ubiquitin. All of the 
resonances displayed in this panel were unambiguously assigned as intermolecular NOE 
interactions with ubiquitin. Ubiquitin and Rpn13 Pru assignments are provided at the top 
and bottom of the expanded regions, respectively. (B) Stereo representation of the 
mRpn13 Pru–ubiquitin complex oriented with ubiquitin at the top. At the interaction 
surface, secondary structural elements of ubiquitin and Rpn13 Pru are displayed in green 
and blue, respectively. Residues at the contact surface with intermolecular NOEs are in 
yellow (ubiquitin) or red (Rpn13 Pru), whereas those suggested to be at the contact 
surface only by the NMR titration experiments are displayed in purple (ubiquitin) or cyan 
(Rpn13 Pru). M31, C88 and E111, which shift upon hRpn2 (amino acids 797–953) 
addition, are displayed in dark green. (C) Specific amino-acid substitutions were made 
within the S2–S3, S4–S5 and S6–S7 loops of mRpn13 Pru by in vitro mutagenesis. The 
protein products were expressed as GST fusions and used in GST pull-down assays to 
highlight the importance of these loops for tetraubiquitin binding. (D) Ubiquitin (blue), 
hRpn2 (amino acids 797–953) (green) or ubiquitin and hRpn2 (amino acids 797–953) 
(red) were added to the hRpn13 Pru domain, which was monitored by 1H, 15N 
heteronuclear single-quantum coherence experiments. Comparison with the spectrum 
acquired on the protein alone (black) indicates that S55, F76 and D78 bind ubiquitin in a 
manner that is independent of hRpn2 (amino acids 797–953), whereas M31, C88 and 
E111 bind hRpn2 in a ubiquitin-independent manner. 
 
Additional hydrophobic contacts exist, as Rpn13’s side-chain methyl group of 
A100 and the Cα group of G101 partly bury ubiquitin’s F45, which is solvent-exposed in 
the free protein. Similarly, Rpn13’s strictly conserved F98 located on S6 also becomes 
less solvent-accessible through interactions with A46 and G47 of ubiquitin. Calculation 
of the electrostatic potential of mRpn13 illustrates that a hydrophobic region within its 
ubiquitin-binding surface that contains L56 and F76 is available to interact with 
ubiquitin’s L8, I44 and V70 (Figure 3.S3). Complementary electrostatic interactions 
between Rpn13 Pru and ubiquitin also stabilize the complex, including interactions of 
D78 and D79 of Rpn13 Pru with ubiquitin’s H68, as well as D53 and D54 with 
ubiquitin’s R42 and R72. 
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In total, the contact surface of Rpn13 Pru and ubiquitin comprises 1256  Å2, which 
is large for ubiquitin receptors. Thus, the relatively high affinity of hRpn13 binding to 
monoubiquitin, described in Chapter 2, is partly explained by the enlarged contact surface 
compared with that of EAP45 GLUE (1000  Å2 in total) (95). Published values for the 
total buried surface of Cue2-1cue and Dsk2UBA upon ubiquitin binding are even smaller: 
960 and 800  Å2, respectively (65, 198). 
To analyze the significance of specific interactions identified in the mRpn13–
ubiquitin complex, we made several amino-acid substitutions including L56A, I75R, 
F76R, D79N and F98R. The ubiquitin-binding competency of the resulting amino-acid-
substituted proteins was tested by using GST-4xUb (created by the in-frame expression 
of glutathione S-transferase (GST) and four ubiquitin sequences) in pull-down assays 
(Figure 3.2C). These experiments validated our mRpn13–ubiquitin structure and 
provided strong evidence for the importance of the S2–S3, S4–S5 and S6–S7 loops in 
ubiquitin binding by mRpn13. In particular, the single amino-acid substitutions L56A, 
I75R, F76R and F98R abrogate ubiquitin binding, and a strong reduction is observed for 
the D79N mutation. We tested how three of these mutations affect mRpn13 structural 
integrity. In particular, NMR experiments were performed on mRpn13 Pru with the 
L56A, F76R or D79N mutations incorporated and compared with the wild-type mRpn13 
Pru domain. These comparisons demonstrated that the loss of ubiquitin binding was not 
caused by loss of structural integrity (Supplementary Figure 3.S4). Altogether, our results 
demonstrate that ubiquitin binding is defined by key interactions with residues within the 
S2–S3, S4–S5 and S6–S7 loops. 
  85 
To function as a proteasomal ubiquitin receptor, Rpn13 must bind ubiquitin and 
proteasome components simultaneously. In yeast and mammals, Rpn13 binds to Rpn2 
through its Pru domain (169, 172, 173). Although the Pru domain also binds ubiquitin, 
we found that Rpn2 binding does not disturb the Rpn13 loops that bind ubiquitin. By 
using a nested set of N-terminal deletions in human Rpn2 (hRpn2), we determined a 
fragment spanning amino acids 797–953 to bind mRpn13 (Figure 3.S5). The addition of 
this fragment (hRpn2 (797–953)) to hRpn13 did not affect residues at the ubiquitin 
contact surface, which shift only upon ubiquitin addition, as demonstrated for S55, F76 
and D78 (Figure 3.2D). By contrast, M31, C88 and E111, which are unaffected by 
ubiquitin, shift after hRpn2 (797–953) addition. Furthermore, when both Rpn2 and 
ubiquitin were added, S55, F76 and D78 contact ubiquitin whereas M31, C88 and E111 
contact Rpn2 (Figure 3.2D), indicating that the two binding surfaces are largely 
independent. M31, C88 and E111 are conserved in mRpn13 and map to S1, the S5–S6 
loop, and the region linking S7 to H1, respectively. These elements are clustered in a 
region that is opposite to the ubiquitin-binding loops of Rpn13. 
26S proteasomes exhibit high affinity for ubiquitinated substrates. Ubiquitin 
chains linked by isopeptide bonds between K48 and the C-terminal glycine of 
neighboring ubiquitin molecules are known to trigger proteasomal degradation of the 
labeled protein (200, 201). We found that Rpn13 Pru binds K48-linked tetraubiquitin in a 
manner comparable to that of monoubiquitin. More specifically, tetraubiquitin and 
monoubiquitin caused chemical-shift changes to the same hRpn13 residues (Figure 
3.S6A), including L56, F76 and F98, and shifted them almost identically (Figure 3.3A). 
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Only two residues in hRpn13 exhibit changes that are specific to K48-linked 
tetraubiquitin, namely L73 and R104 (Figure 3.3A and Figure 3.S6A, red). These 
residues and the side-chain atoms of neighboring K103 are proximal to each other; in the 
mRpn13–monoubiquitin structure they are directed towards the side-chain atoms of K48. 
This arrangement is congruent with Rpn13 binding the proximal subunit of diubiquitin, 
namely that which forms an isopeptide using K48 (Figure 3.3B). We tested this model 
further by monitoring the side-chain atoms of the proximal or distal subunit of diubiquitin 
upon addition of hRpn13 Pru. More specifically, unlabeled hRpn13 Pru was added to 
diubiquitin with either its proximal or distal subunit 13C labeled, and the effect recorded 
by 1H, 13C heteronuclear multiple-quantum coherence experiments. Significant resonance 
shifting characteristic of hRpn13 binding was observed for the I44 γ1, I44 δ1 and A46 
methyl groups of the proximal subunit (Figure 3.3C, left panel, and Figure 3.S7A). By 
contrast, resonances of the distal subunits exhibited only minor perturbations, most likely 
because of loss of intramolecular interactions with the proximal subunit. These data 
provide strong evidence that the major contacts formed between hRpn13 Pru and 
diubiquitin involve residues of the proximal subunit, at least when these two proteins are 
at equimolar concentration. Further evidence of this binding mode is provided by 
analytical ultracentrifugation data, which revealed 1:1 binding stoichiometry between 
hRpn13 Pru and diubiquitin (Figure 3.S7B). 
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Figure 3.3. Preferential binding to the proximal subunit of K48-linked diubiquitin by 
Rpn13 Pru allows Uch37 access to the distal subunit. (A) Comparison of spectra acquired 
with monoubiquitin versus K48-linked tetraubiquitin reveals identical effects for Rpn13's 
L56, F76 and F98 but differences for L73 and R104. Monoubiquitin (red) or 
tetraubiquitin (cyan) was added to hRpn13, which was monitored by 1H, 15N 
heteronuclear single-quantum coherence experiments. The spectrum of free hRpn13 is 
indicated in black, and the molar ratio of monoubiquitin (red) or tetraubiquitin (cyan) to 
hRpn13 was 1:1 in the represented spectra. (B) Computer-generated model of the 
mRpn13 Pru–diubiquitin complex. White and grey ribbon diagrams display the proximal 
and distal ubiquitin, respectively, whereas a balls-and-sticks representation is used for the 
K48-G76 isopeptide bond linkage. Rpn13 Pru is cultured in yellow and loops recognizing 
ubiquitin in blue, whereas L73, K103 and R104 are displayed in red. Diubiquitin was 
created by Insight II software based on atomic coordinates for the mRpn13 Pru–ubiquitin 
complex and monoubiquitin (PDB entry 1D3Z). In this model, the distal subunit of 
diubiquitin is positioned arbitrarily, as its only constraints prohibit steric clashes with 
other atoms. (C) hRpn13 Pru interacts with the I44 1 and A46 methyl groups of the 
proximal subunit. 1H, 13C heteronuclear multiple-quantum coherence spectra were 
acquired on samples containing either no (black) or equimolar unlabeled hRpn13 (amino 
acids 1–150) (red) mixed with diubiquitin in which its proximal (left) or distal (right) 
subunit is labeled with 13C. The shifted resonances are labeled. (D) Model for how Rpn13 
participates in Uch37 deconjugation of ubiquitinated substrates. Rpn13's C-terminal 
domain (grey) binds Uch37 (orange) as its N-terminal domain binds the polyubiquitin 
chain and Rpn2/S1 (yellow). In this model, Uch37 binds to the distal subunit (light blue) 
of the chain while Rpn13 binds the proximal subunit (dark blue). 
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3.3 Conclusion 
In conclusion, we reveal that the ubiquitin-binding region of proteasome subunit 
Rpn13 adopts a PHD fold, and we solve its structure complexed with ubiquitin to unveil a 
new ubiquitin-binding mode. PHDs are present in a remarkably large number of proteins 
(202), but Rpn13 Pru is the first example of a PHD structure within the 26S proteasome. 
Rpn13, like many other ubiquitin receptors, binds to the L8, I44 and V70 hydrophobic 
pocket of ubiquitin (Figure 3.2B). However, it is the first to bind this region using 
exclusively loops (Figure 3.4A). Most of the ubiquitin receptors characterized so far use 
α-helices to bind this surface of ubiquitin, including the ubiquitin-associated (UBA)-
domain, coupling ubiquitin to endoplasmic reticulum degradation (CUE)-domain, 
ubiquitin-interacting motif (UIM), double-sided UIM (DUIM), inverted UIM (MIU), as 
well as GAT (GGA and TOM)-binding motifs (GGA, golgi-localized, γ-ear-containing, 
Arf (ADP-ribosylation factor)-binding protein; TOM, target of Myb). Among them, the 
UBA and CUE domains are structurally homologous, with a common three-helical 
bundle architecture. Cue2-1cue binds ubiquitin through the α1 and α3 helices (Figure 
3.4B) (198), whereas the Dsk2UBA uses the loop between α1 and α2, as well as the C-
terminal part of α3 (Figure 3.4C) (65). Structural characterization of the UIMs 
demonstrated that a single α-helix is sufficient for binding this region of ubiquitin (49, 
51, 203). The UIM helix includes a conserved alanine neighbored by a bulky 
hydrophobic residue, each of which packs against ubiquitin’s I44 as demonstrated in the 
S5a UIM1–ubiquitin complex (Figure 3.4D) (51). Rabex-5 MIU/IUIM (56, 57) and the 
polymerase η ubiquitin-binding zinc finger domain (204) similarly bind this region in 
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ubiquitin through a single α-helix, but in the reverse orientation (Figure 3.4E). The 
GLUE domain of ESCRT-II EAP45, which exhibits a split pleckstrin-homology 
topology, is the only previously known ubiquitin-binding PHD (94). However, it binds 
ubiquitin in a different manner: the I44-containing surface of ubiquitin is contacted by 
residues within secondary structural elements including the EAP45 C-terminal helix 
corresponding to H1 in Rpn13 (94) (Figure 3.4F). Moreover, although the longer S6–S7 
loop of EAP45 is involved in binding ubiquitin, the S2–S3 and S4–S5 loops are not; 
instead, contacts are formed by residues from S5 and S6. 
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Figure 3.4. Structural comparison of ubiquitin receptors complexed with ubiquitin.  
Complex structures of ubiquitin and specific receptors displayed with ubiquitin in the 
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same orientation (grey) and ubiquitin's I44 shown in black sticks. Each receptor has a 
unique color coding: (A) Rpn13 Pru (red); (B) Cue2-1CUE (PDB code 1OTR; light green); 
(C) Dsk2UBA (PDB code 1WR1; dark green); (D) S5a-UIM1 (PDB code 1YX5; light 
blue); (E) Rabex-5 MIU/IUIM (PDB code 2FIF; dark blue); (F) EAP45 GLUE domain 
(PDB code 2HTH; yellow). All structures are compared by a best-fit superposition of 
bound ubiquitin (grey). In (C) L1 denotes the loop connecting α1 and α2. 
 
In addition to its unique monoubiquitin-binding mode, we have demonstrated that 
Rpn13 has a novel preference for diubiquitin elements within K48-linked chains, as 
described in Chapter 2, and that it most likely interacts directly with the isopeptide bond 
within a ubiquitin chain. This ubiquitin-binding mode is consistent with Rpn13’s 
functional relationship with Uch37, which it adds to the collection of chain-processing 
enzymes in the proteasome’s regulatory particle (163, 169, 171). For diubiquitin, hRpn13 
binding to the proximal subunit would leave the distal one available to interact with 
Uch37 (Figure 3.3D). Evidence exists for Uch37 binding to the distal subunit of 
polyubiquitin; it is reported to be incapable of disassembling ubiquitin chains in which 
the distal ubiquitin contains the L8A and I44A mutations (205) and dismantles chains by 
removing one ubiquitin moiety at a time from the distal end (174). Uch37’s distal-end 
deconjugation of ubiquitin chains (174) complements that of Ubp6 and Rpn11, as Ubp6 
can deconjugate multiple ubiquitins in a single cleavage event (189) and Rpn11 performs 
‘en bloc’ deubiquitination from the proximal end (206, 207). Deubiquitinating activities, 
particularly that of Ubp6, are antagonized by another regulatory particle component, the 
chain elongation factor Hul5 (208). With so many receptors and chain-processing 
enzymes within the regulatory particle, the detailed pathway by which a substrate is 
degraded may be subject to many stochastic variations. Whether this unanticipated design 
promotes high substrate flux through the proteasome is unclear, but it seems well suited 
  92 
to allow the cell to fine-tune proteasome activity. 
 
3.4 Methods Summary 
3.4.1 Expression, purification, crystallization and structure determination of 
mRpn13 Pru 
mRpn13 Pru was overexpressed in Escherichia coli strain BL21(DE3) RIL 
(Stratagene) and purified by GST-affinity chromatography using a PreScission Protease 
(GE Healthcare) cleavage site followed by size-exclusion chromatography. Rpn13 Pru 
was crystallized by the hanging-drop vapor-diffusion method and frozen in a stream of 
liquid nitrogen during X-ray exposure. Single anomalous dispersion methods were 
performed using synchrotron radiation at the BW6 beamline at the DESY-centre in 
Hamburg, Germany. Native data were collected to 1.7-Å resolution (Table 3.S1). Details 
about recombinant DNA modifications, expression and purification of mutant forms of 
Rpn13 Pru, data processing, phase determination, model building and structural 
refinement are described in Section 3.6.1. 
 
3.4.2 NMR Spectroscopy 
Chemical shift assignments and spectra were acquired as described in Section 
3.6.1. mRpn13 Pru–ubiquitin and mRpn13 Pru–diubiquitin complexes were generated as 
described in Section 3.6.1. 
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3.5 Supplementary information 
3.5.1 Material and methods 
3.5.1.1 Cloning of murine Rpn13 Pru 
The mammalian expression vector pcDNA3.1/myc-his containing the full-length 
cDNA of mRpn13 (murine Adrm1/Rpn13, Swiss-Prot: Q9JKV1; was kindly provided by 
Dr. Lamerant, Centre de Biophysique Moléculaire, France, (185) and used for subcloning 
into pcDNA3-myc (EcoRI/XhoI). The N-terminal part (1-150) of the mRpn13 cDNA was 
amplified by PCR using primers 5`-GCGGATCCATGACGACTTCAGGCGCTCTG-3` 
and 5`- GCGGATCCTCACAGTGCTGAAAGCTC-3`, thereby introducing flanking 
BamHI (underlined) restriction sites. The BamHI-cleaved PCR product was subcloned 
into E. coli expression vector pRSET-GST-PP. The pRSET-GST-PP vector was derived 
from the pRSET vector (Invitrogen) by cutting out the MCS with restriction enzymes 
NdeI and BamHI and insertion of the DNA encoding GST-tag followed by a PreScission 
Protease cleavage site. Mutants of mRpn13 (S55E, L56A, I75R, F76R, D79N, and F98R) 
were created b site-directed mutagenesis (Stratagene). Deletion mutants of hRpn2 (695-
953, 797-953, 881-953, and 902-953) were amplified by PCR, subcloned into pEGFP-C1 
(Clontech) and pGEX-4T1 (Amersham).  
 
3.5.1.2 Expression and Purification of Rpn13 Pru 
Rpn13 Pru was overexpressed in E. coli strain BL21(DE3) RIL (Stratagene). 
Expression was induced by addition of 0.5 mM IPTG at an OD600nm of ~0.6 and cells 
were grown at 24 °C overnight. Cell pellets were resuspended in 1/100 of culture volume 
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in buffer A (20 mM Tris-Cl, pH 8.0; 100 mM NaCl; 1 mM DTT). Cells were lysed by 
sonication at 0°C and the suspension was clarified by centrifugation at 4°C and 20000 g 
for 20 min. GST-fused protein was purified from bacterial lysate by affinity 
chromatography using Glutathione Sepharose 4B (Amersham Biosciences). Recombinant 
protein was eluted from glutathione beads by cleavage with PreScission Protease at 30°C 
for 1 h in buffer A. The eluted protein was further purified in buffer B (20 mM Tris-Cl, 
pH 8.0; 40 mM NaCl; 1 mM DTT) on a Superdex 200 gel filtration column (Amersham 
Biosciences). The typical yield of purified soluble Rpn13 Pru from 3 L of culture was ~4 
mg. For selenomethionine labeling, Rpn13 Pru was overexpressed in the methionine 
auxotroph E. coli strain B834(DE3) (Novagen). Cells were grown in New Minimal 
Medium (209) at 37°C to an OD600nm of ~0.6, expression was induced with 0.5 mM 
IPTG. Incubation was continued at 24°C overnight. Purification of selenomethionine-
labeled protein was performed according to the same procedure as for native protein. 
 
3.5.1.3 Biochemical pull-down assays 
 For GST pull-down of purified proteins, GST-fused tetraubiquitin coupled to 
beads was cleaved with thrombin (Novagen) 4 h at 4°C in a cleavage buffer containing 
20 mM Tris-HCl (pH 8.4), 150 mM NaCl, 2.5 mM CaCl2 and 1 mM DTT. Thrombin 
was inactivated with addition of PMSF and GST bound to beads was removed by 
centrifugation. Supernatant was further used for GST pull-down with GST and various 
GST-fused proteins in incubation buffer containing cleavage buffer, 10% glycerol and 
1% Triton X-100. After 5 hours of incubation at 4°C, beads were washed three times with 
  95 
incubation buffer. Bound proteins were boiled for 5 minutes in SDS sample buffer and 
analyzed by SDS-PAGE and immunoblotting. 
 
3.5.1.4 Crystal growth  
Crystals grew at 20°C within two days to the size of 500 x 200 x 200 µm3. 
Crystallization drops contained equal volumes of protein (5 mg/ml) and reservoir solution 
(15 % (w/v) PEG 4000, 200 mM NaOAc, 1 mM DTT, 100 mM Tris-HCl, pH 8.5). 
Before exposure to X-rays, crystals were soaked in a solution of mother liquor including 
15% PEG 400 for 5 min and subsequently frozen in a stream of cold nitrogen gas at 100 
K (Oxford Cryosystems).  
 
3.5.1.5 Data processing and structure determination  
Data were processed with DENZO and SCALEPACK (210). The space group of 
Rpn13 Pru was P212121 with unit cell dimensions of a=42.4 Å, b=56.2 Å, c=63.2 Å. 
Phase determination was performed by crystal structure analysis of an Rpn13 Pru-SeMet-
derivative. SAD data were collected at 2.7 Å resolution using absorption peak 
wavelengths (0.9793 Å, see Table 3.S1). Two Se-sites were localized using SHELXD 
(211). Subsequent phasing with MLPHARE (212, 213) and solvent flattening with DM 
(214) resulted in an interpretable electron density map, which was traced and phase 
extended to the native data set at 1.7 Å resolution using ARP-WARP (215). The model 
was completed using the interactive three-dimensional graphic programs MAIN (216) 
and refined with REFMAC5 (217). Temperature factors were refined with restraints 
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between bonded atoms and between non-crystallographic symmetry related atoms. Rcrys 
and Rfree have been refined to 0.202 and 0.227, respectively (218). 
 
3.5.1.6 NMR spectroscopy and the assignment of hRpn13 
NMR spectra were acquired at 25°C on a Varian NMR spectrometer operating at 
800 MHz with a cryogenically cooled probe. Processing was performed in NMRPipe 
(196) and the resulting spectra visualized with XEASY (219). Protein concentrations 
were calculated by using extinction coefficients based on amino acid composition and 
absorbance at 280 nm for protein dissolved in 6M guanidine-HCl. All NMR samples 
were dissolved in buffer C (20 mM NaPO4 (pH 6.5), 30 mM NaCl, 2mM DTT, 0.1% 
NaN3, and 10% D2O). 
We performed optimized triple resonance experiments to assign chemical shift 
values to hRpn13 Pru domain’s backbone (N,HN,Cα,C’) and Cβ  atoms. Chemical shift 
assignments were made by using 3D HNCA/HNCOCA and HNCACB experiments on 
0.6 mM 15N-, 13C- and 70% 2H-labeled hRpn13 Pru in buffer C. An 15N dispersed 
NOESY spectrum (200 ms mixing time) acquired on 15N-, 50% 2H-labeled human Rpn13 
Pru was used to confirm the assignments and that the secondary structural elements 
match those of the crystal structure (example provided in Figure 3.S8). Due to its 
favorable chemical shift dispersion, we were able to assign all of the backbone atoms of 
hRpn13 (1-150), except for V38 and S90. 
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3.5.1.7 Chemical shift perturbation data  
We performed three sets of chemical shift perturbation analyses on hRpn13 Pru 
complexes with monoubiquitin and tetraubiquitin. In particular, unlabeled monoubiquitin 
or tetraubiquitin was added to 15N labeled hRpn13 Pru (Figure 3.S6A) or alternatively 
unlabeled hRpn13 Pru was added to 15N labeled monoubiquitin (Figure 3.S6B). In each 
case, the 15N labeled protein was observed by 1H, 15N HSQC experiments as it bound its 
unlabeled binding partner. We mapped the amide nitrogen and hydrogen chemical shift 
changes for each residue according to Equation 3.S1.  
€ 
CSP = 0.2ΔδN2 + ΔδH2  (3.S1) 
In this equation ΔδN and ΔδH represent the changes in the amide nitrogen and proton 
chemical shifts (in parts per million), respectively. S55, L56, I75, F76, D79, F82, L96, 
F98 and G101 all exhibited significant amide resonance shifting as hRpn13 Pru bound 
ubiquitin (Figure 3.S6A, black). Only two residues in Rpn13, L73 and R104, exhibited 
effects that were specific to K48-linked tetraubiquitin (Figure 3.S6A, red). 
 
3.5.1.8 Rpn13:ubiquitin structure calculations  
We solved the structure of the Rpn13:ubiquitin complex by using NOE-derived 
distance constraints between hRpn13 and monoubiquitin. These were derived by using an 
15N dispersed NOESY experiment acquired on 15N-, 13C- and 70% 2H-labeled hRpn13 
Pru mixed with equimolar ratio of unlabeled ubiquitin. For this experiment, no 13C or 2H 
decoupling was implemented to enable the ready identification of intermolecular NOE 
interactions. Further validation that the assigned NOEs were intermolecular was achieved 
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by their absence in an 15N dispersed NOESY experiment acquired under identical 
conditions on 15N-labeled hRpn13 Pru alone. Chemical shift assignment of the sidechain 
ubiquitin atoms was obtained by following the assigned resonances of the free protein 
upon addition of increasing molar rations of unlabeled hRpn13 Pru. In total, we identified 
twelve explicit intermolecular NOE interactions between L8, F45, A46, Q49, H68, and 
V70 of ubiquitin and F76, D78, D79, F98, A100, G101, K103, and R104 of hRpn13, 
Figure 3.2A.  
Only five amino acid residues differ between the N-terminal ubiquitin-binding 
domain of human and murine Rpn13 Pru, and none of these are implicated by the NMR 
data as binding ubiquitin. Moreover, an 15N dispersed NOESY experiment confirmed that 
hRpn13 Pru in solution is similar to the crystal structure of mRpn13 in terms of topology 
and architecture, as well as in the disordered state of the N-terminal 21 and C-terminal 20 
amino acids. Therefore, the mRpn13 Pru crystal structure (Figure 3.1A) was used as a 
starting structure along with the NMR data on hRpn13 to determine the structure of the 
mRpn13 Pru:ubiquitin complex.  
 The mRpn13 Pru:ubiquitin complexes were generated by using HADDOCK1.3 
(High Ambiguity Driven protein-protein DOCKing) (220) in combination with CNS 
(221). The atomic coordinates for ubiquitin were obtained from PDB entry 1D3Z (222). 
All atom pairs exhibiting an intermolecular NOE interaction were constrained to be 
within 1.8 – 6.0 Å of each other. In addition, the constraints from the hydrogen bonds 
published for ubiquitin (PDB code 1DZ3) were used to maintain its fold, as the protein 
does not undergo any gross structural change upon binding. Data afforded by NMR 
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titration experiments that record amide chemical shift changes that result from complex 
formation have been successfully used to determine the structure of protein complexes 
(42, 223, 224). We therefore generated so-called Ambiguous Interaction Restraints 
(AIRs) to complement our unambiguous NOE-based distance constraints. Briefly, 
residues with chemical shift perturbation values greater than one standard deviation value 
above the average were defined as “active” (Table 3.S2) and their neighbors as “passive” 
provided they have >50% accessibility. AIRs restrict active residues to be within 2.0 Å of 
any atom of the binding partner’s active or passive residues, as described (220). Our 
mRpn13:ubiquitin complex is well defined and the omission of any one NOE interaction 
yields identical results. 
 For the first step of rigid-body energy minimization, 1000 structures were 
generated. 200 structures having the lowest energy from the rigid-body docking were 
subjected to semi-flexible simulated annealing in torsion angle space followed by 
refinement in explicit water. During semi-flexible simulated annealing, atoms at the 
interface were allowed to move but constrained by the AIRs and unambiguous NOE-
derived distance constraints. After water refinement, the resulting structures were sorted 
according to intermolecular energy and clustered using 1.5 Å cut-off criterions. This 
treatment resulted in an ensemble of 200 structures with the average RMSD of 0.94 ± 
0.31 Å for all backbone atoms and 0.75 ± 0.23 Å for the backbone atoms at the interface. 
The ten lowest energy structures in the lowest energy cluster were evaluated according to 
the following criteria: all intermolecular hydrophobic contacts between heavy atoms 
being less than 3.9 Å, intermolecular hydrogen bond distances between proton-acceptor 
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and donor-acceptor pair being within 2.7 Å and 3.35 Å, respectively, and minimum 
angles of 90° for donor-hydrogen-acceptor, hydrogen-acceptor-acceptor antecedent, 
donor-acceptor-acceptor antecedent atoms of hydrogen bonds (225). The ten lowest 
energy structures are provided as Figure 3.S9. It is worth noting that the NOE-derived 
distance constraints define the mRpn13 Pru:ubiquitin structure, which does not change 
upon omission of the AIRs. 
 
3.5.1.9 Modeling the mRpn13 Pru:diubiquitin complex  
The model structure of mRpn13 Pru:diubiquitin was built from the structures of 
the mRpn13 Pru:ubiquitin complex and ubiquitin (PDB entry 1D3Z) by using Insight II 
(Accelrys, Inc). For diUb, the two monoubiquitin molecules were conjugated by forming 
the G76-K48 isopeptide bond and allowing rotations in the K48 sidechain of proximal 
ubiquitin to avoid steric clashes between the distal ubiquitin subunit and Rpn13. The 
structure was subsequently energy-minimized by using SYBYL (Tripos, Inc.).   
 
3.5.2 Supplementary tables 
Table 3.S1: Data collection and refinement statistics 
 mRpn13 Pru mRpn13 Pru SeMet 
   
Crystal parameters   
Space group P212121 P21212 
Cell constants  a=42.4 Å; b=56.2 Å; 
c=63.2 Å 
a=42.7 Å; b=56.4 Å; 
c=64.2 Å 
Heavy metal - 2 
   
Data collection   
Beamline BW6, DESY BW6, DESY 
Wavelength (Å) 1.05 0.9793 
  101 
Resolution range (Å)a 99-1.7 (1.70-1.67) 99-2.62 (2.7-2.66) 
No. observations 1007679 227878 
No. unique reflectionsc 25165 8927 
Completeness (%)b 99.5 (99.9) 98.9 (100) 
Rmerge (%)b, c 5.1 (27.2) 10.0 (35.3) 
I/σ (I)b 19.1 (2.9) 32.6 (11.4) 
   
Refinement (REFMAC5)   
Resolution range (Å) 15-1.7  
No. reflections working set 16267  
No. reflections test set 813  
No. non hydrogen 973  
Solvent water  106  
Rwork/Rfree (%)d 19.9 / 22.4  
Rwork/Rfree (2.74-1.70 Å ) 
(%)d 
24.5 / 27.7  
rmsd bond lengths (Å) / (°)e 0.012 / 1.75  
Average B-factor (Å2) 30.67  
Ramachandran Plot (%)f 92.7 / 7.3 / 0.0  
 
 
a The values in parentheses of resolution range, completeness, Rmerge and I/σ (I) correspond 
to the last resolution shell. 
b Friedel pairs were treated as different reflections. 
c Rmerge(I) = ΣhklΣj |[I(hkl)j - I(hkl)] |/[Σhkl Ihkl , where I(hkl)j is the jth measurement of the 
intensity of reflection hkl and <I(hkl)> is the average intensity. 
d R = Σhkl | |Fobs| - |Fcalc| |/Σhkl |Fobs|, where Rfree is calculated without a sigma cutoff for a 
randomly chosen 5% of reflections, which were not used for structure refinement, and 
Rwork is calculated for the remaining reflections. 
e Deviations from ideal bond lengths/angles. 
f Number of residues in favored region / allowed region / outlier region. 
 
Table 3.S2. List of active and passive residues defined in hRpn13 Pru and Ubiquitin as 
defined by chemical shift perturbation plots for HADDOCK 
Protein Active residues Passive residues Flexible segments 
hRpn13 Pru 55,76,78,99,101,104 53,54,74,77,81,83,100,102,103 51-57,72-85,97-106 
Ubiquitin 47,48,49,68 6,8,9,10,11,12,16,42,46,51,72 4-18,40-53,66-74 
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3.5.3 Supplementary Figures 
 
Figure 3.S1. Sequence alignment of Rpn13 Pru homologues from Mus musculus (Mm), 
Homo sapiens (Hs), Drosophila melanogaster (DM), Caenorhabditis elegans (Ce), 
Arabidopsis thaliana (At), Schizosaccharomyces pombe (Sp), Saccharomyces cerevisiae 
(Sc). Identical residues of Rpn13 Pru are highlighted against a yellow background, 
conserved residues against a grey background. Sequence stretches given in grey are 
disordered in the crystal structure. Residues involved in formation of the hydrophobic 
core of the PH domain are conserved among all eukaryotes and indicated by red boxes. 
Secondary structure elements of Rpn13 Pru contributing to the topology of the PH 
domain are indicated in blue and additional secondary structure elements in grey. 
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Figure 3.S2. Zoomed view of Figure 3.2B to highlight several key hydrophobic (green 
dashed lines) or hydrogen bond (red dashed lines) interactions. Several contact residues 
from ubiquitin (yellow) or Rpn13 (red) are displayed.  
 
 
 
Figure 3.S3. Stereo representation of the electrostatic surface potential of mRpn13 Pru’s 
ubiquitin-binding surface with several of its key ubiquitin-binding residues labeled in 
black. The surface is color coded according to electrostatic potential, contoured from -
25kT/e (intense red, negative charges) to +25kT/e (intense blue, positive charges). A 
ribbon representation of ubiquitin is displayed with certain contact residues in balls-and-
sticks representation and labeled in green. 
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Figure 3.S4. The L56A, F76R and D79N point mutations do not compromise the 
structural integrity of the mRpn13 Pru domain. Only local effects are observed in 
superimposed 1H, 15N HSQC spectra of 15N labeled mRpn13 Pru wild-type (black) and 
L56A (cyan), F76R (red), or D79N (green) protein. Shifted resonances are labeled. 
 
 
 
 
Figure 3.S5. Different deletion mutants of hRpn2 (695-953, 797-953, 881-953 and 902-
953) were expressed as GST-fused proteins and tested for their ability to bind mRpn13 
(1-150) transiently expressed as myc-tagged protein in HEK293T cells. All deletion 
mutants of hRpn2 could bind mRpn13, showing that the last 52 amino acids of hRpn2 are 
sufficient for mRpn13 binding. 
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Figure 3.S6. (A) Chemical shift perturbation analysis reveals residues within Rpn13 Pru 
that bind monoubiquitin (black) and K48-linked tetraubiquitin (red). Amide chemical 
shift values of hRpn13 Pru alone were compared to values with equimolar quantities of 
unlabeled ubiquitin (black) or K48-linked tetraubiquitin (red). Data were recorded and 
quantified by 1H, 15N HSQC experiments as described in Supplementary Information. 
Residues that were significantly affected by monoubiquitin or tetraubiquitin are labeled. 
L73 and R104 (labeled in purple) of hRpn13 Pru exhibit effects specific to K48-linked 
tetraubiquitin. (B) Comparison of amide chemical shift values of free and Rpn13 Pru-
bound ubiquitin at equimolar concentration, as described in (A). For this experiment, 
ubiquitin is 15N labeled and its significantly shifted resonances are labeled; residues that 
undergo severe broadening are marked with asterisks and emphasized with a black arrow. 
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Figure 3.S7. (A) As observed for the proximal subunit of diubiquitin, the I44 δ1 and A46 
methyl groups of monoubiquitin undergo significant resonance shifting upon hRpn13 (1-
150) addition. 1H,15N HMQC spectra are displayed for 13C-labeled 
monoubiquitin:hRpn13 (1-150). (B) The weight average sedimentation coefficient as a 
function of diubiquitin to hRpn13 molar ratios reveals 1:1 binding stoichiometry 
Experimentally determined values obtained by using sedimentation velocity analysis 
(black) and theoretical plot for 1:1 binding stoichiometry (red) are included.  
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Figure 3.S8. The NOE patterns observed in an 15N dispersed NOESY spectrum confirm 
that the solution structure of hRpn13 Pru matches the solved crystal structure of mRpn13 
Pru. An example is provided for a helical region spanning D115-N130, in which amide-
to-amide NOE interactions confirm its helical structure. Consistency with the crystal 
structure is also evident from chemical shift index analysis for Cα and C’ atoms (data not 
shown). 
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Figure 3.S9. Stereoview of the ten lowest energy structures of the Rpn13 Pru:ubiquitin 
complex. The lowest energy structure was selected to represent the model. Backbone 
atoms of Rpn13 Pru and ubiquitin secondary structural elements are displayed in dark 
blue and red, respectively. Atoms in loops of Rpn13 Pru and ubiquitin are sky blue and 
orange, respectively. 
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4.1 Synopsis 
Degradation by the proteasome typically requires substrate ubiquitination. Two 
ubiquitin receptors exist in the proteasome, S5a/Rpn10 and Rpn13. Whereas Rpn13 has 
only one ubiquitin-binding surface, S5a binds ubiquitin with two independent ubiquitin 
interacting motifs (UIMs). In this Chapter, we use NMR and analytical 
ultracentrifugation to define at atomic level resolution how S5a binds K48-linked 
diubiquitin, in which K48 of one ubiquitin subunit (the “proximal” one) is covalently 
bonded to G76 of the other (the “distal” subunit). We demonstrate that S5a’s UIMs bind 
the two subunits simultaneously with a preference for UIM2 binding to the proximal 
subunit while UIM1 binds to the distal one. In addition, NMR experiments reveal that 
Rpn13 and S5a bind K48-linked diubiquitin simultaneously with subunit specificity, and 
a model structure of S5a and Rpn13 bound to K48-linked polyubiquitin is provided. 
Altogether, our data demonstrate that S5a is highly adaptive and cooperative towards 
binding ubiquitin chains. 
 
4.2 Introduction 
Ubiquitin conjugation plays a key regulatory role in a wide array of biological 
processes. In its most established role, ubiquitination targets proteins for degradation by 
the 26S proteasome (226), a process important for controlling the lifespan of regulatory 
proteins, removing misfolded proteins, producing immunocompetent peptides (227), and 
regulating cell cycle progression (228, 229). 
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The 26S proteasome contains a 20S catalytic core particle (CP) capped at either or 
both ends by 19S regulatory particles (RPs), which prepare substrates for hydrolysis in 
the CP. RP ubiquitin receptors S5a/Rpn10 (230) and Rpn13 (231) capture substrates by 
recognizing their covalently attached ubiquitin chains, which are removed and 
disassembled by three deubiquitinating enzymes Rpn11 (206), Ubp6/Usp14 (184) and 
Uch37/UCHL5 (174). These actions of the RP’s ubiquitin processing enzymes are 
complemented with that of six ATPases that unfold protein substrates to allow their 
passage into the CP for degradation.  
Ubiquitin receptors play an integral role in substrate capture and apparently 
contribute to ubiquitin chain deconjugation, as Rpn13 binds and activates 
deubiquitinating enzyme Uch37 (163, 169, 171). S5a and Rpn13 may receive 
ubiquitinated proteins from extra-proteasomal receptors, including the hHR23 and hPLIC 
proteins, which bind to them with ubiquitin-like (UBL) domains (164, 166, 231) and to 
ubiquitin with ubiquitin-associated (UBA) domains (124, 161, 162). UBL-UBA proteins 
can also dock substrates into the proteasome by binding to Rpn1/S2 (232), a scaffolding 
protein that may also bind S5a (233). S5a is also abundant free of the proteasome, where 
it has been demonstrated in budding yeast to prevent the hPLIC homolog Dsk2 from 
binding to proteasome and inhibiting substrate degradation (234). Although not essential 
in budding yeast (235), S5a is essential in mice (236) and Drosophila melanogaster 
(237). 
Unique roles for the ubiquitin receptors associated with proteasome degradation 
are suggested by their diverse ubiquitin binding properties. hHR23a is sandwiched 
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between the ubiquitin subunits of K48-linked diubiquitin (42), effectively sequesters 
subunits of polyubiquitin up through octaubiquitin (238), and protects ubiquitin chains 
from deubiquitination (157, 239). By contrast, Rpn13 binds preferentially to the proximal 
subunit of K48-linked diubiquitin leaving the distal one available for other interactions 
(240), presumably including that of Uch37, which may facilitate its distal end (174) 
deubiquitinating activity (163, 169, 171).  
Although S5a was the first proteasome ubiquitin receptor discovered (230), its 
structure complexed with polyubiquitin has not yet been solved. Like Rpn13, the yeast 
Rpn10 protein is significantly truncated compared to its human S5a homologue (Figure 
4.1A). Whereas mammalian Rpn13 gains a deubiquitinating enzyme binding domain 
(that of Uch37), the extension in mammalian S5a affords a second UIM that binds 
ubiquitin more strongly than the conserved one (241). In previous work, we solved the 
structure of S5a (196-306) alone and complexed with monoubiquitin to reveal that its two 
UIMs act independently in each of these structures (241).  
In this chapter, we use NMR spectroscopy and analytical ultracentrifugation to 
solve the S5a (196-306):K48-linked diubiquitin structure. In contrast to S5a’s binding of 
monoubiquitin, its two UIMs bind a common diubiquitin molecule rather than recruit two 
diubiquitins simultaneously. Moreover, it exhibits subunit specificity and binding 
determinants that make its interaction with ubiquitin chains unique from that of Rpn13 or 
hHR23a. In addition, we demonstrate that S5a and Rpn13 bind K48-linked diubiquitin 
simultaneously with subunit specificity. This research provides fundamental information 
on how the proteasome recognizes polyubiquitinated substrates. 
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4.3 Results 
4.3.1 S5a’s UIMs bind to ubiquitin subunits of K48-linked diubiquitin 
simultaneously and with different affinities 
We used NMR spectroscopy to determine whether S5a’s two UIMs bind 
independently to K48-linked diubiquitin. We added unlabeled K48-linked diubiquitin to 
15N labeled human S5a (196-306), which contains its two UIMs (Figure 4.1A), and used 
1H,15N HSQC experiments to detect binding. NMR signals belonging to UIM1 and UIM2 
residues were affected by diubiquitin addition, thus demonstrating diubiquitin’s 
interaction with both UIMs. Different binding behavior was observed for each of the 
UIMs however. Upon diubiquitin addition, UIM1 signals shift and broaden progressively 
to their fully saturated state (Figure 4.1B), indicating that these residues exchange rapidly 
on the NMR timescale (100 milliseconds) between their free and bound states. UIM2 
signals by contrast exhibit two peaks prior to saturation, which are not broadened by 
exchange (Figure 4.1C, blue spectrum) and are representative of their free and 
diubiquitin-bound states, according to comparisons of spectra recorded on free (Figure 
4.1C, blue spectrum) and fully saturated S5a (Figure 4.1C, red spectrum). Hence, UIM2 
with its readily observed diubiquitin-bound state is the stronger binding partner.  
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Figure 4.1. S5a’s affinity for diubiquitin is enhanced by its two UIMs binding to 
ubiquitin subunits simultaneously. (A) Sequence alignment of the ubiquitin-binding 
region of human and mouse S5a with their Saccharomyces cerevisiae homologue Rpn10. 
The helices of S5a are highlighted in red and a strictly conserved region N-terminal to 
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UIM1 is boxed. The UIM’s hallmark LALAL/IAYAM motif is underlined. (B) UIM1 
resonances shift and broaden upon binding to K48-linked diubiquitin. 1H,15N HSQC 
spectra expanded to view L218 are displayed for 15N labeled S5a (196-306) alone (black) 
and at 2:1 (blue), 1:1 (green), 1:2 (orange), and 1:3 (red) S5a:K48-linked diubiquitin 
molar ratio. The amide resonance of I248, which is not involved in diubiquitin-binding 
and does not shift with increasing quantities of diubiquitin, overlaps with the L218’s 
unbound resonance. (C) UIM2 resonances exhibit slow exchange dynamics upon binding 
to K48-linked diubiquitin. 1H,15N HSQC spectra expanded to view E284 are displayed 
for S5a alone (black) and at 2:1 (blue), 1:1 (green), and 1:3 (red) S5a:K48-linked 
diubiquitin molar ratio. (D) Sedimentation velocity results reveal S5a (196-306) to bind 
K48-linked diubiquitin with 1:1 stoichiometry and with an affinity of 8.9+0.6 mM. 
Experimentally determined averaged sedimentation coefficients (diamonds) are plotted. 
(E) Binding affinities are displayed for S5a (196-306) binding to diubiquitin, as 
determined with the data of (D), and for each UIM binding to monoubiquitin (241, 242). 
(F) Model depicting the two S5a:diubiquitin states present at 1:1 molar ratio. The weaker 
binding UIM1 exchanges between an unbound and bound state. Ub, ubiquitin; UIM1, 
S5a’s ubiquitin interacting motif 1; UIM2, S5a’s ubiquitin interacting motif 2. 
 
 
Unexpectedly, diubiquitin causes signals from the internal helix of S5a (196-306), 
which spans residues D257-E269, to shift (Figure 4.S1A). Such perturbations were not 
observed in S5a with monoubiquitin (Figure 4.S1B). This region does not contain a 
known ubiquitin-binding element and shows no direct contact with monoubiquitin. We 
tested whether it contacts diubiquitin by using a 13C half-filtered NOESY spectrum in 
which S5a (196-306) was 13C labeled and diubiquitin was unlabeled. This experiment 
records intermolecular NOE interactions between S5a and diubiquitin hydrogen atoms 
that are within 5 Å while selecting against intramolecular NOEs. Whereas such 
interactions were observed between S5a’s UIMs and diubiquitin (as described below), no 
residues within the intervening helix exhibited such intermolecular NOE interactions 
(data not shown). Therefore, the spectral perturbation of residues in this region upon 
diubiquitin addition is not due to its direct contact with diubiquitin. Moreover, the helical 
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structure of this region is preserved according to 15N and 13C dispersed NOESY spectra 
(Figure 4.S2). We therefore hypothesized that the spectral changes to this region are 
caused by physical constraints imposed by the simultaneous binding of both UIMs to 
diubiquitin.  
To test directly whether the two UIMs of S5a bind to the same diubiquitin 
molecule, we performed sedimentation velocity experiments. Data were recorded at 
molar ratios of diubiquitin to S5a (196-306) spanning 1:7 to 8:1 and the weight average 
sedimentation coefficients (sw) were plotted against molar ratio (Figure 4.1D). This 
analysis revealed a maximum at a 1:1 mixing ratio, indicating 1:1 binding stoichiometry. 
The decrease in sw at lower and higher mixing ratios is due to the presence of free 
diubiquitin and S5a, respectively. Global analysis of the sedimentation velocity data 
using this 1:1 binding model gives a best-fit Kd of 8.9+0.6 µM. This value is substantially 
lower than that determined for UIM1 and UIM2 binding to monoubiquitin (241) (listed in 
Figure 4.1E). Altogether, these data indicate that the two UIMs bind ubiquitin subunits of 
diubiquitin simultaneously and that this coordinated binding affords a greater affinity. 
The estimated Kd for S5a (196-306) binding to diubiquitin predicts that 86% of 
S5a is bound to diubiquitin when these two proteins are at equimolar ratio and 0.4 mM 
protein concentration. As mentioned above, however, S5a’s UIM2 exhibits stronger 
affinity compared to UIM1. The NMR titration experiments revealed that the binding 
between S5a’s UIM1 and diubiquitin is not saturated until diubiquitin is at 3-fold molar 
excess (Figure 4.1B). Two shifted peaks are observed for L278, S279, E284, A288 and 
S294 of S5a’s UIM2 at equimolar ratio (as demonstrated for E284 in Figure 4.
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which remains when diubiquitin is at 3-fold molar excess. We propose that the peak 
present with 3-fold molar excess diubiquitin corresponds to a state in which UIM2 and 
UIM1 fully occupy diubiquitin whereas the other stems from diubiquitin-bound UIM2 
when UIM1 is not bound (Figure 4.1F).   
 
4.3.2 UIM2 binds the proximal subunit while UIM1 binds the distal one 
To determine whether distinct binding preferences exist between K48-linked 
diubiquitin’s subunits and S5a’s UIMs, we acquired 3D 13C half-filtered NOESY 
experiments on two different samples (Figure 4.2A, top panel). In these, S5a (196-306) is 
unlabeled and mixed with diubiquitin with either its proximal (Figure 4.2B, black and 
Figure 4.S3A) or distal (Figure 4.2B, red) ubiquitin subunit 13C labeled. A hydrophobic 
patch formed by L8, I44, and V70 is used by ubiquitin to bind many of its receptors. 
These residues in the proximal, but not distal ubiquitin subunit, exhibit multiple 
intermolecular NOEs with S5a (196-306). Similarly, NOEs unique to the distal subunit 
were observed for the C-terminal b-strand of ubiquitin, especially L71 and L73. 
Importantly, intermolecular NOEs were observed to the residues in the diubiquitin linker 
region, namely K48 and Q49 of the proximal subunit and G75 or G76 of the distal 
subunit. Altogether, our data indicate that the two ubiquitin subunits form unique 
interactions with S5a and that contacts are made to the diubiquitin linker region of K48-
linked chains. 
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Figure 4.2. S5a prefers to bind K48-linked diubiquitin with its UIM1 bound to the distal 
subunit while its UIM2 binds the proximal one. (A) Schematic illustrating the NMR 
samples used for the 13C half-filtered NOESY spectra displayed in (B; top panel) and (C 
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and D; bottom panel). Coloring matches the associated spectrum, such that the labeled 
black and red subunits produced the spectra displayed in black and red, respectively. (B) 
13C half-filtered NOESY experiments recorded on K48-linked diubiquitin with either its 
proximal (black) or distal (red) subunit 13C labeled and mixed with unlabeled S5a (196-
306). Abundant NOE interactions are observed between UIM2 and the proximal subunit 
as well as between UIM1 and the distal subunit. Selected interactions are labeled and 
greater detail is provided in Figure 4.S3A. (C, D) 13C half-filtered NOESY spectra 
recorded with 13C-labeled S5a (196-306) and 3-fold molar excess unlabeled K48-linked 
diubiquitin (black) or K48-linked diubiquitin with its proximal subunit deuterated (red). 
Most interactions with UIM2 residues are mitigated by 2H labeling the proximal subunit 
(C), whereas those involving UIM1 resonances are not (D). Breakthrough diagonal peaks, 
which should be treated as noise, are circled in grey. NOE crosspeaks involving UIM2 
that are only slightly affected by deuterating the proximal subunit are circled in green; 
these indicate the presence of a minor species in which UIM2 binds the distal subunit. 
The sidechain atoms of (E) S5a and (F) diubiquitin residues that form intermolecular 
NOE contacts in the major binding species are highlighted with UIM1 and UIM2 in green 
and red, respectively, and diubiquitin’s proximal and distal subunits in black and red, 
respectively. 
 
We next sought to establish whether UIM1/2 binds to the proximal versus distal 
subunit of diubiquitin. We were able to assign all of the intermolecular NOEs involving 
diubiquitin’s proximal subunit to residues within UIM2 (Figure 4.2B and Figure 4.S3A). 
To confirm these assignments and to facilitate assigning the intermolecular NOEs 
involving the distal subunit, we acquired 3D 13C half-filtered NOESY experiments on 
samples containing 13C labeled S5a (196-306) and unlabeled diubiquitin (Figure 4.2C and 
4.2D, black) or diubiquitin in which the proximal subunit is 100% 2H labeled (Figure 
4.2C and 4.2D, red), illustrated in the bottom panel of Figure 4.2A. The latter spectrum 
contains NOE interactions between S5a and the distal ubiquitin subunit only as the 2H 
labeling silences the proximal subunit in this experiment.  
Consistent with our analysis of the 13C half-filtered NOESY experiments 
described above (Figure 4.S3A), residues of UIM2 displayed abundant intermolecular 
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NOEs with the L8-I44-V70 hydrophobic patch of diubiquitin (Figure 4.2C, black). Most 
of these were either eliminated or greatly reduced when the proximal subunit was 
silenced with 2H labeling (Figure 4.2C, red). A few intermolecular NOEs were only 
slightly affected by 2H labeling of the proximal ubiquitin subunit; these are between 
M291 and L295 in the UIM2 motif and A46 and K48 of diubiquitin (Figure 4.2C, circled 
in green). The comparable intensities of these intermolecular NOEs in the two spectra 
indicate that a population of S5a:diubiquitin is formed with UIM2 binding to the distal 
subunit. Moreover, the unique NOE pattern between UIM2 and diubiquitin’s distal versus 
proximal subunit suggests slightly different UIM2:ubiquitin binding motifs, as 
necessitated by the involvement of K48, which is chemically different in the two 
subunits. 
M291’s and L295’s side chain methyl groups have slightly different chemical 
shift values when bound to diubiquitin’s proximal versus distal subunit (Figure 4.S4). By 
obtaining the volume of M291’s methyl group NOE to K48 Ha in the proximal versus 
distal subunit, we estimated that UIM2 binding to diubiquitin’s proximal subunit is at 3-
fold molar excess compared to distal binding. Consistent with this analysis, NOE 
interactions between UIM1 and diubiquitin were only slightly affected by 2H labeling of 
the proximal subunit (Figure 4.2D, black versus red). Altogether, these data provide 
strong evidence that UIM2 is predominately bound to the proximal subunit of diubiquitin 
while UIM1 binds the distal subunit, and that a minor population exists with UIM2 bound 
to the distal subunit. In the next section, we present these two structures; however, it is 
worth noting here that the difference in the volume of the NOEs from M291’s methyl 
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group and diubiquitin’s proximal versus distal K48 Ha is not due to differences in their 
distances from each other in the two structures as only a 0.2 Å difference is observed. We 
used standard thermodynamics equations relating population to binding constants and 
Gibbs free energy (see Section 4.8) to estimate that an energy difference of 2.7 kJ/mol is 
sufficient for a 3:1 binding preference.  
 
4.3.3 Structure of S5a (196-306):K48-linked diubiquitin 
We assigned 59 and 31 NOE interactions between UIM2 and diubiquitin’s 
proximal and distal subunits, respectively. Unambiguous NOEs were also identified 
between F206, E215, A219, L220 and V222 and diubiquitin’s distal subunit (Figure 4.2B 
and 4.2D and Figure 4.S3B). We were surprised to find intermolecular NOEs between 
L73’s methyl groups of ubiquitin and F206, a conserved S5a residue that is nine amino 
acids N-terminal to the well-known LALAL ubiquitin-binding motif (Figure 4.1A). The 
S5a and diubiquitin residues that exhibited intermolecular NOEs are highlighted in 
Figures 4.2E and 4.2F. 
By using our intermolecular NOEs, we calculated a well defined structure for the 
major S5a (196-306):K48-linked diubiquitin species with no NOE violation above 0.3 Å 
(Figure 4.3, Table 4.1). For the minor species, we were able to use intermolecular NOEs 
between UIM2 and distal ubiquitin (Table 4.1). However, there were no NOE 
interactions between UIM1 and the proximal subunit, most likely because the protein 
concentration of this species is low (estimated at 0.125 mM) and, in contrast to UIM2, 
UIM1’s binding to diubiquitin causes resonance broadening (Figure 4.1B). Therefore, we 
  122 
modeled the UIM1:proximal ubiquitin interaction based on our UIM1:distal ubiquitin 
NOEs. In the S5a (196-306):monoubiquitin complex, the relative position of UIM1 and 
UIM2 is not defined as the two UIMs are separated by two flexible linker regions in 
addition to the intervening a-helix (241). The relative orientation of the two UIMs is 
more restricted in the complexes with diubiquitin by the simultaneous binding of the two 
UIMs to the ubiquitin subunits (Figure 4.3A). This restriction provides an explanation for 
the resonance broadening and shifting observed for residues in the intervening helix 
(Figure 4.S1A). Diubiquitin’s flexible linker region does, however, enable some freedom 
in the location of UIM1 relative to UIM2 (Figure 4.S5). 
 
 
 
The structure of S5a (196-306) complexed with K48-linked diubiquitin revealed 
interesting changes to the strictly conserved 206FGVDPS211 region N-terminal to UIM1  
(Figure 4.1A). Contacts between F206 and distal ubiquitin’s L73, as demonstrated in 
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Figure 4.2B (red) and Figure 4.3B, promote additional intramolecular interactions 
between 206FGVDPS211 and the LALAL motif to result in a more ordered structure. This 
consequence is apparent in our NMR data, as NOEs between P210 and A217 were strong 
in diubiquitin-bound S5a (196-306), but weak in spectra recorded on the unbound protein 
(data not shown).  
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Figure 4.3. Structure of S5a:K48-linked diubiquitin complexes. (A) Ribbon 
representation of the major and minor binding modes for S5a:K48-linked diubiquitin with 
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S5a’s UIM1 and UIM2 motifs in white and black, respectively, and diubiquitin’s 
proximal and distal subunits in blue and green, respectively. Diubiquitin’s K48-G76 
linkage is highlighted in yellow. (B) Expanded view of the UIM1:distal ubiquitin 
complex reveals critical interactions. Residues of UIM1 and distal ubiquitin are 
highlighted in red and cyan, respectively, whereas their ribbon structures are grey and 
green respectively. (C) Multiple contacts become more compact when UIM2 binds to the 
proximal subunit of K48-linked diubiquitin. UIM2’s M291 and L295 are displayed bound 
to proximal (pink and red) or distal (blue) ubiquitin. Selected distances are listed between 
M291 and L295 of UIM2 and proximal or distal ubiquitin atoms.  
 
We sought to understand why the preferred diubiquitin binding mode was with 
UIM2 bound to the proximal subunit and UIM1 bound to the distal subunit and 
conversely, how the two UIMs could accommodate the minor binding species with such a 
small energy difference between the two. Comparison of the UIM2:distal ubiquitin and 
UIM2:proximal ubiquitin structures revealed M291 to form unique van der Waals 
interactions with I44 and more compact contacts with G47 and Q49 of the proximal 
compared to distal subunit (Figure 4.3C). These differences are derived from our 
experimental data. For example, the intermolecular NOEs between G47’s Ha protons and 
L295’s methyl group are greatly diminished in the spectrum recorded on the sample with 
the proximal subunit silenced by deuterium labeling (Figure 4.2C). Some distances 
however lengthen in the proximal subunit, the most significant of which is that between 
one of L295’s methyl groups and A46’s Cb, as supported by the corresponding 
intermolecular NOEs displayed in Figure 4.2C. Therefore, UIM2 favors slightly different 
interactions with the two subunits. 
UIM1 showed the strongest interactions with the C-terminal end of distal 
ubiquitin (Figure 4.2B, red). This region’s dynamic motions are more restricted in the 
distal subunit due to the presence of the isopeptide linker (243), which apparently 
  126 
enhances its interaction with UIM1. These effects likely contribute to S5a’s preferred 
diubiquitin binding mode. UIM1’s importance in determining S5a’s diubiquitin binding 
mode is supported by previous studies on a UIM2 fragment, which exhibited little 
preference for the proximal versus distal subunit (244). 
 
4.3.4 S5a binds the distal subunit of K48-linked diubiquitin while Rpn13 binds the 
proximal subunit 
Rpn13’s ubiquitin binding domain binds to K48-linked diubiquitin with an 
affinity of 90 nM (92). Therefore, we tested whether it precludes S5a from binding to 
K48-linked diubiquitin. We added equimolar quantities of K48-linked diubiquitin and 
Rpn13 (1-150) to 13C labeled S5a (196-306). A 1H,13C HMQC experiment revealed S5a 
UIM1 and UIM2 resonances that shift upon addition of K48-linked diubiquitin (Figure 
4.4A, green) to appear at similar positions when Rpn13 was added with diubiquitin 
(Figure 4.4A, blue). Hence, Rpn13 does not preclude S5a from binding to K48-linked 
diubiquitin. To test whether Rpn13 and S5a bind diubiquitin simultaneously, we added 
equimolar quantities of unlabeled K48-linked diubiquitin and S5a to 15N labeled Rpn13. 
Rpn13 amino acids that are close to the isopeptide bond linkage when bound to the 
proximal subunit shift in a different manner when bound to K48-linked polyubiquitin 
versus monoubiquitin (240). We found these Rpn13 resonances to shift to their proximal-
bound state when S5a (196-306) is present (Figure 4.4B). Therefore, we hypothesized 
that Rpn13 binds to the proximal subunit while S5a binds to the distal subunit. 
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Figure 4.4. Ubiquitin receptors Rpn13 and S5a bind K48-linked diubiquitin 
simultaneously. (A) 1H, 13C HSQC experiments recorded on 13C labeled S5a (196-306) 
alone (black) or with equimolar K48-linked diubiquitin (green) or K48-linked diubiquitin 
and Rpn13 (1-150) (blue) reveal P276 (left panel) and V222 (right panel) to interact with 
diubiquitin when Rpn13 is present. B) 1H, 15N HSQC experiments on 15N labeled Rpn13 
(1-150) alone (black) and with monoubiquitin (orange), K48-linked diubiquitin (red) or 
K48-linked diubiquitin and S5a (196-306) (blue) reveals L73 to shift to its diubiquitin-
bound state when S5a is present. K48-linked diubiquitin with its (C) proximal or (D) 
distal subunit 15N labeled alone (black) or with Rpn13 (1-150) (red), S5a (196-306) 
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(green), or both of these receptors (blue) indicates shifting that mimics Rpn13 binding to 
the proximal subunit, but S5a binding to the distal one, as shown for F45 and Q62 of the 
proximal subunit and I44 and I61 of the distal subunit. Additional data is provided in 
Supplementary Figure 6. (E) Model illustrating Rpn13 bound to K48-linked diubiquitin’s 
proximal subunit and S5a’s UIMs interacting dynamically with the distal one. 
 
To test more directly which receptor binds K48-linked diubiquitin’s proximal 
subunit, we added S5a (196-306) and Rpn13 (1-150) or just one of these proteins to 
equimolar quantities of K48-linked diubiquitin with its proximal subunit 15N labeled. The 
observed chemical shift changes with both receptors present were similar to those caused 
by only Rpn13 addition, as demonstrated for F45 and Q62 (Figure 4.4C; see also Figure 
4.S6). By contrast, the addition of equimolar quantities of S5a (196-306) and Rpn13 (1-
150) to K48-linked diubiquitin with its distal subunit 15N labeled revealed the larger 
chemical shift changes characteristic of S5a (196-306) interaction, as illustrated for I44 
and I61 in Figure 4.4D. Altogether, our data indicate that S5a binds predominately to 
diubiquitin’s distal subunit while the stronger binding Rpn13 maintains its position at the 
proximal subunit.  
Although UIM2 has the stronger affinity for K48-linked diubiquitin, 13C 
resonances from both UIM motifs shift upon addition of K48-linked diubiquitin when 
Rpn13 is present (Figure 4.4A, blue). Rpn13 however either mitigates the chemical shift 
perturbations, as shown in Figure 4.4A for V222, or causes attenuation, as shown in 
Figure 4.4A for P276. These differences suggest that UIM1 and UIM2 compete for K48-
linked diubiquitin’s distal subunit when Rpn13 occupies the proximal one (Figure 4.4E). 
Dynamic binding behavior was also evident in spectra recorded on the proximal subunit, 
although to a lesser extent. The observed spectral changes with both receptors present 
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largely mimic those caused by only Rpn13; however, additional attenuations are observed 
for A46 and H68 (Figure 4.S6).  
We tested the model presented in Figure 4.4E directly by labeling either S5a’s 
UIM1 or UIM2 region with the paramagnetic spin label S-(2,2,5,5-tetramethyl-2,5-
dihydro-1H-pyrrol-3-yl)methyl methanesulfonothioate (MTSL). MTSL causes distance-
dependent attenuation with effects apparent up to distances of ~20 Å. It forms a disulfide 
bond with cysteine residues and since S5a (196-306) contains no cysteines, it was 
straightforward to produce proteins samples with either UIM1 or UIM2 labeled. UIM1 
and UIM2 labeling was performed by substituting Q227 and A298 with cysteine, 
respectively. These two residues were chosen based on our NMR structure. They do not 
contact diubiquitin directly and their mutation is therefore not expected to disrupt 
S5a:diubiquitin interaction; however, they are close enough for MTSL-induced 
attenuation of diubiquitin atoms (model structures are provided for the major 
conformation in Figure 4.5A).  
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Figure 4.5. MTSL-labeling demonstrates hRpn13’s preference for K48-linked 
diubiquitin’s proximal subunit as S5a’s two UIMs bind the distal subunit. (A) Ribbon 
representation of the major S5a (196-306):K48-linked diubiquitin structure displaying 
MTSL covalently attached to C227 (left) or C298 (right). Each of these cysteines was 
introduced for UIM1 or UIM2 spin labeling by MTSL. Q62 is also displayed as well as 
approximate distances in Å between its backbone amide proton atom and MTSL’s single-
electron center (oxygen atom). It is worth noting that MTSL and the cysteine sidechain 
atoms are flexible such that the distances shown are only approximations. D21, A28 and 
D58 are also displayed and highlighted in purple, as they are used for comparison. (B) 
Expanded view of 1H, 15N HSQC spectra for the proximal (top panels) or distal (bottom 
panels) subunit of K48-linked diubiquitin alone (left panel) with added MTSL labeled 
C227 (UIM1) or C298 (UIM2) only (middle panel), or with hRpn13 (1-150) in addition 
(right panel), as labeled. S5a-SL refers to MTSL labeled S5a (196-306). (C) Ribbon 
representation of Rpn13:K48-linked diubiquitin structure displaying MTSL covalently 
attached to C75 of the proximal ubiquitin. D53 of hRpn13 is displayed as well as the 
approximate distance in Å between its backbone amide proton atom and MTSL’s single-
electron center (oxygen atom). T39 is displayed and highlighted in purple, as it is used 
for comparison. (D) Expanded view of 1H, 15N HSQC spectra for the hRpn13 (1-150) 
alone (left panel) with MTSL labeled K48-linked diubiquitin only (middle panel), or with 
S5a (196-306) in addition (right panel), as labeled. Proximal Ub-SL refers to K48 
diubiquitin with its proximal subunit MTSL labeled. (E) Expanded view of 1H, 15N 
HSQC spectra for the hRpn13 (1-150) alone (left panel) and with either spin label 
quenched K48-linked diubiquitin G75C only (middle panel) or with unlabeled S5a (196-
306) in addition (right panel). All spectra of protein mixtures were acquired with all 
components at 0.3 mM. (F) Model of one possible binding configuration for Rpn13 (1-
150) (green) and S5a (196-306) (blue) simultaneously bound to K48-linked tetraubiquitin 
(grey with K48-G76 linker region in red). In a tetraubiquitin chain, a ubiquitin subunit is 
available to each ubiquitin-binding module and K48 and G76 of the interior subunits are 
both engaged in isopeptide bonds with neighboring units. It is worth noting that the 
highly dynamic nature of S5a binding to polyubiquitin ensures that other configurations 
are possible. 
 
We produced samples in which either diubiquitin’s proximal or distal subunit is 
15N labeled and mixed these at 1:1 molar ratio with S5a (196-306) samples with either 
Q227C or A298C MTSL labeled. The amide resonance of Q62 from diubiquitin’s 
proximal subunit was partially attenuated by UIM1 spin labeling, but obliterated by 
UIM2 spin labeling (Figure 4.5B, middle panel compared to one on left). Q62 is not 
attenuated upon S5a (196-306) addition when S5a is not spin labeled (Figure 4.S7). 
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Moreover, D21 and A28, which are over 20 Å away from each of S5a’s MTSL labels, are 
not greatly attenuated, whereas D58, which is ~15 Å away is slightly attenuated (Figure 
4.5B). This finding is consistent with the presence of two S5a:diubiquitin conformations, 
with the predominant species having UIM2 bound to the proximal subunit and the minor 
species with it bound to the distal one. Consistent with this model, UIM1 spin labeling 
resulted in partial attenuation of Q62 from the proximal subunit, but obliterated this 
residue’s amide resonance from the distal subunit (Figure 4.5B, middle panel compared 
to one on left). Similarly, D58 is slightly affected by the induced paramagnetic relaxation 
effects from S5a MTSL labeling whereas the more remote D21 and A28 are not affected. 
Altogether, these data are consistent with the NOE-derived S5a:diubiquitin structures of 
Figure 4.3A. Confident that our approach is effective, we next tested the effect of having 
hRpn13 (1-150) present.  
hRpn13 (1-150) and S5a (196-306) with either its UIM1 or UIM2 spin labeled 
was added to diubiquitin with either its proximal or distal subunits 15N labeled. All three 
proteins were at 0.3 mM concentration. In this case, general resonance broadening is 
observed due to the larger size of the ternary complex. However, Q62 of the proximal 
subunit is only slightly more broadened than D21, A28, and D58 when either UIM1 or 
UIM2 is MTSL labeled (Figure 4.5B, right panel compared to left one). By contrast, the 
NMR signal of this residue in the distal subunit is almost obliterated by UIM1 and UIM2 
MTSL labeling. The greatly reduced attenuation of the proximal subunit’s Q62 upon 
Rpn13 addition indicates that S5a’s UIM2 is largely displaced from this subunit by 
Rpn13, as modeled in Figure 4.4E. That UIM2 spin labeling causes increased attenuation 
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of Q62 from the distal subunit indicates that it now interacts with this ubiquitin moiety. 
The UIM2-distal ubiquitin interaction causes partial restoration of Q62 in the sample with 
UIM1 labeled and hRpn13 present (Figure 4.5B, right panel compared to one on left). 
Hence, UIM1 and UIM2 appear to compete for diubiquitin’s distal subunit when Rpn13 
is present. 
We tested directly whether hRpn13 binds to K48-linked diubiquitin’s proximal 
subunit when S5a (196-306) is present by substituting G75 of the proximal subunit with 
cysteine and then labeling it with MTSL. Proximal G75 is not in the immediate Rpn13 
binding surface and therefore its mutation is not expected to disrupt binding; however, it 
is close enough to some residues to cause paramagnetic attenuation when labeled with 
MTSL (Figure 4.5C). Addition of proximal G75C MTSL diubiquitin to 15N labeled 
hRpn13 (1-150) obliterates NMR signals from Rpn13 residues that are close to the 
proximal subunit in the Rpn13 (1-150):K48-linked diubiquitin complex (231), as 
demonstrated for D53 in Figure 4.5D, middle panel. When this experiment is repeated 
with unlabeled S5a (196-306) present, the obliteration due to hRpn13 binding to the 
proximal subunit is preserved (Figure 4.5D, right panel). These experiments were 
performed with all three proteins at 0.3 mM. Residues with distances to the MTSL label 
that are too far for paramagnetic relaxation enhancement effects do not exhibit such 
dramatic signal attenuation, as demonstrated for T39 in Figure 4.5D. Moreover, the D53 
resonance reappears in the binary and ternary complexes after spin label quenching 
(Figure 4.5E). The quenching reaction was done by reducing the MTSL moiety with 5-
fold molar excess ascorbic acid (Figure 4.5E). Therefore, the attenuation observed in 
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Figure 4.5D is due to the distance-dependent paramagnetic relaxation enhancement 
induced by MTSL. This data indicates that Rpn13 predominately binds to the proximal 
subunit when S5a is present, as suggested by the chemical shift perturbation data and the 
results of spin labeling S5a.  
Altogether, our data indicate that Rpn13 and S5a can bind to a common K48-
linked polyubiquitin chain, even for diubiquitin, which has only two ubiquitin subunits. 
In longer chains, each ubiquitin-binding element can readily bind a ubiquitin subunit. The 
internal subunits of longer chains harbor the advantages of both the proximal and distal 
subunits of a diubiquitin chain, as K48 and G76 of these subunits are both engaged in 
isopeptide bonds with neighboring ubiquitin subunits. Internal ubiquitins therefore 
provide the additional contact of the linker region preferred by S5a’s UIM2 and Rpn13 as 
well as the increased rigidity of the C-terminal stretch of residues (243), which is 
preferred by UIM1. A model of Rpn13 and S5a’s UIMs bound to internal and proximal 
subunits is provided in Figure 4.5F. 
 
4.4 Discussion 
We demonstrate in this Chapter that the coordinated binding of S5a’s two UIMs 
greatly enhances its affinity for K48-linked diubiquitin over monoubiquitin and that 
although the UIMs can be accommodated on either subunit, a preference exists for UIM1 
on the distal subunit while UIM2 occupies the proximal one. We find that S5a and Rpn13 
are able to bind a common diubiquitin chain and that as Rpn13 retains its preferred 
position at the proximal subunit, S5a binds the distal one. In a diubiquitin chain, the two 
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UIMs compete for the distal subunit when Rpn13 is present; however, in a longer chain 
these two ubiquitin binding elements would no doubt occupy separate subunits, as they 
did in Rpn13’s absence (Figure 4.3). In the absence of the proteasome, our data suggest 
that multiple binding configurations are available for Rpn13 and S5a binding to K48-
linked tetraubiquitin, one of which is shown in Figure 4.5F.   
It is not yet clear whether such coordinated binding occurs in the context of the 
proteasome; however, it is possible that Rpn13 and S5a bind chains simultaneously to 
orient substrates for optimal capture and deubiquitination. The distance across the 
proteasome’s regulatory particle is similar to that spanned by an opened tetraubiquitin 
structure and therefore, even if S5a and Rpn13 are not docked next to each other it is still 
conceivable for them to bind a common ubiquitin chain, as modeled in Figure 4.S8. The 
proteasome appears to require most substrates to be conjugated to a chain of four or more 
ubiquitins (245). This minimal chain length may be preferred to allow for the coordinated 
binding of ubiquitin receptors, which may in turn, orient the chain in a manner conducive 
for the effective activity of deubiquitinating enzymes. For example, S5a and Rpn13 
coordinated binding may lead to the substrate end of the ubiquitin chain being proximal 
to Rpn11, which performs degradation-coupled deubiquitination (206, 207, 246) and the 
distal end of the chain near Uch37, which performs distal end deubiquitination (174). 
Future experiments are required to test this hypothetical model. 
We focused here on K48-linked chains because of their established importance in 
triggering degradation by the proteasome. S5a can also bind to K63-linkages with no 
apparent reduction in affinity compared to K48-linked chains (241). Rpn13’s ubiquitin 
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binding domain has high affinity for even monoubiquitin (240), suggesting that it too can 
bind chains of varying linkage. Although K63-linked chains mediate non-proteasomal 
events, they can support degradation by the proteasome (247). We propose that the 
outcome of K63-linked ubiquitination is not determined by the proteasome’s ubiquitin 
receptors. Rather, as demonstrated here, S5a and Rpn13 are adaptive and collaborative in 
their binding to ubiquitin chains, which supports their primary job of enabling 
proteasome to capture ubiquitinated proteins.  
Although contacts were revealed between the UIMs and diubiquitin that were 
unique to the conjugated subunits, their overall binding mode is similar to that used to 
bind monoubiquitin. Moreover the two UIMs share the same basic ubiquitin-binding 
scaffold. The key residues involved in binding to ubiquitin units are 216LALAL220 for 
UIM1 and 287IAYAM291 for UIM2 and, in both cases residues N-terminal to these helical 
structures participate in binding ubiquitin (Figure 4.3). UIM1 is conserved in 
Saccharomyces cerevisiae, and we propose that UIM2 evolved in higher eukaryotes by 
UIM1 duplication and optimization for ubiquitin binding, as UIM2 is the stronger 
binding partner for diubiquitin (Figure 4.1B and 4.1C) and monoubiquitin (241). We 
determined S5a (196-306)’s affinity for diubiquitin to be significantly higher than either 
UIM’s affinity for monoubiquitin (Figure 4.1E) (241, 242) and showed that S5a binds 
diubiquitin with 1:1 stoichiometry even when diubiquitin is 8-fold in excess. Thus, UIM2 
is apparently not used to recruit in multiple substrates simultaneously, but rather to 
enhance affinity for each substrate. 
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Although not essential in budding yeast (235), S5a is required for murine 
embryonic development (236). It is also essential in Drosophila melanogaster, in which 
its deletion results in larval-pupal polyphasic lethality, multiple mitotic defects, as well as 
accumulation of ubiquitinated proteins and defective 26S proteasome (237). Therefore, in 
higher eukaryotes, Rpn13 and the UBL-UBA proteins cannot substitute for S5a. 
In a prior study, we demonstrated S5a-bound K48-linked tetraubiquitin can also 
bind to hHR23a, even though hHR23a precludes additional UBL-UBA family members 
from binding a common ubiquitin chain (238). In this ternary complex, S5a’s UIM1 
physically contacts the ubiquitin chain, as UIM2 binds to hHR23a’s UBL domain. S5a 
therefore appears to be able to share ubiquitinated substrates with other ubiquitin 
receptors. Altogether, our data support a model in which S5a has evolved to bind 
polyubiquitinated substrates in a manner that takes advantage of other ubiquitin receptors. 
 
4.5 Methods summary 
4.5.1 Preparation of NMR samples and NMR spectroscopy 
S5a (196-306), K48-linked diubiquitin and hRpn13 (1-150) were produced as 
described in the Section 4.8. Methods used for the NMR experiments and their analyses 
as well as for solving the S5a (196-306):K48-linked diubiquitin complexes and for 
modeling the S5a (196-306):Rpn13 (1-150):K48-linked tetraubiquitin complex are 
described in the Section 4.8.  
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4.5.2 Analytical ultracentrifugation 
Sedimentation velocity experiments were performed as previously described 
(238). Seven samples were prepared in which the molar ratio of K48-linked diubiquitin to 
S5a (196-306) was varied from 1:7 to 8:1.  The sw for each mixture was calculated as 
previously described (238). Dissociation constants were obtained by global analysis using 
SEDPHAT (248).  
 
4.5.3 Spin labeling experiments 
Based on the S5a (196-306):K48-linked diubiquitin complex structure of the 
major species (Figure 4.3A), two S5a (196-306) mutants were designed for MTSL 
labelling, namely Q227C and A298C. These two residues are not directly involved in 
binding diubiquitin, so their mutation was not expected to disrupt binding. They were 
also chosen because they are close enough to K48-linked diubiquitin amide atoms to 
cause distance-dependent attenuations (Figure 4.5A). After being treated with the spin 
labeling reagent (1-oxyl-2,2,5,5-tetramethylpyrroline-3-methyl) methane thiosulfonate 
(MTSL), a single electron (carried by oxygen atom) containing moiety will be attached to 
the sulfur atom of cysteine residue in S5a mutants. The strong magnetic field of the NMR 
instrument causes the single electron carried by oxygen atom to accelerate the relaxation 
of residues within ~20 Å. Sample preparation and NMR spectra recorded for spin 
labeling experiments are described in Section 4.8. 
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4.6 Data Bank accession numbers 
The atomic coordinates of S5a (196-306) in complex with K48-linked diubiquitin 
have been deposited in the Protein Data Bank with the accession codes of 2KDE and 
2KDF. 
 
4.7 Supplementary information 
4.7.1 Material and methods 
4.7.1.1 Preparation of NMR samples  
S5a (196-306) and K48-linked diubiquitin were produced as described (50, 124, 
194, 249, 250). Briefly, we used recombinant monoubiquitin in which either an aspartic 
acid is added to the chain (Ub-D77) or the lysine at position 48 was mutated to an 
arginine (Ub-K48R). Using these two monoubiquitin samples, K48-linked diubiquitin 
could be synthesized. Ub-D77 and Ub-K48R that were selectively labeled or unlabeled 
were incubated with 0.1 µM UBE1 (E1, Boston Biochem), 25 µM UBE2K (E2), 2 mM 
ATP, and 1/5 total volume PBDM8 buffer at 37°C for ~12 hours. The diubiquitin formed 
was subsequently purified by using a monoQ column, followed by monoS ion-exchange 
columns (GE Healthcare). A similar procedure was used to produce K48-linked 
diubiquitin mutant with its proximal subunit MTSL labeled. In this case, however, a 
ubiquitin truncated mutant (Ub-G75C) with the C-terminal G75 substituted with cysteine 
was used.  
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His-tagged S5a (196-306) and GST-tagged hRpn13 (1-150) are expressed in 
Escherichia coli and purified by using a combination of affinity chromatography and size 
exclusion chromatography on an FPLC system. hRpn13 (1-150) is cleaved from its GST-
tag during elution from glutathione S-sepharose resin by using PreScission protease (GE 
healthcare). 15N, 13C, and 2H labeled samples are produced by growth in M9 minimal 
media with 15N labeled ammonium chloride, 13C labeled glucose, and D2O used as the 
nitrogen, carbon, and water sources, respectively. Amide atoms are exchanged into D2O 
when desired by using lyophilisation.  
 
4.7.1.2 NMR spectroscopy 
Chemical shift perturbation analysis was done by using 1H,15N HSQC 
experiments which were recorded on 15N labeled S5a (196-306) with increasing molar 
ratios of unlabeled diubiquitin. Since UIM1 and UIM2 binding to diubiquitin was in the 
intermediate to slow exchange regime, the affected resonances could not be readily 
followed from their free to their bound states as increasing amounts of the binding partner 
was added. Therefore, an 15N-dispersed NOESY spectrum recorded on 15N labeled S5a 
(196-306) and unlabeled diubiquitin was used to obtain chemical shift assignments for 
diubiquitin-bound S5a (196-306). The concentration of S5a (196-306) for the 1H,15N 
HSQC titration and 15N dispersed NOESY experiments was 0.40 mM. The spectra were 
recorded at 25°C and in Buffer 1 (20 mM NaPO4, 100 mM NaCl, at pH 6.5).  
Since many backbone HN groups belonging to UIM1 resonances were broadened 
beyond detection, a 3D 13C-edited NOESY spectrum (100 ms mixing time) on 13C-
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labeled S5a (196-306) mixed with 3-fold molar excess unlabeled diubiquitin was 
recorded to assign the diubiquitin-bound state of S5a. This molar ratio ensures that 
essentially all of S5a is diubiquitin-bound. Since sedimentation velocity analysis revealed 
a 1:1 binding stoichiometry for the S5a (196-306):diubiquitin complex, even with either 
component is at 7-fold molar excess (Figure 4.1D), we are able to use molar ratios greater 
than 1:1 to increase sensitivity by increasing the population of the bound state for the 
labeled protein. Unlike amide groups, the NMR resonances for aliphatic CH groups in 
proteins are less sensitive to dynamic motions and therefore those of UIM2, the internal 
helix, and part of UIM1 are observable in the recorded 13C-edited NOESY spectrum 
(Figure 4.S2B).  
Intermolecular NOE interactions between S5a (196-306) and K48-linked 
diubiquitin were obtained through four sets of NOESY experiments including 13C-
filtered, 13C-edited NOESY spectra acquired 13C-labeled S5a (196-306) mixed with 3-
fold molar excess unlabeled diubiquitin, 13C-labeled S5a (196-306) mixed with 3-fold 
molar excess diubiquitin with its proximal subunit 100% deuterated, diubiquitin with its 
proximal subunit 13C labeled mixed with 2-fold molar excess unlabeled S5a (196-306), 
and diubiquitin with its distal subunit 13C labeled mixed with 2-fold molar excess 
unlabeled S5a (196-306). In all spectra, the concentration of 13C labeled protein was 0.4 - 
0.5 mM and they were recorded at 25°C and on either 800 or 900 MHz spectrometers 
equipped with cryogenically cooled probes in Buffer 2 (20 mM NaPO4, 50 mM NaCl, at 
pH 6.5). Whereas assignment of diubiquitin-bound S5a (196-306) resonances required 
the NOESY experiment described in the previous section, S5a-bound diubiquitin was 
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straightforward to assign. Firstly, the chemical shift dispersion of ubiquitin is greater than 
S5a (196-306) and secondly, the chemical shift values for each subunit differed little 
from monoubiquitin’s S5a-bound state. With the four half-filtered experiments, we 
readily assigned intermolecular NOEs, as NOEs between 13C-labeled S5a and unlabeled 
ubiquitin were matched with though of 13C labeled ubiquitin and unlabeled S5a. For 
example, the intermolecular NOE between K48’s Ca proton from proximal ubiquitin and 
UIM2’s M291’s methyl protons was observed in S5a was 13C labeled (Figure 2C) as well 
as when the proximal subunit of ubiquitin was 13C labeled (Figure 4.S3A). 
Chemical shift perturbation analysis was conducted by recording 1H, 15N HSQC 
or 1H, 13C HMQC experiments. Samples contained 15N labeled Rpn13 (1-150), 13C 
labeled S5a (196-306) and unlabeled diubiquitin or unlabeled Rpn13 (1-150), 13C labeled 
S5a (196-306) and diubiquitin with one of its subunits 15N labeled. The NMR spectra 
were acquired at 0.3 mM and all mixtures were equimolar. Spectra were taken in Buffer 2 
on a Varian Inova 800 MHz spectrometer with a cryogenically cooled probe. 
 
4.7.1.3 Structure calculations 
Structure calculations of the S5a (196-306):K48-linked diubiquitin complex were 
performed based on the NOE-derived distance and dihedral angle constraints. 
Intramolecular constraints for S5a (196-306) and those published for ubiquitin (PDB 
code 1D3Z) (251) were incorporated to maintain the structure of each component, as 
neither protein undergoes gross structural change upon binding (see Section 4.3). The 
structure of the major binding mode was defined by 34 UIM2:proximal ubiquitin and 12 
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UIM1:distal ubiquitin intermolecular NOE derived distance restraints. The UIM2:distal 
interaction for the minor S5a:diubiquitin complex was defined by 24 intermolecular NOE 
derived distance restraints, which were still observable when the proximal subunit of 
diubiquitin was fully deuterated (Figure 4.2C red). Intermolecular NOEs between UIM1 
and proximal ubiquitin were too weak to be observed and therefore the UIM1 constraints 
to distal ubiquitin were used to model the UIM1:proximal interaction. For both 
S5a:diubiquitin complexes, simulated annealing in XPLOR version 3.851 was performed 
on a Linux operating system. 30 randomly coiled structures were subjected to 15,000 
simulated annealing and cooling steps of 0.005 ps to generate seven converged structures. 
These were selected because they have no NOE violation > 0.3 Å or dihedral angle 
violation > 10°. For the model demonstrating expected distances between MTSL and 
specific amide atoms of interest, the exact MTSL orientation is not known. 
 
4.7.1.4 Gibbs free energy calculation 
The Gibbs free energy required for a 3:1 population difference was determined by 
using Equations 4.1 and 4.2, in which R, T, and K are the gas constant (8.3145 JK-1mol-
1), temperature of the NMR experiments (298K), and equilibrium constant, respectively.  
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4.7.1.5 Spin labeling experiments 
The expression plasmids for the S5a (196-306) mutants and hRpn13 (1-150) CtoA 
mutant, in which all of its cysteines are mutated to alanine, were made by using Quick 
Change Site Directed Mutagenesis Kit (Stratagene). S5a (196-306) Q227C and A298C 
mutants (His-tagged) and hRpn13 (1-150) CtoA mutant (GST-tagged) were expressed 
and purified from Escherichia coli by using a combination of affinity and size exclusion 
chromatography on an FPLC system, as described above for the wild-type proteins. 
Diubiquitin with G75 of its proximal subunit substituted with cysteine was also produced 
as described above. Purified diubiquitin-proximal G75C as well as S5a (196-306) Q227C 
and A298C proteins were spin labeled by reacting them with MTSL purchased from TRC 
(Toronto). Spin labeling reactions were performed in 50 mM Tris, pH 7.6, in a 10-fold 
excess of MTSL, and the reaction tubes were incubated in the dark at 4 °C overnight. 
Excess MTSL reagent was removed by extensive dialysis at 4 °C into NMR buffer (20 
mM sodium phosphate, 50 mM sodium chloride, pH 6.5). 
A series of 1H,15N HSQC experiments were recorded on 0.3 mM K48-linked 
diubiquitin with its proximal or distal subunits 15N labeled without or with the addition of 
equimolar MTSL labeled S5a Q227C or A298C. 1H,15N HSQC experiments for protein 
samples of K48-linked diubiquitin with its proximal or distal subunits 15N labeled in the 
presence of equimolar hRpn13 (1-150) CtoA and MTSL labeled S5a Q227C or A298C 
were also acquired under identical conditions. 
We also recorded a series of 1H,15N HSQC experiments on 0.3 mM 15N labeled 
Rpn13 (1-150) CtoA protein without or with the addition of equimolar MTSL labeled 
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diubiquitin G75C. These experiments were also done with equimolar S5a (196-306) 
present under identical conditions. For both the binary and ternary NMR samples, two 
HSQC experiments were acquired, one with MTSL in the oxidized state (paramagnetic 
state) and one with MTSL reduced to ensure effects were MTSL specific. The spin label 
quenching was achieved by addition of 5-fold molar excess ascorbic acid to the binary 
NMR sample (Rpn13 plus spin labeled diubiquitin G75C) and also the ternary NMR 
sample (Rpn13 plus spin labeled diubiquitin G75C and S5a (196-306)). Samples were 
placed in the magnet at 25 °C for 1 hour to ensure complete reduction of the spin label 
moiety.  
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4.7.2 Supplemental figures 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.S1. Amide chemical shift perturbation experiments reveal new spectral changes 
for diubiquitin binding. (A) Amide chemical shift perturbation analysis reveals the 
residues of S5a involved in binding diubiquitin. Residues that disappear upon diubiquitin 
binding and prolines, which lack amide protons, are labeled with blue and red stars, 
respectively. R237 of S5a could not be followed during the titration series due to 
resonance overlap. (B) Amide chemical shift perturbation analysis reveals the residues of 
S5a involved in binding monoubiquitin. Prolines are labeled with red stars. Chemical 
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shift perturbation values (Δδavg) for 15N and 1H nuclei were derived from 
€ 
CSP = 0.2ΔδN2 + ΔδH2 , where ΔδN and ΔδH represent the changes in the amide nitrogen 
and proton chemical shifts (in parts per million), respectively. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4.S2. S5a binding to diubiquitin does not disrupt the secondary structure of the 
helix between UIM1 and UIM2. (A) An 15N-dipersed NOESY spectrum recorded on 15N-
labeled S5a (196-306) and 3-fold molar excess unlabeled diubiquitin reveals strong 
amide-to-amide NOE crosspeaks, which are a signature for helices. (B) A 13C-dipersed 
NOESY spectrum recorded on 13C-labeled S5a (196-306) and 3-fold molar excess 
unlabeled diubiquitin reveals NOE crosspeaks between Hα (i) and Hβ (i+3) atoms, which 
are a hallmark of helices. 
 
 
 
 
 
 
 
 
 
 
 
 
 A  B 
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Figure 4.S3. UIM2 binds the proximal subunit while UIM1 binds the distal one. (A) 
Abundant intermolecular interactions appear between UIM2 and K48-linked diubiquitin’s 
proximal subunit. The spectrum of Figure 4.2A displayed in black, which contains NOEs 
between S5a and the proximal subunit of diubiquitin, is expanded to illustrate abundant 
NOE interactions. Intermolecular NOEs between S5a and proximal K48 reveal that S5a 
has contacts with the atoms connecting the two ubiquitin subunits. (B) Selected regions 
of experiments containing intermolecular NOE interactions between UIM1 of S5a (196-
306) and diubiquitin (black and red) or monoubiquitin (light blue). 13C half-filtered 
NOESY spectra recorded on 13C-labeled S5a (196-306) mixed with 3-fold molar excess 
unlabeled K48-linked diubiquitin (black) or K48-linked diubiquitin with its proximal 
subunit deuterated (red) indicates the interactions to be unaffected by deuterating the 
proximal subunit. The binding pattern between UIM1 and diubiquitin mimics that with 
monoubiquitin, which is demonstrated by analogous intermolecular NOEs (light blue). 
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Figure 4.S4. The population of S5a’s UIM2 bound to K48-linked diubiquitin’s proximal 
subunit is in 3-fold molar excess over that bound to the distal one. 13C half-filtered 
experiments were recorded in an identical manner on K48-linked diubiquitin with either 
its proximal (left) or distal (right) subunit 13C labeled and mixed with unlabeled S5a 
(196-306). Intermolecular NOE interactions between M291’s sidechain methyl group and 
proximal (left) or distal (right) K48’s Ha proton were integrated to reveal population 
differences. Both experiments were performed with diubiquitin at 0.5 mM and S5a at 2-
fold molar excess. 
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Figure 4.S5. Although significantly more restricted than when bound to monoubiquitin, 
S5a’s UIMs retain some freedom in their relative positions due to the flexibility of the 
diubiquitin’s linker region. The S5a (196-306):K48-linked diubiquitin structures with no 
NOE violation above 0.3 Å are displayed with the backbone heavy atoms of proximal 
ubiquitin and UIM2 superimposed. 7 structures are displayed from 30 randomly coiled 
starting structures. UIM1, the internal helix, and UIM2 of S5a are colored in dark grey, 
purple and black, respectively, whereas diubiquitin’s distal and proximal subunits are 
highlighted in green and blue, respectively. The linker residues of diubiquitin (proximal 
K48 and distal G76) are highlighted in red. 
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Figure 4.S6. Diubiquitin’s proximal subunit binds predominately to Rpn13. 1H,15N 
HSQC spectra of K48-linked diubiquitin with its proximal subunit 15N labeled in the 
presence of equimolar Rpn13 (left, red), S5a (right, red), or both of these ubiquitin 
receptors (blue). Selected ubiquitin resonances are labeled, including T7, F45, L67, and 
H68, which shift in a manner that reflects Rpn13 binding. Attenuation of A46 and H68 in 
the presence of Rpn13 and S5a suggests that, although a large fraction of the proximal 
subunit is bound to Rpn13, some minor exchange most likely occurs. 
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Figure 4.S7. Q62 of diubiquitin’s proximal and distal subunits is not attenuated upon 
addition of unlabeled S5a (196-306). Expanded view of 1H, 15N HSQC spectra for the 
proximal (top panels) or distal (bottom panels) subunit of K48-linked diubiquitin alone 
(left panel), or with added unlabeled S5a (196-306) (right panel). 
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Figure 4.S8. Proposed model of Rpn13 and S5a binding simultaneously to a 
ubiquitinated substrate in the proteasome. Rpn13’s ubiquitin-binding domain and S5a’s 
N-terminal VWA domain are displayed bound to the S1 and S2 scaffolding proteins of 
the proteasome’s regulatory particle as their ubiquitin-binding regions bind ubiquitin 
subunits of a ubiquitinated substrate. This coordinated binding may serve to properly 
orient the ubiquitin chain for subsequent processing by deubiquitinating enzymes in the 
proteasome. 
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5.1 Synopsis 
 Regulated protein degradation by proteasome is essential and contributes to a 
large spectrum of cellular events, including cell cycle progression, DNA repair, and 
signal transduction. Substrate ubiquitination by a 3-step E1-E2-E3 enzymatic cascade is 
typically used to signal for proteolysis by proteasome, which houses two ubiquitin 
receptors in its 19S regulatory particle, Rpn13 and S5a. Prior to proteolysis, substrates are 
deubiquitinated and Rpn13 recognizes ubiquitin with an N-terminal Pru (pleckstrin-like 
receptor for ubiquitin) domain and deubiquitinating enzyme Uch37 with a C-terminal 
domain. We reveal here that human Rpn13’s Pru domain also binds to the human E2 
ubiquitin-conjugating enzyme Cdc34, which functions in cell cycle progression. NMR 
titration experiments reveal that an hRpn13 surface that neighbors its ubiquitin-binding 
loops binds to the unique C-terminal tail of hCdc34 and that this interaction does not 
restrict hRpn13 binding to ubiquitin. Immunoprecipitation experiments performed with 
HeLa cells demonstrate that this interaction occurs in the cellular environment. 
Altogether, these data suggest that hRpn13 may contribute to regulated substrate 
ubiquitination by Cdc34 in proliferating cells. 
 
5.2 Introduction 
The ubiquitin-proteasome pathway is the major route for regulated protein 
degradation in eukaryotes, reviewed in (252, 253). Substrates are ubiquitinated by the 
coordinated efforts of E1, E2 and E3 enzymes and in turn, recognized by ubiquitin 
receptors in the proteasome’s regulatory particle or that associate with it, reviewed in 
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(254, 255). E1 activating enzymes prime ubiquitin for a thioester bond with an E2’s 
catalytic cysteine, reviewed in (255-257). The vast majority of E3 ligating enzymes 
contain RING domains that bind ubiquitin-charged E2s to serve as scaffolds, which 
enable the transfer of ubiquitin from the E2 to a substrate, reviewed in (258). HECT 
domain E3s and two reported RING-in-between-RING E3s (259) can accept activated 
ubiquitin from E2s at their own catalytic cysteine for subsequent transfer to a substrate. 
Multiple rounds through the E1-E2-E3 enzymatic cascade enables substrates to be 
monoubiquitinated at multiple sites or conjugated with a ubiquitin chain that is linked 
together through ubiquitin’s seven lysines or its N-terminal methionine. Ubiquitination 
signals for a myriad of cellular events, the outcome of which is generally governed by 
multivalent interactions defined by the type of ubiquitin modification and subcellular 
context (254, 260). 
Humans are predicted to have ~650 E3s with nearly half being cullin-RING 
ligases (CRLs) (258), which use a cullin scaffold (CUL1, CUL2, CUL3, CUL4A, 
CUL4B, CUL5, or CUL7), a catalytic RING domain (Rbx1 or Rbx2), and adaptor-
substrate receptor proteins, reviewed in (261). CRLs are activated by the conjugation of 
ubiquitin-like modifier Nedd8 to a conserved lysine on the cullin subunit, which is 
thought to promote RING-E2 conformational heterogeneity and in turn processive 
substrate ubiquitination (262-266). 
The first discovered CRLs were the SCF (Skp1-Cul1-F-box protein) complexes, 
which contain RING E3 Rbx1 bound to the Cul1 catalytic C-terminal domain and various 
F-box adaptor proteins that recruit specific substrates. The E2 UbcH5 functions with the 
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SCF to attach the initial ubiquitin to substrates while E2 Cdc34 adds successive ubiquitin 
moieties to form a chain (267). E1 and E3 binding surfaces overlap on E2s (268-271) and 
ubiquitin-charged Cdc34 binds Rbx1 with 50-fold greater affinity compared to 
unmodified Cdc34 (272), which would facilitate its release from Rbx1 after ubiquitin 
transfer. Cdc34 also contains a unique intrinsically disordered C-terminal acidic tail that 
binds ubiquitin (273) and a basic canyon of Cul1 (274, 275), with the latter interaction 
promoting processive Lys48-linked ubiquitin chain assembly on substrates (274, 275).  
 Through its interaction with the SCF complex, Cdc34 ubiquitinates numerous 
proteasome substrates, including p27/Kip1 (276-278), IκBα (279, 280), and the Wee1 
kinase (281). Recently, a small molecule inhibitor of Cdc34 (CC0651) was reported and 
found to cause p27/Kip1 accumulation and to inhibit proliferation of human cancer cell 
lines (282). Cdc34 protein levels are elevated in pediatric T cell acute lymphoblastic 
leukemia (283) and it is a target of the tumor suppressor (284) let-7 microRNA (285).  
Proteasome ubiquitin receptors Rpn13 (92, 93) and S5a/Rpn10 (132) recognize 
ubiquitinated substrates through a Pru (pleckstrin-like receptor for ubiquitin) domain (92, 
93) and UIMs (ubiquitin-interacting motifs) (286, 287), respectively. Prior to 
translocation into the proteasome’s catalytic core particle, substrates are deubiquitinated 
by the proteasome’s deubiquitinating enzymes, which include Rpn11 (206, 207, 288), 
Ubp6/Usp14 (289) and Uch37/UCHL5 (174). Ubiquitin receptor Rpn13 contributes 
Uch37 to the proteasome (290-292), which has been proposed to act as an editing 
isopeptidase, capable of freeing poorly ubiquitinated substrates from proteasome prior to 
degradation (174). When free of proteasome, hRpn13’s C-terminal Uch37-binding 
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domain interacts with its Pru domain and restricts its ubiquitin-binding affinity (293). 
CryoEM studies in yeast map Rpn13 to an apical location in proteasome (294, 295) and 
immunodepletion analysis suggest that not all proteasome contains hRpn13 (290).  
Unexpectedly, we found that human Rpn13’s Pru domain binds to human 
Cdc34’s unique C-terminal tail. NMR spectroscopy experiments demonstrated the 
hRpn13:hCdc34 interaction to be specific and to not interfere with Rpn13 binding to 
ubiquitin. Rpn13 and Cdc34 interact in HeLa cells according to immunoprecipitation 
experiments and this interaction is preserved with hRpn13 F76R, which cannot bind 
ubiquitin (93). Altogether these data suggest that Rpn13 may influence substrate 
ubiquitination by Cdc34 in proliferating cells. 
 
5.3 Results 
5.3.1 Ubiquitin receptor hRpn13 binds E2 conjugating enzyme hCdc34  
We use ubiquitinated hCdc34 as a model substrate and therefore, as a negative 
control, tested whether unmodified hCdc34 interacts with hRpn13. Unexpectedly, we 
found that hCdc34 is retained on glutathione sepharose resin preincubated with GST-
hRpn13 or GST-hRpn13 Pru domain; as expected, it was not retained with GST (Figure 
5.1A). We next tested whether endogenous Rpn13 and Cdc34 interact in HeLa cell lysate 
by using anti-Cdc34 antibody (Novus Biologicals) for immunoprecipitation and anti-
Rpn13 antibody (Biomol) for visualization. Rpn13 was observed to immunoprecipitate 
with Cdc34 (Figure 5.1B). This interaction was also detected in HeLa cells expressing 
FLAG-tagged hCdc34. Rpn13 was immunoprecipitated and Cdc34 visualized with anti-
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FLAG antibody (Figure 5.1C); endogenous Cdc34 overlaps with light chain. We used 
hRpn13 F76R, which does not bind ubiquitin (93), to test whether this interaction is 
mediated by ubiquitin. Lysates from HeLa cells expressing FLAG-hRpn13 F76R were 
subjected to immunoprecipitation by anti-Cdc34 antibody and immunoblotting with anti-
FLAG antibody. FLAG-hRpn13 F76R immunoprecipitated with hCdc34 (Figure 5.1D), 
indicating that the hRpn13:hCdc34 complex is not formed due to hRpn13 binding to 
ubiquitin. 
 
Figure 5.1. hRpn13 and hCdc34 interact in vitro and in vivo. (A) The retention of Cdc34 
on glutathione sepharose resin pre-bound with GST, GST-hRpn13 Pru domain (1-150), 
or GST-hRpn13 full length protein (FL) is tested, as indicated by Western blot analysis. 
Direct load (DL) of hCdc34 is included in lane 1. (B) Endogenous levels of hCdc34 from 
HeLa cells is immunoprecipitated (IP) by anti-hCdc34 antibody (Novus Biologicals) and 
Western blot analysis used to detect the presence of endogenous hRpn13 by using anti-
hRpn13 antibody (Biomol) (lane 2). Lane 1 shows a direct load of HeLa lysate used for 
immunoprecipitation. (C) HeLa cells transfected with FLAG-tagged hCdc34 were 
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subjected to an immunoprecipitation experiment with anti-hRpn13 antibody (Biomol) 
followed by Western blot analysis for FLAG-tagged hCdc34 with anti-FLAG antibody 
(Sigma) (lane 3). A control experiment with empty vector is included (lane 2), as is a 
direct load of the transfected HeLa cell lysate (lane 1). (D). In vivo immunoprecipitation 
of hCdc34 from HeLa cells transfected with p3xFLAG-CMV7.1 empty vector (lane 2) or 
Flag-hRpn13 F76R mutant (lane 4). hCdc34 was immuniprecipitated with anti-hCdc34 
antibody (Novus Biologicals) and the resulting samples were probed with anti-FLAG 
(Sigma) antibody. 
 
5.3.2 hRpn13 binds hCdc34 through a surface that abuts its ubiquitin-binding loops 
 We used NMR spectroscopy, to test whether hRpn13 and hCdc34 can directly 
bind each other. hRpn13 (1-150), which includes its Pru domain, and full length hCdc34 
were expressed and purified as described previously (93, 273). Unlabeled hCdc34 was 
titrated into 15N labeled hRpn13 Pru domain, which was monitored by 1H, 15N HSQC 
experiments. A select group of hRpn13 signals shift upon hCdc34 addition, thus 
confirming their interaction (Figure 5.2A). The binding occurred in the fast exchange 
regime on the NMR time scale such that hRpn13 signals could be readily followed from 
their free state to their hCdc34-bound state; an example is provided for Lys34 in Figure 
5.2B.  
In the absence of structural rearrangement, NMR signal shifting upon titration of 
a binding partner can be used to map binding surfaces (296, 297). We therefore 
quantified the extent to which each hRpn13 amide signal is affected by hCdc34 addition, 
as described in Materials and Methods. The most affected amino acids localize to a 
surface that neighbors, but does not overlap with hRpn13’s ubiquitin-binding loops 
(Figure 5.2C and 5.2D). Electrostatic analysis of the hRpn13 surface demonstrated its 
hCdc34-interacting region to be basic (Figure 5.2E). 
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Figure 5.2. hCdc34 binds hRpn13 at a surface that juxtaposes its ubiquitin binding loops. 
(A) 1H, 15N HSQC spectra of 15N-labeled hRpn13 alone (black) and with 2-fold excess 
unlabeled hCdc34 (red) (B) hRpn13 exhibits ‘fast exchange’ dynamics on the NMR 
timescale (100ms) when binding to hCdc34 as exhibited by Lys34 which is exhibited 
with different molar ratios of hRpn13 Pru:hCdc34 as indicated. (C) Chemical shift 
perturbation analysis reveals residues within hRpn13 that bind hCdc34. Residues that 
were significantly affected (>Avg+StDEV) are labeled and highlighted in red on the 
Rpn13 structure (D). (E) Electrostatic image of hRpn13 showing acidic and basic 
residues with residues implicated in hCdc34 binding labeled. 
 
5.3.3 hRpn13 binds to Cdc34’s C-terminal tail 
To define the region of hCdc34 that binds to hRpn13, we added unlabeled 
hRpn13 to 15N labeled hCdc34 (Figure 5.3A and Supplementary Figure 5.S1A) or its N-
terminal catalytic domain, hCdc34 (7-182) (Supplementary Figure 5.S1B). Whereas 
chemical shift assignments are not available for hCdc34’s catalytic domain, those of its 
C-terminal tail were generously provided by Dr. Gary S. Shaw and Dr. Donald E. Spratt. 
1H, 15N HSQC experiments revealed significant signal shifting for amino acids in the C-
terminal tail of the full-length protein and not for the unassigned signals (Figure 5.3A and 
Supplementary Figure 5.S1A). Similarly, hRpn13 did not affect the NMR signals of 
hCdc34 (7-182) (Supplementary Figure 5.S1B). Quantification of hRpn13’s effect on 
hCdc34’s C-terminal tail demonstrates signal shifting that spans Glu201 – Asp230 
(Figure 5.3B). Altogether, these results demonstrate that hRpn13 binds to hCdc34’s 
unique C-terminal tail and not its catalytic domain. 
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Figure 5.3. hRpn13 binds hCdc34’s C-terminal tail. (A) Expanded 1H,15N HSQC spectra 
of 15N-labeled full length hCdc34 alone (black) and with 3-fold molar excess unlabeled 
hRpn13 (red). (B) Chemical shift perturbation analysis upon hRpn13 addition for 
hCdc34’s assigned C-terminal tail by using the data of (A). Amides that were shifted by a 
standard deviation greater than average are labeled.  
 
5.3.4 hRpn13 and hCdc34 can form a ternary complex with ubiquitin, but not S1 
(797-953) 
To test whether hRpn13 can bind to ubiquitin and hCdc34 simultaneously, we 
added unlabeled hCdc34 and ubiquitin to 15N labeled hRpn13 Pru domain, which was 
monitored by NMR. This experiment revealed hRpn13 interaction with both proteins 
simultaneously. In particular, hRpn13 signals that shift upon hCdc34 addition (Figure 
5.3A, red) remain shifted in the presence of hCdc34 and ubiquitin (Figure 5.3A, cyan), as 
demonstrated for Lys34. Similarly, Rpn13 signals that shift in a ubiquitin-specific 
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manner are also shifted with both binding partners present, as demonstrated for Ile75 
(Figure 5.3A, dark blue versus cyan). 
In previous work (93, 293), we mapped the hRpn13 amino acids that are affected 
by binding to S1 (797-953), a fragment of Rpn13’s binding partner in the proteasome’s 
regulatory particle (293). The hRpn13 amino acids identified to be affected by hCdc34 
overlap with those involved in binding to S1 (797-953) and this region is also implicated 
in binding to the S1 S. cerevisiae analog Rpn2, as scRpn13 Lys119, which corresponds to 
hRpn13 Glu118, cross-linked to Lys911 in Rpn2 (298). We tested directly whether 
hRpn13 can bind to hCdc34 and S1 (797-953) simultaneously. 15N labeled hRpn13 was 
saturated with unlabeled S1 (797-953) and then mixed with 2-fold molar excess 
unlabeled hCdc34. Comparison of this 3-protein mixture with spectra derived from 15N 
labeled hRpn13:Cdc34 and 15N labeled hRpn13:S1 (797-953) demonstrates that Rpn13 
binds preferentially to S1 (797-953) at the exclusion of hCdc34 (Figure 5.4B). Met109 
illustrates this effect as it shifts to its S1-bound state and is unperturbed by hCdc34 
(Figure 5.4B). In addition, we did not find hCdc34 to immunoprecipitate with proteasome 
from HeLa cells (data not shown), although the SCF complex has been found to co-purify 
with proteasome from Saccharomyces cerevisiae (299). 
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Figure 5.4. hRpn13 can interact with hCdc34 and monoubiquitin at the same time but not 
S1. (A) Expanded 1H,15N HSQC spectra are displayed of 15N-labeled hRpn13 alone 
(grey), with 2-fold excess hCdc34 (red) or with 2-fold excess hCdc34 and monoubiquitin 
(cyan) (B) 1H, 15N HSQC spectra are displayed of 15N-labeled hRpn13 alone (grey), with 
hCdc34 (green) or proteasome scaffolding protein S1 (797-953) (red), or with hCdc34 
and the S1 fragment (cyan). 
 
 
5.4 Concluding Remarks 
We provide evidence that proteasome ubiquitin receptor hRpn13 binds to the E2 
enzyme hCdc34. IkBa (279, 280) is also a Cdc34 substrate and interestingly, it and iNOS 
are the only other reported hRpn13 substrates (300). Since hRpn13’s hCdc34-binding 
surface overlaps with its S1 (797-953)-binding surface, we do not expect hCdc34 to 
interact with hRpn13 when docked into proteasome. The SCF complex has been 
demonstrated in landmark studies to function in vitro with Cdc34 and without addition of 
Rpn13 (274, 275, 301-304). Therefore, Rpn13 is not required for substrate ubiquitination 
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by this complex. Rather, it appears to play a regulatory role. Future experiments are 
needed to dissect the mechanistic relationship between hRpn13 and hCdc34. Testing the 
effect of hRpn13 knockdown on an hCdc34 specific substrate, such as p27/Kip1, could 
do this. It would also be worthwhile to test whether Uch37 plays an important role in 
p27/Kip1 protein stability. Nonetheless, we have described here a novel interaction 
between hRpn13 and hCdc34 that suggests an important regulatory role for hRpn13 in 
proliferating cells.  
 
5.5 Materials and Methods 
5.5.1 Protein expression and cell culture 
 hRpn13, hRpn13 (1-150), hCdc34, hCdc34-cat, and S1 (797-953) were expressed 
and purified as described previously (93, 273, 293). Ubiquitin was purchased (R&D 
Systems). All NMR experiments were done in 20 mM NaPO4 pH 7.3, 100 mM NaCl, 1 
mM DTT, 0.1% NaN3 and 10% D2O. The hCdc34 plasmid for mammalian expression 
was generated by PCR amplification of its prokaryotic expression vector followed by 
cloning into empty mammalian expression vector p3xFLAG-CMV-7.1 (Sigma). FLAG-
hRpn13 F76R was produced by using the QuickChange Site-Directed Mutagenesis Kit 
(Agilent Technologies) and a p3xFLAG-CMV-7.1 plasmid encoding wild-type hRpn13 
(92). HeLa cells were transfected with expression vectors using Lipofectamine 2000 
transfection reagent (Life Technologies) according to the manufacturer’s instruction. 
HeLa cells were grown at 37°C in EMEM supplemented with 10% FBS in a humidified 
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atmosphere of 5% CO2. To harvest cells, 0.25% Trypsin-EDTA (Gibco) was used and 
after washing in PBS, cell pellets were stored at -80 °C. 
 
5.5.2 NMR experiments  
Chemical shift perturbation analysis was performed as described previously (93, 
287). Briefly, 1H, 15N HSQC experiments were recorded on either 15N hRpn13, 15N 
hCdc34, or 15N hCdc34-Cat with increasing molar ratios of either unlabeled hCdc34 or 
hRpn13. All experiments were performed at 25°C on a Bruker 850 MHz spectrometer 
equipped with a cryogenically cooled probe. NMRPipe (305) was used for NMR data 
processing and the resulting spectra visualized with XEASY (306). The amide and 
hydrogen chemical shift perturbations (CSP) were mapped for each residue according to 
Equation 5.1. 
€ 
CSP = 0.2ΔδN2 + ΔδH2    (5.1) 
 
5.5.3 GST pull-down 
GST-fused hRpn13 and hRpn13 (1-150) were bound to GST resin (GE 
Healthcare) and then rocked with His-tagged hCdc34 (Boston Biochem) for 3 hours at 
4°C. Unbound protein was removed by washing in 20 mM NaPO4, 50 mM NaCl, 0.5% 
Triton X-100, pH 6.5. Proteins retained on the resin were dissolved in 8M urea-SDS 
loading dye, heated to 70°C for 7 minutes, resolved by SDS-PAGE, transferred to PVDF 
membrane (Life Technologies) and immunoblotted with anti-Cdc34 antibody (Santa Cruz 
Biotechnology). 
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5.5.4 Immunoprecipitation experiments 
HeLa cells used for immunoprecipitation experiments were harvested and 
sonicated in Buffer 1 (20 mM Hepes, 150 mM NaCl, 5 mM MgCl2, 1 mM EDTA, 0.1 
mM PMSF, pH 7.5) supplemented with protease inhibitor cocktail (Roche). After 
removing cellular debris by centrifugation, 500-1000 µg of total protein, as measured by 
a Bradford assay (Sigma), was pre-cleared and rocked at 4°C overnight with primary 
antibodies, anti-Rpn13 (Biomol) or anti-Cdc34 (Novus Biologicals). 40 µL of washed 
protein G beads were added and the samples rocked for an additional 5 hours followed by 
washing in Buffer 1. The proteins were eluted by the addition of 8 M urea-SDS loading 
buffer, heated at 70°C for 7 minutes, resolved by SDS-PAGE and transferred to PVDF 
membranes for visualization with anti-Rpn13 (Biomol) or anti-FLAG (Sigma) antibodies 
and ECL Western blotting detection reagents (Amersham).  
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5.6 Supplemental Figures 
 
Figure 5.S1. hRpn13 binds exclusively to hCdc34’s C-terminal tail. (A) 1H, 15N HSQC 
of 15N labeled hCdc34 full-length alone (black) and with 3-fold molar excess unlabeled 
hRpn13 (red). (B) 1H, 15N HSQC of 15N labeled hCdc34 catalytic domain (7-182) alone 
(black) and with 2-fold molar excess unlabeled hRpn13 (red).   
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Chapter 6 
 
Summary and Future Directions 
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In this thesis, I have provided evidence that Rpn13 is a ubiquitin receptor in the 
proteasome’s regulatory particle, the only other of which is S5a. I have shown that Rpn13 
and S5a can bind simultaneously to ubiquitin chains, although we are not yet sure 
whether this happens at the proteasome. Furthermore, we know that loss of ubiquitin-
binding by Rpn13 and S5a does not completely abrogate ubiquitin-mediated protein 
degradation. Therefore, we expect there to be other proteins in proteasome capable of 
binding to ubiquitin. Future experiments are needed to identify such components and to 
decipher whether the multiple ubiquitin receptors in proteasome act in concert or 
independently. It is currently not clear why proteasome requires more than one ubiquitin 
receptor. 
I have also shown that Rpn13 binds to the E2 conjugating enzyme Cdc34. This 
finding is surprising and the interaction seems to occur when Rpn13 is not docked into 
proteasome. Future experiments are needed to dissect whether Rpn13 binding to Cdc34 
serves a regulatory role. Rpn13’s effect on the Cdc34 specific substrate p27/Kip1 will be 
assayed using RNAi specific to Rpn13. Rescue experiments using Rpn13’s ubiquitin-
binding domain are also planned to test whether Uch37 plays a role in p27/Kip1 protein 
stability. Nonetheless this work suggests that Rpn13 may play an important role in 
proliferating cells. 
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